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Abstract 
 
Follicular lymphoma is the second most common non-Hodgkin’s lymphoma (NHL). The 
clinical course of disease is heterogeneous, typically with multiple relapses. Most patients 
live 10 years or more. However, another group of patients deteriorate rapidly and may 
progress to death within two years. Activation induced cytidine deaminase (AID) is an 
enzyme that plays an important role in somatic hypermutation (SHM) and class switch 
recombination (CSR) of immunoglobulin genes (IG). It induces mutations in IG and non-IG 
genes leading to genomic instability and chromosomal breaks that are important in the 
pathogenesis of B-cell malignancies. 
In this study, we wanted to first measure AID mRNA and protein levels and its biological 
function in follicular lymphoma (FL) and then correlate each of these variables with clinical 
features. Our cohort consisted of 87 patients recruited into the Purine-Alkylator Combination 
In Follicular lymphoma Immuno-Chemotherapy for Older patients (PACIFICO) trial which 
is comparing alternative frontline chemoimmunotherapy regimens in older patients with FL. 
The patient samples were in the form of formalin fixed, paraffin embedded (FFPE) biopsies, 
which are notorious for nucleic acid degradation. We first chose the best kits for extracting 
RNA and DNA from FFPE biopsies then optimized the procedure to obtain higher quantity 
of RNA and DNA from the minimum amount of tissue. We then degraded RNA from an 
AID positive cell line by heating and compared the degraded material with intact material 
obtained from the same cells to identify a cut-off point for RNA degradation to be applied 
in a quantitative polymerase chain reaction (qPCR) experiments. This was followed by a 
qPCR experiment to identify AID mRNA expression in 59 patients. AID protein was then 
quantified by Immunohistochemistry (IHC) in all samples. We also aimed to measure the 
functional readout of AID, first by exploring the nuclear/cytoplasmic (N/C) ratio of AID 
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(AID is stored in the cytoplasm and translocates to the nucleus to function), which was 
calculated for 20 patients using confocal microscopy. A second AID functional measurement 
was applied using cloning and PCR to detect ongoing mutation and AID-induced mutation 
in the immunoglobulin heavy variable gene (IGHV) in 18 cases. Finally, we correlated AID 
expression and functional readouts with available baseline and longitudinal clinical data 
obtained from the Clinical Trials Unit. 
In summary, a significant positive correlation was found between AID mRNA and protein 
expression (P= 0.001). We also found a significantly higher AID N/C ratio in the patient 
group with higher total AID mRNA and protein expression (P= 0.025 and 0.023 
respectively). No correlation was identified between AID mRNA or protein levels and 
baseline or longitudinal clinical data. However, AID functionality measured as N/C ratio of 
AID and AID-related or ongoing IGHV mutation was positively correlated with disease 
status, treatment response and patient survival times.  
In conclusion, we found that functional readouts of AID are more strongly associated with 
adverse clinical features in FL compared to AID mRNA or protein expression. 
 
 
 
 
 
 
 
 
 
 
3 
 
Acknowledgments 
 
First, I would like to acknowledge my three supervisors: Professor Andrew Pettitt, Professor 
Sarah E. Coupland and Dr. Ke Lin for their help and support throughout my Ph.D. journey.  
They built my knowledge step by step to where I am now. Without their precious help and 
guidance, I would not be able to perform this work. 
In addition, I would like to thank all the members of the haematology group in the 
Department of Molecular and Clinical Cancer Medicine for their support in my laboratory 
work. Everyone in the group helped me at some point in my Ph.D. I am particularly thankful 
to Dr. Kathy Till and Dr. Gina Eagle for their help with confocal microscopy and to members 
of the Liverpool Ocular Oncology Research Group (LOORG), especially Dr. Helen Kalirai, 
for helping me with immunohistochemistry and immunofluorescent staining of my slides. 
Also, I am grateful to Dr. Geetha Menon for her help throughout the project. 
I want to thank Fotis Polydoros from the Liverpool Cancer Trials Unit (LCTU) for his aid 
with statistical analyses of chapter 7 of the thesis, as well as Dr. Melanie Oates and the Good 
Clinical Laboratory Practice (GCLP) technicians for providing me with samples from the 
PACIFICO trial. 
I am grateful to Prof. Robert Sutton and Dr. Muhammad Awais for allowing me to use the 
confocal microscope, performing the associated training and alleviating the cost.  
I thoroughly enjoyed the friendship of many who have supported me during my Ph.D. study. 
I thank all my colleagues, Dr. Sozan Kareem, Mr. Faris Tayeb, Mr. Moses Lugos, Mr. Jehad 
Alhmoud, Mr. Venkateswarlu Perikala, Dr. Ishaque Mohammad, Mr. Ahmed Alshatti, Ms. 
Sofia Karatasaki, Ms. Faten Yasen and Dr. Ola Alsanabra. 
4 
 
I would also like to thank the Higher Committee for Education Development in Iraq for 
funding this project and Dr. Awaad Farhan, Dr. Miqdam Aljumaily and Mr. Khalid Al-
Angood from Al-Sherqat General Hospital for their kind support.  
Special thanks should go to my parents Mr. Ahmed Alishlash and Mrs. Alia Hamid, my 
brothers and sister who have inspired me to be a hardworking person.  
Finally, I would like to dedicate my thesis to my wife Dr. Reem Saleh and my sons 
Mohammad and Zakariya for their limitless patience and their encouragement since the start 
of this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
Declaration 
 
 
With the exception of the statistical analysis of the clinical trial data presented in Chapter 7, 
which was performed by Mr. Fotis Polydoros (LCTU statistician), all of the work presented 
in this thesis is entirely my own. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 
 
Publications arising from this work  
 
1- Optimizing Technical Protocols to Detect AID Expression in Archived FFPE 
Samples of Patients with Follicular Lymphoma. Journal of Pathology. March 2017, 
Volume 241, Issue Supplement S1:S11. 
2- Optimization of RNA extraction and RT-qPCR for the quantification of AID in 
archived FFPE biopsy samples: only two sections of 4µm tissue are required; British 
journal of haematology. April 2015, Vol. 169: 74.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 
 
Presentations arising from this work at University of Liverpool, national 
and international conferences 
 
1- Omar Alishlash, Ke Lin, Sarah Coupland, Melanie Oates, Helen Kalirai and Andrew 
Pettitt. AID expression from gene to protein to function and its correlation with 
clinical data of Follicular Lymphoma. (Oral presentation) 2017, Belfast pathology 
2017 meeting, Belfast, UK.        
2- Omar Alishlash, Ke Lin, Sarah Coupland, Melanie Oates, Helen Kalirai and Andrew 
Pettitt. Nuclear AID expression in archived FFPE tissue samples may associate with 
ongoing IGHV mutation and advanced stage in follicular lymphoma. (Poster 
presentation) 2017, NWCR-University of Liverpool Cancer Research Centre's 
Annual Scientific Symposium, 28th April 2017, Liverpool, UK.        
3- Omar Alishlash, Ke Lin, Sarah Coupland, Melanie Oates, Helen Kalirai and Andrew 
Pettitt. Correlation of FL clinical features with AID gene and protein expression. 
(Poster presentation) 2017, Genomics and Oncology Study Day, Liverpool, UK.  
4- Omar Alishlash, Ke Lin, Sarah Coupland, Melanie Oates, Helen Kalirai and Andrew 
Pettitt. Optimizing Technical Protocols to Detect AID Expression in Archived FFPE 
Samples of Patients with Follicular Lymphoma. (Poster presentation) 2017, 
Pathological Society of Great England and Ireland winter meeting, London, UK. 
(This poster received the Cambridge University press poster prize). 
5- Omar Alishlash, Ke Lin, Sarah Coupland and Andrew Pettitt. Optimisation of RNA 
extraction and RT-qPCR for the quantification of AID in archived FFPE biopsy 
samples: only two sections of 4µm tissue are required. (Poster presentation) 2015, 
BSH Conference, Edinburgh, UK. 
8 
 
6- Omar Alishlash, Ke Lin, Sarah Coupland and Andrew Pettitt. Validation of qPCR 
for AID expression in FFPE samples of follicular lymphoma. University of Liverpool 
poster day (Poster presentation), 11th of April, 2014. 
 
 
 
                                                                         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9 
 
Grants to support attending conferences and courses related to Ph.D. 
project 
 
1- Grant from Pathological Society of Great Britain to present a poster in Pathological 
Society winter meeting 19-20 January 2017, the poster won Cambridge University 
press poster prize. 
2- Grant from Pathological Society of Great Britain to participate in the “National 
Undergraduate Histopathology and Molecular Pathology Introduction” in Leeds, 10-
11/April/2017.  
3- Full grant from European Association for Cancer Research to attend “Accelerating 
Cancer Immunotherapy” conference in London at 29-30 March/2017. 
4- Grant from European Association for Cancer Research (EACR) to attend 
Accelerating Cancer Immunotherapy conference in London (19-20/ March/2017) 
5- The Royal College of Pathologists travel grant to attend Pathology Summer School 
in London at 19 –20 August 2016. 
6- Grant from European Society for Medical Oncology to participate in ESMO 
Preceptorship on Immuno-oncology in Sweden, Lund, 4-5 December 2015. 
7- Grant from The Organisation of European Cancer Institutes (OECI) to participate in 
Eurocan Platforms Summer course in Translation Cancer Research, Portugal, 
October 12th - 16th 2015. 
8- British Society for Haematology bursary to present a poster at 55th BSH conference 
in Edinburgh, Scotland, 20th-22nd April, 2015. 
9- European Society for Pathology grant to attend 5th EACR-OECI Joint Training 
Course (Molecular Pathology Approach to Cancer) in Amsterdam 11 - 13 May 2015. 
10 
 
10- Two free of charge places from “Hartley Taylor Medical Communications Ltd” to 
attend “Current Treatment Options in Haematological Malignancies” workshop in 
2013 and “Manchester Post-ASH Meeting” on 8th February 2017. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11 
 
Contents 
 
Abstract............................................................................................................................1 
Acknowledgements..........................................................................................................3 
Declaration.......................................................................................................................5 
Publications arising from this work.................................................................................6 
Presentations arising from this work at University of Liverpool, national and             
international conferences.................................................................................................7 
Grants to support attending conferences and courses related to Ph.D. project………....9   
Contents………………………………………………………………………….…......11 
List of Figures...................................................................................................................21 
List of Tables....................................................................................................................25   
List of Abbreviations........................................................................................................29  
Chapter 1: General introduction...................................................................................34-71   
1.1 Normal B-cell biology………………………………………………………………34   
1.1.1 B-cell differentiation, maturation and immunoglobulin gene recombination.........34  
1.1.2 Somatic hypermutation in immunoglobulin variable genes…..........……………..35  
1.1.3 Class-Switch Recombination ..........…………………………………………...…37  
1.1.4 The germinal centre reaction……………………………………………………...38   
1.2 Follicular lymphoma………………………………………………………………..40  
1.2.1 Definition and epidemiology of lymphoma………………………………………40   
1.2.2 Aetiology of follicular lymphoma………………………………………………...41      
1.2.3 Pathology of FL…………………………………………………………………...42  
1.2.3.1 t(14;18) in FL……………………………………………………………….…..42    
1.2.3.2 Other genomic aberrations may also contribute to FL pathogenesis……….......44 
12 
 
1.2.3.3 Early lesions and clonal expansion in FL………………………...…...….…….44 
1.2.3.4 Ongoing mutations in FL………………………………………………………..45   
1.2.3.5 The tumour microenvironment in FL………...........………………………..….47 
1.2.4 Clinical features of FL………………………………………………………....….48   
1.2.5   Laboratory features…………………………………………………...………….49   
1.2.5.1 Blood findings…………………………………………………………………..49     
1.2.5.2 Radiological investigations and imaging techniques…………………......…….49   
1.2.5.3 Histopathological diagnosis of FL……………………………………...…...….50   
1.2.5.4 Immunohistochemical staining…………………………………………….…...50   
1.2.5.5 Grading of FL………………………………………………….………………..52  
1.2.5.6 Cytogenetics and molecular genetics……………………….…………...….…..52    
1.2.5.7 Next generation sequencing………………………………….…..….……...…..53    
1.2.6 Ann Arbor staging of FL……………………………………….……….….…......53   
1.2.7 Prognosis of FL……………………………………………………….….…….....54  
1.2.8 Transformation of FL to high-grade aggressive disease………….…….….…......56   
1.2.9 Treatment of FL ......................... ………………………………….….….…...…...57   
1.2.9.1 Treatment options………………………………………………….….…...…....57   
1.2.9.1.1 First-line therapy……………………………………………….…….…..…...57   
1.2.9.1.2 Maintenance therapy for FL…………………..…………………….………...58  
1.2.9.1.3 Treatment of relapsed FL…………………………………..…………..…......59   
1.2.9.2 Updated research and new approaches for treating FL…………..…...…....…...59 
1.2.9.3 The criteria for treatment responses……………………………..…….....…......61 
1.2.10 PACIFICO clinical trial…………………………………………...……..……....61 
1.3 AID………………………………………………………………….…..………..…62   
1.3.1 Structure and chromosomal localization………………………….………………62   
13 
 
1.3.2 Function of AID in normal B-cell maturation…………………….…………........63 
1.3.3 Potential role of AID in FL……………………………………………….……....64  
1.3.3.1 Initiating DNA damage in B-cells and its potential roles in genomic instability.64  
1.3.3.2 Role of AID in ongoing IGV SHM……………………………….….….……...65  
1.3.3.3 Hot motifs of AID-induced mutation……………………………...…….………66 
1.3.4 Regulation of AID…………………………………………………….…...………66 
1.3.4.1 AID Transcription………………………………………………….……………66   
1.3.4.2 Post-translational modification…………………………………….…………....67   
1.3.5 Cellular localization of AID………………………………………………………67  
1.3.6 AID targets………………………………………………………..……………....68 
1.3.7 Correlation between AID and cancers…………………………………………....68 
1.3.8 Methods used for measuring levels of AID expression………………………......69 
1.3.8.1 AID mRNA level………………………………...………………...…….......69 
1.3.8.2 AID at protein level……………………………………...………………...........70 
1.4. Hypotheses of this thesis and approaches applied………………..……………......71  
1.4.1 Hypothesis………………………………………………...………....……….......71   
1.4.2 Experimental Approach………………………………………………………......71   
1.4.3 Outline of thesis………………………………………………………………......71  
Chapter 2: Materials and methods……………………….....…………………..….73-104 
2.1 Tissue samples used in experiments………………...…...…….….……………......73 
2.1.1. Patients……………………………………………………….………….…….....73 
2.1.2 FFPE tissue samples from local Biobank………………….………….…….........73    
2.1.2.2 Storage conditions and duration…………………………….………………......73 
2.1.3 Tissue samples from the PACIFICO trial…………….….…………………….....74 
2.1.3.1 Patient consent and diagnosis criteria…………………….………………….....74   
14 
 
2.1.3.2 Storage conditions and length………………………………….…………….....74 
2.2 Control cell lines and tissue culturing……………………………………...…….....74     
2.2.1 Raji and K562 cell lines..………………………………………………….….......74   
2.2.2 Culture, passaging and quantitation of Raji and K562 cells………………….......74   
2.2.3 RNA and DNA extraction from cell lines………………………….…….…….....75   
2.3 RT-PCR experiments……………………………………………….……………....76   
2.3.1 RNA extraction from FFPE tissues…………………………………………….....76 
2.3.2 Detection of RNA quantity by Qubit® 2.0 fluorometer………………………......77 
2.3.3 Detection of RNA quality………………………………………..……………......77 
2.3.4 Reverse transcription of mRNA to cDNA…………………………….....……......78 
2.3.5 Polymerase Chain Reaction (PCR)…………………………………….……….....79 
2.3.6 Agarose gel electrophoresis………………………………………...…………......80  
2.3.7 qPCR measurement of AID transcriptional level……….....……..…………….....81 
2.4 DNA-based experiments……………………………………………...………….....82 
2.4.1 DNA extraction from FFPE tissues…………………………………………….....82 
2.4.2 Measuring concentration and purity of DNA extracted from PACIFICO  
FFPE tissues………………………………………………………………………….....83 
2.4.3 Detecting length of DNA extracted from FFPE specimens…………...……….....84 
2.4.4 Full length IGHV amplification in the FFPE samples………………………….....85 
2.4.5 BIOMED-2 protocol for study of IGHV clonality by multiplex PCR……....….....87 
2.4.5.1 PCR amplification of IGHV genes in families…………………….……...….....87 
2.4.5.2 Agarose gel electrophoresis and PCR purification of IGHV gene………….......89 
2.4.5.3 Cloning of IGHV DNA……………………………………………………….....90 
2.4.5.4 Clonal selection………………………………………………………………....91   
2.4.5.5 Analysis of IGHV gene sequences………………...…………………………....91 
15 
 
2.5 Protein-based experiments………………………………………….…………….....92 
2.5.1 Immunohistochemical (IHC) detection of AID protein…………….…….……....92 
2.5.1.1 IHC staining of AID………………………………………………..……….......92     
2.5.1.1.1 PT link epitope retrieval…………………………………..……..…………....93 
2.5.1.1.2 Staining slides with AID antibody using Dako autostainer………..….……...93  
2.5.1.2 Scoring system for AID quantification………………...……………..………....94 
2.5.2 Immunofluorescent double staining of AID with CD3, CD20 or CD68.............…94 
2.5.3 Subcellular localization of AID by immunofluorescence……………….......……96 
2.5.3.1 Protocol for immunofluorescent staining confocal microscopy visualization.....96 
2.5.3.2 Analysis of immunofluorescent images…………………......….………………97 
2.6 qPCR quantification of genes associated with microenvironment in FL……....…...100 
2.6.1 Optimizing qPCR protocol……………………………………...…………….......100 
2.6.2 Selection of cell lines to be used as controls for expression of these genes….......102   
2.7 Statistical analysis……………………………………………….…………….........103 
Chapter 3: Optimization of RNA and DNA extraction from FFPE tissue samples  
of FL..........................................................................................................................104-118 
3.1 Introduction………………………………………………………….......….………104    
3.2. Procedures and Results…………………………………..………………….......…106 
3.2.1 Optimization of RNA extraction from FFPE samples.............................…...........106   
3.2.1.1 Choosing the best kit for extraction of RNA from FFPE tissues……...…..........106    
3.2.1.2 Thickness of FFPE tissue sections used for RNA extraction...….......…….........108  
3.2.1.3 RNA degradation in FFPE samples during storage…………...………...…........108 
3.2.2. Optimization of DNA extraction from FFPE tissues……………...…...…….......110 
3.2.2.1 Optimizing DNA extraction kit to obtain higher quality and   
quantity of DNA...............................................................................................................111   
16 
 
3.2.2.2 Adaption of a system to measure DNA integrity………..………...…........……115 
3.3 Discussion………………………………………………………………..........……116 
Chapter 4:  AID expression in FL............................................................................119-148 
4.1 Introduction................................................................................................................119 
4.2 Patients and Methods.................................................................................................120 
4.2.1 AID mRNA expression using qPCR.......................................................................120 
4.2.1.1 Quality and quantity of RNA extracted from FFPE……………….....……........120  
4.2.1.2 Storage conditions and duration of PACIFICO FFPE tissues…………..........…121   
4.2.1.3 Checking the quality of RNA required for reliable qPCR results……...….........123   
4.2.1.4 Selecting the best EC gene for qPCR reaction of AID gene…………...........…..126   
4.2.2 AID protein expression by IHC…………………………………………….......…128   
4.2.3.AID mRNA and protein expression profiles in the cohort of patients with 
 FL studied........................................................................................................................130   
4.3 Correlation between AID protein and AID mRNA expression………................…..131   
4.4 Immunofluorescent expression of AID………………………………..…….......….132   
4.4.1 Immunofluorescent co-expression of AID with CD3, CD20 and CD68…........... 132 
4.4.2 Subcellular localization of AID………………………….……….…………........134   
4.5   Correlation between clinical data at diagnosis and AID level ..........................…..139  
4.6 Discussion…………………………………………………….……….……..…......143   
 
Chapter 5: Correlation between AID expression and ongoing IGHV mutation in 
FL..............................................................................................................................149-186 
5.1 Introduction……………………………………………………………..…...….......149   
5.1.1 Background……………………………………………………………..…........…149  
5.1.2   Aims.......................................................................................................…...........150   
17 
 
5.1.3   Hypothesis………………...……………………….………….………….......….150 
5.2   Approaches to study ongoing IGHV mutation in FL………………….……......…150 
5.3 Materials and methods…………………..………………………………….…........150    
5.3.1 Patients and samples……………………………………………………….......…150 
5.3.1.1 Clinical data of cases…………..………………………………………........…..152   
5.3.2 Technical approaches to study SHM in IGH gene……………….………........….153  
5.3.3   PCR amplification of clonal IGH in the FFPE samples using BIOMED-2  
protocol........................................................................................................................…154   
5.3.3.1   Optimizations for BIOMED-2 protocol for IGHV amplification……..........…154 
5.3.3.2   Investigating the faint bands resulted from BIOMED-2 PCR amplification….155 
5.3.4 SHM analysis……………………………………………………...……….......…155 
5.3.4.1 Database used…………………………………………………………….......…155   
5.3.5 Strategy to identify ongoing mutations…….….………………………..…….......156 
5.3.6 Identifying clone branching…………………….……………….………......……156 
5.3.7 AID hotspot mutation in IGHV gene analysis………………...…...……….......…157 
5.3.8 Statistical analysis…………………………………………………….……......…157   
5.4 Results………………………………………………………..………………......…158  
5.4.1 Optimizations of SHM identification in IGHV gene………………….……......…158 
5.4.1.1 Successful IGHV gene amplification using BIOMED-2 PCR reaction..…….....158 
5.4.1.2 Optimizations for BIOMED-2 PCR reaction……..……………....………….....158   
5.4.2 Investigating the extra faint bands generated in BIOMED-2 PCR reactions for 
amplifying IGHV gene of PACIFICO trial samples………………...………...……......159 
5.4.3 Performing BIOMED-2 reaction, cloning and analysing FL cohort….………......162 
5.4.4 Percentage of SHM……………………………………………………………. ....164   
5.4.5 Divergence of ongoing IGHV mutation……………………………….………......164   
18 
 
5.4.6 Number of subclonal generations……………………...……………………….....168    
5.4.7 Types of mutations in IGHV……………..…………………………..……………….....169   
5.4.8 AID-induced IGHV mutations…………………….……………….….………......169   
5.4.9 Correlation of AID expression with different parameters tested in this chapter.....170   
5.4.9.1 Relation between AID/GAPDH mRNA expression and ongoing mutation.........170   
5.4.9.2 Correlation between total AID protein expression and ongoing mutation….......172  
5.4.10   Correlation between clinical parameters of FL at time of entry to clinical  
trial and parameters tested in this chapter............................................................…........175  
5.4.10.1 Relation between percent of AID induced mutations and FL clinical data........175  
5.4.10.1 Correlation of percentage of IGHV mutation with FL clinical data…..…….....176 
5.4.10.2 Relationship between number of subclones and FL clinical data…..................178 
5.4.10.3 Correlation of ongoing mutation with FL clinical data……………….…….....181 
5.5 Discussion……………………………………………………………...………...... 185 
Chapter 6: Investigation of relationships between transcriptional levels of genes associated 
with T cells and macrophages and AID expression in lymph node tissue, and their 
correlations with clinical status of FL…………………………....…………........…188-205 
6.1 Introduction.................................................................................................................188 
6.1.1 Aim and hypothesis.................................................................................................190  
6.2 Materials and methods................................................................................................190 
6.2.1 Samples used for qPCR measurement of TME gene expression............................190 
6.2.2 Approaches to identify genes expression of TME in FL.........................................190 
6.2.3 Selecting genes for Taqman qPCR reaction for TME genes in FL.........................190   
6.2.4 Selecting cell lines to be used as a control for selected genes.................................192 
6.3 Results of TME gene expression profile………………...........….…………………192   
6.3.1 Correlations between different gene expressions………………............…………194   
19 
 
6.3.1 Correlation between AID expression and gene signatures of FL   
microenvironment.............................................................................................................195   
6.3.1.1 Relation between AID/GAPDH mRNA expression and TME 
genes………..................................................................................................…...............196   
6.3.2 Relationship between AID protein and TME gene signatures of .......................…196   
6.3.3 Association between TME genes and nuclear/cytoplasmic percentage of AID.....198   
6.3.4 Correlation between EC gene in qPCR and Taqman qPCR reactions....................198   
6.3.5 Association between TME genes’ expression and ongoing mutation….................199   
6.3.6 Relationship between TME gene expressions with clinical data at entry to clinical 
trial……………………………………………………………………………...............200 
6.3.6.1 Relationship between sex of patients and TME genes………….….…...............200 
6.3.6.2 Correlation between age of patients and TME genes……….….…..…...............201  
6.3.6.3 Association between number of LNs and TME genes…………..…...............…201  
6.3.6.4 Relationship between TME genes and LDH level………........………...............202  
6.3.6.5 Association between grade of FL and TME genes……..….…………................203 
6.3.6.6 Association between stage of FL and TME genes………..….….…...............…204  
6.4 Discussion……………………………………………………….…..…................…205   
Chapter 7: Correlations between AID expression and function against clinical  
outcome of FL……………………………………………..………….….................208-220 
7.1 Introduction………………………………………………....…….…...............……208   
7.2 Materials and methods……………………………………….......................….……209    
7.2.1 Patients and data………………………………………..………................………209 
7.3 Statistical analysis………………………………………..………...............….……210   
7.4 Results……………………………………………………………....................……210 
7.4.1 Relationship between AID expression and trial endpoints………...…...............…210 
20 
 
7.4.2. Relationship between AID N/C ratio and trial endpoints…………...............……211 
7.4.3 Relationship between overall cumulative IGHV mutation and trial endpoints.......213  
7.4.4 Relationship between AID-related cumulative IGHV mutation and trial 
endpoints...........................................................................................................................213   
7.4.5 Relationship between AID-unrelated cumulative IGHV mutation and trial  
endpoints...........................................................................................................................214  
7.4.6. Relationship between ongoing IGHV mutation and trial endpoints…...................214  
7.4.7 Relationship between genes expressed in the TME and trial endpoints..................215    
7.5 Discussion………………………………………………………………...................218 
Chapter 8: General discussion……………………………….…..........................…220-226 
Conclusion.......................................................................................................................227 
References........................................................................................................................228 
Appendices……………………………………………………………...............………279 
Appendix Table 1: Clinical data of PACIFICO trial patients used in our study.............279 
Appendix Table 2: Clinical data of FL FFPE samples borrowed from Liverpool 
BioInnovation Hub........................................................................………...............……282 
Appendix Table 3: 161 important genes in pathogenesis of FL that will be studied by 
NGS..................................................................................................................................283 
Appendix table 4: Permissions to use published figures in my Ph.D. thesis............288-292 
 
 
 
 
 
 
21 
 
List of Figures 
 
Figure 1.1: Stages of B-cell development........................................................................35 
Figure 1.2: IGHV gene rearrangement……………………………….............................36  
Figure 1.3: CSR from IgM to IgE....................................................................................37 
Figure 1.4: Germinal centre reaction………………………… .......................................39 
Figure 1.5: t(14;18) in FL. ...............................................................................................43  
Figure 1.6: Ongoing mutation and divergent evolution of CPC clones in FL  
transformation and relapse................................................................................................46   
Figure 1.7: Histopathology of FL.....................................................................................51  
Figure 1.8: Structure of AID protein................................................................................63 
Figure 1.9: Consequences of AID deamination of cytidine to uridine.............................64  
Figure 1.10: Binding regions for factors controlling AID transcription...........................67 
Figure 2.1: Workflow experiment for AID staining by IHC............................................92  
Figure 2.2: Workflow for immunofluorescent double staining of AID with  
CD3, CD20 or CD68 experiments....................................................................................96  
Figure 2.3: Calculating nuclear cytoplasmic AID using Image j1x software..................99 
Figure 3.1: Comparison of yields of total cellular RNA extracted from FFPE samples 
with two different kits......................................................................................................107 
Figure 3.2: Comparison of RIN of RNA extracted from FFPE samples stored for       
different periods of time...................................................................................................109 
Figure 3.3: Examples of RNA degradation measured by 2100 bioanalyzer…................110 
Figure 3.4: Comparison of DNA yield extracted from FFPE samples after protein digestion 
for different durations......................................................................................................112 
 
22 
 
Figure 3.5: Comparison of length of GAPDH gene fragments amplified using  
gDNA extracted from FFPE tissue samples pre-treated with proteinase K for different 
periods of time..................................................................................................................114 
Figure 3.6: PCR primers to amplify GAPDH gene at 200, 300 and 400 bp....................115 
Figure 4.1: RNA integrity was reduced during storage of FFPE samples.......................121 
Figure 4.2: No amplification of genes from RNA of FFPE when primers amplifying         
large PCR products were used……………………………………………………...…..122 
Figure 4.3: RNA RIN ≥2.1 produced reliable AID/GAPDH qPCR results.....................125 
Figure 4.4: Comparison between different EC genes to choose the most suitable gene          
to produce the AID/EC gene ratio...................................................................................127 
Figure 4.5: Hyperplastic tonsil was used as a positive and negative control for AID       
protein expression by IHC...............................................................................................129 
Figure 4.6: Different FL LNs stained with AID mAb using IHC technique...................129 
Figure 4.7: Expression of AID is variable among FL cases............................................131 
Figure 4.8: A positive significant correlation was obtained by comparing mRNA and 
protein level of AID..........................................................................................................132 
Figure 4.9: AID is expressed in B-cells of the GC, and not T cells or macrophages or..133 
Figure 4.10: Three different nuclear stains were tried in co-expression with AID..........133 
Figure 4.11: Positive and negative controls for subcellular AID IF................................136 
Figure 4.12: Choosing closest GC to areas 12, 3, 6 and 9 o’clock positions in  
addition to the middle of LN to study subcellular localization of AID ……..........……137 
Figure 4.13: Expression of N/C ratio of AID protein in 20 cases of the PACIFICO 
trial...................................................................................................................................138 
Figure 4.14: Correlation between N/C ratio of AID and AID total protein by IHC.......139 
Figure 5.1: Platform of work to identify ongoing IGHV mutation in FL........................153 
23 
 
Figure 5.2: Optimization of PCR conditions harmonising BIOMED-2 protocol to          
amplify IGHV in Raji cell line……………………….....................................................159 
Figure 5.3: PCR faint bands in IGHV gene amplification are background normal B-
cells..................................................................................................................................161 
Figure 5.4: Sanger sequencing and IGHV analysis…………...........……......................163 
Figure 5.5: Percentage of IGHV mutations in the 18 patients studied............................164  
Figure 5.6: An example of ongoing mutations shown in IGHV sequences of different 
subclones originating from one original clone.................................................................165 
Figure 5.7: Phylogenetic tree of four different patients produced by phylogeny.fr 
software............................................................................................................................166 
Figure 5.8: Examining the relationship between AID/GAPDH mRNA and number of 
subclones …......................................................................................................................172 
Figure 5.9: Examining the relationship between AID total protein IHC level and 
percentage of mutation.....................................................................................................173 
Figure 5.10: Examining the relationship of ongoing mutation and total AID protein by   
IHC score.........................................................................................................................174 
Figure 5.11: A positive significant correlation between ongoing mutations with          
advanced disease grade…………………………………………....................................183 
Figure 5.12: Difference in ongoing IGHV mutation between FL patients at different  
disease stages...................................................................................................................184  
Figure 6.1: Heat map of genes representing TME and predicting prognosis in FL       
among cases of low and high AID.................................................................................. 193 
Figure 6.2: A significant positive correlation was observed between all of the                
three genes expressed in T cells in TME and reportedly associated with good        
prognosis in FL................................................................................................................194 
24 
 
Figure 6.3: Results of Spearman’s correlation analyses between genes expressed in         
TME and associated with poor prognosis in FL..............................................................195 
Figure 6.4: A significant negative correlation was found between AID protein         
expression and two genes predicting good prognosis in FL….................................…....196 
Figure 6.5: A positive significant correlation between Ct values of GAPDH measured       
by qPCR and Taqman qPCR………………............................................................……199 
Figure 7.1: Lower N/C ratio of AID is associated with better response 
rate....................................................................................................................................212 
Figure 7.2: Summarises all correlations between AID expression and function with the 
clinical features and outcome in our FL patients..............................................................217 
 
 
 
 
 
 
 
 
 
 
 
 
25 
 
List of Tables 
 
Table 1.1: Grading of FL..................................................................................................52  
Table 1.2: Staging of FL...................................................................................................54  
Table 1.3: Comparison of FLIPI1 and FLIPI2 prognostic parameters for FL..................55 
Table 2.1: Reagents for PCR amplification of AID, GAPDH and CD19.........................79 
Table 2.2: Primers used for PCR amplification of AID, GAPDH and CD19.................. 79 
Table 2.3: PCR protocol for PCR amplification of AID, GAPDH and CD19..................80 
Table 2.4: Primers used for qPCR amplification of AID, GAPDH, TBP and HPRT1....81 
Table 2.5: Components of qPCR reaction........................................................................82 
Table 2.6: Cycle details of qPCR reaction.......................................................................82  
Table 2.7: Primers used to amplify different sizes of GAPDH PCR bands.....................84 
Table 2.8: PCR protocol of GAPDH PCR bands.............................................................85 
Table 2.9: Primers to amplify full length IGHV gene from leader to constant region.....86 
Table 2.10: Contents of PCR master mix to amplify full length IGHV gene from leader        
to constant region……………………................…............................................………..86 
Table 2.11: BIOMED-2 primers.......................................................................................88 
Table 2.12: BIOMED-2 PCR components.......................................................................88 
Table 2.13: BIOMED-2 PCR protocol………………………….......................…...……89  
Table 2.14: FL microenvironment-related genes studied in this thesis.......................…101 
Table 2.15: qPCR protocol used for Taqman reaction………….........................………102 
Table 2.16: Shows cell lines amplifying TME genes that are used as a positive control        
for these genes’ expression in PACIFICO samples….....................................................103 
Table 3.1: Comparison of PCR products of GAPDH between FFPE samples with          
protein digestion for one hour and overnight………...............................................……113 
26 
 
Table 3.2: The number (%) of DNA samples with different length an amount as        
estimated with PCR amplified GAPDH gene fragments.................................................116  
Table 4.1: Scoring system used to score IHC slides stained with AID mAb……..........130 
Table 4.2: Correlation between AID/GAPDH mRNA expression and clinical data of 
patients……….................................................................................................................140 
Table 4.3: Relation between total AID protein expression and clinical data of the 
patients….........................................................................................................................141 
Table 4.4: Correlation between N/C ratio of AID protein expression and clinical data of 
PACIFICO patients…………………………………..........................................………142 
Table 4.5: Comparison of frequency of stage IV FL between patients with high and        
low N/C ratio of AID protein by IF……………..…….......................................………143 
Table 5.1: Samples used for analysis of correlation between AID expression and           
ongoing mutation…………………..................................................……………………152 
Table 5.2: Data derived from ongoing mutation analysis in 10 samples with high total        
AID protein by IHC and 8 samples with low AID protein..............................................168 
Table 5.3: AID expression and ongoing mutation in FL………….....................………169 
Table 5.4: Correlations between AID/GAPDH mRNA and % of IGHV mutation.....….172 
Table 5.5: Comparison of large number of subclones between patients with high and       
low total AID protein by IHC………………………………......................................…175 
Table 5.6: Correlation between percent of AID induced mutations and clinical features      
of FL at time of entry to clinical trial…………...................................................…..…..177 
Table 5.7: Relations between percentage of IGHV gene mutation and clinical parameters  
of FL patients at time of entry to the clinical trial…………............................................178 
Table 5.8: Correlation between age and LDH level against the two groups of low and                         
high number of subclone………………........................................……………………..179 
27 
 
 
Table 5.9: No correlation between sex of patients and number of subclones...................180 
Table 5.10: No relationship between number of LNs and subclones of mutated 
IGHV….............................................................................................................................180 
Table 5:11: Correlation between grade of disease and subclones of mutated IGHV…....181 
Table 5.12: A positive significant correlation was identified between number of        
subclones in mutated IGHV and Ann Arbor stage….........................………….....……..181 
Table 5.13: Correlation between ongoing mutations analysed by method from published 
papers and clinical parameters of FL at entry to clinical trial…..…............................…183 
Table 6.1: Folds of increase in gene expression of the examined genes with decreased        
AID protein……………………………………......................................…………….…197 
Table 6.2: Correlations between ongoing mutation in IGHV and TME gene           
expression........................................................................…………….....................……200 
Table 6.3: Correlations between ongoing mutation and TME gene expression..............202        
Table 6.4: Association between genes predicting good and bad prognosis in FL and 
number of enlarged LNs.……..........................................................................................203 
Table 6.5: Association between grade of disease and TME gene expression..................203 
Table 6.6: Correlations between stage of disease and TME gene expression..................204 
Table 6.7: Correlations between stage of disease and TME gene expression..................205 
Table 6.8: association between TME genes and FLIPI score..........................................205 
Table 7.1: Correlation between AID expression at both mRNA and protein level with        
PFS in our cohort of patients……………………................................………………....210 
Table 7.2: No association was identified between AID expression at both mRNA and 
protein level with OS…………………………………………................………………211 
Table 7.3: Correlation between AID expression and RR……………...............…..……211 
28 
 
Table 7.4: Correlation between five TME genes and PFS…………...............…………216 
Table 7.5: Correlation between TME genes and OS…………………................………216 
Table 7.6: Association between genes expressed in TME of FL and RR…................…217 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
29 
 
List of abbreviations 
 
ABC                         Activated B-Cell germinal centre  
AID                          Activation Induced cytidine Deaminase 
AID                    Activation Induced cytidine Deaminase gene 
ANC                        Absolute neutrophil count  
APE                         Apurinic-apyrimidinic Endonuclease  
ASHM                      A Somatic Hypermutation    
bp                             Base pair        
BCR                         B Cell Receptor   
BSA                         Bovine Serum Albumin    
CDR                         Complementary Determining    
CI                             Confidence Interval       
CLL                         Chronic Lymphocytic Leukemia 
CML                        Chronic Myeloid Leukemia 
CPCs                        Common Precursor Clones 
CR                            Complete Response 
CRM1                      Chromosomal Maintenance 1  
CSR                         Class Switch Recombination 
Ct                              Cycle Threshold  
CTNNBL1               Catenin Beta Like 1 
DAB                        Diaminobenzidine  
DLBCL                    Diffuse Large B Cell Lymphoma 
DSB                         Double Strand Break   
30 
 
EC                            Endogenous Control 
EPP                          Error Prone Polymerases 
ESR                         Erythrocyte Sedimentation Rate 
FDCs                       Follicular Dendritic Cells  
FFS                          Failure-Free Survival 
FISH                        Fluorescence In Situ Hybridisation  
FL                            Follicular Lymphoma 
FLIPI                       Follicular Lymphoma International Prognostic Index 
FLLC                       Follicular Lymphoma Like Cell 
FLIS                        Follicular Lymphoma Insitu 
FR                            Framework  
GAPDH                   Glyceraldehyde-3-Phosphate Dehydrogenase gene 
GC                           Germinal Centre 
GCB                         Germinal Centre B-cell-like of diffuse large B-cell lymphoma  
gDNA                      genomic DNA 
GELF                       Groupe d’Etude des Lymphomes Folliculaires 
GIT                          Gastrointestinal Tract  
HCT                         Hematopoietic Cell Transplantation  
HIV                          Human Immunodeficiency Virus 
HPF                         High Power Field   
HR                           Hazard Ratio   
HRP                         Horseradish Peroxidase  
IF                             Immunofluorescence 
IG                             Immunoglobulin   
IGH                          Immunoglobulin heavy gene 
31 
 
IGHV                       Immunoglobulin heavy variable gene 
IGV                          Immunoglobulin Variable gene 
IMGT                       International ImMunoGeneTics information system 
IPTG                        Isopropyl β-D-1-thiogalactopyranoside 
IHC                          Immunohistochemistry  
IMS                          Industrial Methylated Spirits 
kb                            Kilobase  
LB                            Luria-Bertani agar    
LCTU                      Liverpool Cancer Trials Unit  
LDH                         Lactate Dehydrogenase  
LN                            Lymph Node 
LBIH                        Liverpool BioInnovation Hub  
mAb                         Mono Clonal Antibody 
MHC                        Major histocompatibility complex 
MMR                       Mismatch Repair  
MRD                        Minimal Residual Disease 
mTOR                      Mammalian Target Of Rapamycin  
N/C                          Nuclear/cytoplasmic  
NGS                         Next Generation Sequencing 
NHL                         Non Hodgkins Lymphoma 
OR                           Odds ratio 
OS                            Overall Survival 
PACIFICO               Purine-Alkylator Combination In Follicular lymphoma Immuno-                                                                                  
                                 Chemotherapy for Older patients.   
PBS                          Phosphate Buffer Saline 
32 
 
PCR                         Polymerase Chain Reaction 
PD                            Progressive Disease 
PET                          Positron emission tomography  
PFS                          Progression Free Survival   
PI3K                        Phosphatidylinositol 3-kinase  
qPCR                       quantitative Polymerase Chain Reaction 
PR                            Partial Response 
PTM                         Post-translational Modification 
R                              Rituximab 
RAG                        Recombination Activating Gene 
RIN                          RNA Integrity Number 
RPM                        Revolutions Per Minute 
RPMI                       Roswell Park Memorial Institute  
RR                            Response Rate 
SD                            Standard Deviation 
SDS                         Stable Disease 
SEM                         Slandered Error of Mean 
SHM                        Somatic Hypermutation 
SOC                         Super Optimal broth with Catabolite repression 
TBS                          Tris buffered saline 
TLR                         Toll-like Receptors 
TME                         Tissue Microenvironment 
TP53                        Tumour Protein p53  
UK                           United Kingdom    
U/L                          Unit per Liter 
33 
 
UNG                        Uracil DNA Glycosylase 
VDJ                         Variable, Diversity and Joining gene segments 
WBC                        White Blood Cells 
WHO                       World Health Organization
34 
 
Chapter 1 
 
General introduction 
 
 
1.1 Normal B-cell biology: 
My thesis addresses the role of activation-induced cytidine deaminase (AID) in follicular 
lymphoma (FL), which is a B-cell non-Hodgkin’s lymphoma (NHL) and the most common 
indolent B-cell lymphoma (1). 
To understand the role of B-cell development and AID in this disease, it is essential to 
initially discuss B-cell biology (Section 1). The details of FL will be discussed in Section 2, 
and AID in Section 3 of this introduction. 
1.1.1 B-cell differentiation, maturation and immunoglobulin gene recombination: 
B-cells are essential in the immune system. They carry the B-cell receptor (BCR) that 
identifies antigens, allowing these cells to produce specific antibodies against them (2). 
There are two major stages of B-cell development; one is antigen independent, occurring in 
bone marrow, and the other is antigen dependent, located in the lymph node (LN) (3). 
B-cells originate from haematopoietic stem cells in the bone marrow, which gives rise to 
progenitor B-cells. BCR formation begins at this stage, by combining diversity (D) and 
joining (J) gene segments with immunoglobulin variable region (IGV) gene segments, 
followed by joining one of the constant genes (4). BCRs consist of heavy and light chains, 
and are initially expressed with light chain-like molecules (surrogate light chains) to form a 
pre-B-cell receptor (5). The stages of B-cell development are illustrated in Figure 1.1. 
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Figure 1.1: Stages of B-cell development from stem cells to memory or plasma cells. Figure based on reviews 
by Elgert and Parham (6, 7).  
 
1.1.2 Somatic hypermutation in immunoglobulin variable genes: 
Somatic hypermutation (SHM) is the process of generating highly specific antibodies against 
foreign antigens by inducing mutations (mainly as single nucleotide replacements) in IGV 
genes. SHM occurs at a frequency of 10-2 to 10-3 in immunoglobulin heavy variable (IGHV) 
and immunoglobulin light variable (IGLV) regions (8). AID is a key enzyme in this process 
(9). 
The targeted IGHV gene is approximately 1.25 mega base in length. It is located in the IGHV 
gene cluster on chromosome 14q, and consists of four framework regions (FR) and three 
complementarity-determining regions (CDR) (10, 11). 
In addition to SHM, the process of VDJ recombination occurs in early stages of B-cell 
development and further diversifies BCR to identify antigens. This recombination occurs 
between any of the 50 V (variable), 30 D and 6 J gene segments, creating the possibility of 
up to 104 different combinations with any of the constant genes (12). IGHV gene 
rearrangement and SHM are shown in Figure 1.2. 
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Figure 1.2: IGHV gene rearrangement, VDJ recombination occurs in bone marrow, rearranged mRNA 
contains 4 FR regions and 3 CDR regions. Figure based on Figure 1 of McClure and colleagues’ work (2) and 
Figure 7 of Gagyi Eva Ph.D. thesis (13).  
 
BCR created by VDJ recombination plays a role in the innate immune system. This receptor 
is expressed on the B-cell surface by adding either kappa (IGK) or lambda (IGL) light chains 
to the heavy chain (14). On the other hand, in comparison with the innate immune system, 
the germinal centre (GC) B-cell IGHV mutations produce antibodies with higher specificity 
(2). 
Germinal centre-associated nuclear protein is responsible for directing AID to the IGV gene 
during the process of SHM (15), while the SPT5 protein is important for AID recruitment 
toward both immunoglobulin (IG) and non-immunoglobulin genes (16). Then, AID cofactor 
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replication protein A helps AID to induce conversion of deoxy Cytidine to deoxy Uridine 
within the IGHV gene during transcription (17). 
In B-cell malignancies, a B-cell clone with unique IGHV rearrangement will be produced. 
This IGHV can be amplified by PCR reaction, and adds to microscopic morphology for 
confirming diagnosis in difficult cases of B-cell malignancy (18). 
1.1.3 Class-Switch Recombination: 
Class-Switch Recombination (CSR) is the process of exchanging the constant region (Cµ) 
in the immunoglobulin heavy gene (IGH) with either Cγ or Cε or Cα, allowing B-cells to 
produce antibodies of IgG, IgE, or IgA, respectively, rather than IgM (19). The AID enzyme 
is the keystone for CSR. It deaminates cytosine in two switch regions of the IGH gene, then 
double-stranded DNA breaks occur by a DNA repair mechanism (20) (Figure 1.3). AID can 
be directed to switch regions in the IGH gene by 14-3-3 adaptor proteins (21). 
  
Figure 1.3: CSR from IgM to IgE. AID enzyme deaminates cytidine residues in the S region of the IGH gene 
to create a DNA double-strand break. This process is followed by deletion of the chromosomal part between 
VDJ and required constant segment (in this case, Cε to produce IgE Antibody). Figure taken with permission 
from Stavnezer and colleagues (22).   
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1.1.4 The germinal centre reaction: 
This is the reaction in the lymphoid follicle initiated by antigens, and results in a highly 
specific antibody response against these antigens (23). 
The reaction starts when the cells of the innate immune system catch an antigen, and present 
some of its components on their cell surface. Then, these cells migrate to lymphoid organs 
where they are recognized by T-helper cells. At the same time, B-cells, upon antigenic 
stimulation, migrate to and bind T cells to initiate the GC reaction, which produces specific 
antibodies against the offending antigen (24, 25).  
B-cells proliferate extensively, forming the dark zone of secondary lymphoid follicle, which 
consists of centroblasts surrounding a less condensed zone of cells called the light zone (26). 
After that, B-cells enter the light zone to become centrocytes and the proliferation rate 
decreases. It is the place where only the higher affinity antibody-producing B-cells are 
selected to survive, while cells with low affinity are directed for apoptosis (27). The end 
result of this GC reaction will be specific antibody-producing plasma cells and memory B-
cells (28) (Figure 1.4). 
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Figure 1.4: Germinal Centre reaction. After encountering an antigen, T cell and B-cell interaction stimulates 
B-cells and directs them to the GC. B-cells proliferate at the dark zone of the GC and undergo SHM with the 
help of AID. If the B-cells have high affinity against antigen, then they will enter the light zone and proliferate. 
Otherwise they will undergo apoptosis. B-cells will then become either memory B-cells or plasma cells and 
produce specific antibodies (29). Figure courtesy of Professor Sarah E. Coupland.  
 
Other essential cells in the GC, in addition to B-cells and stromal cells, include: 
1- Follicular dendritic cells (FDCs), which play at least two roles in GC reactions. First, they 
prolong retention of antigen to help the SHM process in selecting B-cells with highest 
affinity against antigen (30). Second, FDCs maintain B-cell survival and proliferation (31). 
2- Macrophages, which contain apoptotic bodies of dead B-cells (32). 
3- T cells, which play a pivotal role in formation and maintenance of the GC. They help B-
cells to initiate the GC reaction, trigger migration cycles of B-cells between dark and light 
zones to achieve high specificity against antigen, and increase B-cell proliferation (33, 34).  
In addition to these cells, AID and BCL6 play an important role in GC reactions. AID 
induces the SHM process to increase antibody affinity (35), and is highly expressed in the 
GC (36). In addition, the AID enzyme may induce genomic instability leading to B-cell 
lymphomas in long-lived GC associated with chronic infections (37).  
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On the other hand, BCL6 is a proto-oncogene and a transcription repressor that plays a major 
role in the creation of GC reactions (26, 38). BCL6 increases cell tolerance to GC-associated 
DNA damage and prevents cells from apoptosis by suppressing DNA damage checkpoints 
(38, 39). Mutations and translocations of the BCL6 gene are associated with lymphomas 
(40). 
1.2 Follicular lymphoma: 
1.2.1 Definition and epidemiology of lymphoma: 
Lymphomas involve malignant proliferation of lymphocytes, and can occur at any stage of 
lymphocyte maturation. About 80% arise from B lymphocytes, and the remaining 
lymphomas arise from T lymphocytes and natural killer cells (41, 42).  
The World Health Organization (WHO) classified lymphomas into two major groups: 
Non-Hodgkin's lymphomas (NHL) forming about 90% of all lymphomas, and Hodgkin's 
lymphomas covering the remainder. Both types consist of more than 50 lymphoma 
subclasses (41).  
In NHL, eleven major subtypes were identified with different geographical distribution 
over the world. The two most common types are diffuse large B-cell lymphoma (DLBCL) 
 .(41, 42)Hodgkin's lymphomas -and FL, both comprising more than two thirds of all Non 
In the UK, NHL is the fifth most common cancer. The annual incidence reached 23 per 
100,000 males and 19 per 100,000 females. In 2013 alone, about 10,000 new cases of NHL 
had been registered, of which 1,884 were FL, according to the UK Office of National 
 .(43)tatistics S 
More than 20 subtypes of lymphoma have been registered in the UK, and in almost all of 
these, males have a higher incidence rate and are affected at younger ages (44). To 
distinguish from the disease in children, the updated WHO classification of lymphoma 
includes paediatric-type FL as a definitive entity (45). 
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FL predominantly affects patients aged between 60 and 70, with overall survival (OS) 
shortening in older-age groups. Unlike most other NHLs, FL is more common in women 
than men (46, 47). However, the progression free survival (PFS) is longer in women, and 
both OS and lymphoma-related mortality are better in female patients younger than 60 
years of age (48). 
Regarding geographical distribution, the highest incidences of FL are in the developed 
world and the lowest in Asia (49). 
1.2.2 Aetiology of follicular lymphoma:    
Despite intensive efforts into determining the causative factors of FL, the aetiology of this 
disease remains unclear, and needs to be investigated in larger multicentre studies (50).  
To date, FL has been correlated with different factors, examples include:  
Farrell and colleagues suggested that using immunosuppressive drugs is correlated with 
increased risk of NHL (50); Morton and colleagues showed that only the FL type of NHL 
is higher in smokers than non-smokers (51).  
Viral infections – e.g. Epstein-Barr virus (EBV), human herpesvirus-8 (HHV-8) and 
Human T-cell leukemia virus-1 (HTLV-1) - were all suggested as causing genomic 
changes which facilitate lymphoma occurrence (52).  
Furthermore, lack of daily exercise, obesity, increased ingestion of milk and meat were 
suggested to be associated with an increased incidence of FL (53). This was supported by 
data suggesting that the intake of sufficient antioxidants, fruit, vegetables and vitamin D 
were correlated with lower risk of FL (53). 
Hair dyes used prior to 1980 were also proposed to lead to an increased risk of FL, with 
only black colour hair dyes after 1980 being associated with an increased risk (54). 
Exposure to pesticides and chemical solvents such as benzene, toluene and xylene were 
also found to be associated with an increased incidence of FL (55, 56). 
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1.2.3 Pathology of FL: 
The development of FL is hypothesized to require multiple genomic aberrations. The early 
precursors of FL may include variants, such as “follicular lymphoma in situ”, duodenal 
follicular lymphoma and t(14;18)-positive circulating B-cells.  
It was proposed that t(14;18), which is the hallmark of FL, is the initial and underlying 
genetic alteration (see below). This is followed by ‘second hits’, or additional genetic 
aberrations (discussed below). It was hypothesized that the risk for subsequent mutation that 
resulted in FL development occurs when cells re-enter the GC and are exposed to the effect 
of AID and somatic hypermutations (57). 
1.2.3.1 t(14;18) in FL: 
The most common genetic aberration in FL is the translocation of genes on chromosomes 
14 and 18, i.e. t(14;18), which occurs in about 85-90% of cases. This results in the 
translocation of the BCL2 gene from chromosome 18 to the enhancer loci of the IGHV gene 
on chromosome 14 (58). This leads to increased expression of the anti-apoptotic BCL2 
protein, and therefore facilitates the survival and accumulation of lymphoma cells initially 
within the germinal centre (Figure 1.5) (58, 59). Other rare translocations in FL, such as 
t(2;18) and t(18;22), also lead to a dysregulation of the BCL2 gene and the abnormal 
overexpression of its protein (60). 
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Figure 1.5: t(14;18) present in 85-90% of FL patients. The BCL2 gene is translocated from chromosome 18 to 
chromosome 14 to be enhanced by IGH gene. This leads to elevated expression of anti-apoptotic BCL2 protein. 
Figure based on translocation review of Blacker and Leich papers (58, 59). 
 
This t(14;18) can occur as a result of a defect in repair of DNA double strand breaks, 
mediated by recombination activating gene (RAG) in either both BCL2 and IGH loci, or the 
latter gene alone. It can also result from CpG gene segment fragility in BCL2 (59).  
In addition to RAG, AID was also found to contribute to t(14;18) in B-cells (61). The 
expression of AID in B-cells is associated with double-strand breaks (DSB) in points across 
the whole genome (62).  
Furthermore, AID affects other oncogenes: about 25% of expressed genes in B-cells were 
not fully protected against AID mutagenic effects (63). 
Breaks in the BCL2 gene are located in a number of locations across the gene. The most 
important break points are major breakpoint regions, minor cluster regions and intermediate 
cluster regions (64-66). Other uncommon breakpoints are the 3' BCL2 (67) and 5' ends of 
BCL2 (68). These points can be detected by PCR to provide a rapid, sensitive and 
reproducible method for minimal residual disease (MRD) detection. 
Fluorescence In Situ Hybridisation (FISH) is the preferred method for routine detection of 
t(14;18) (69). In addition to t(14;18), more genetic hits are required for FL development (70).  
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1.2.3.2 Other genomic aberrations may also contribute to FL pathogenesis: 
It is hypothesised that t(14;18) occurs during the early stages of FL. Subsequently, the 
t(14;18)+ B-cells acquire other mutations in genes that ultimately lead to FL. Later on, other 
genomic aberrations – e.g. loss (or mutation) of tumour protein p53 (TP53) and CDKN2A  
may occur that cause the transformation of FL from a low-grade to a high-grade or 
aggressive disease (71). 
Besides t(14;18), genomic aberrations in FL include losses of 1p, 6q, 10p, 17p, genetic gains 
in chromosomes: 1,3q, 6p, 7, 8, 12q, X and 18q, t(2:18) and t(18;22) (72). 
In addition to structural aberration of chromosomes, mutations in multiple genes contribute 
to FL. The most important genes affected are histone modifiers, including EZH2, MLL2, 
CREBBP, MEF2B, and EP300 and TNFRSF14. Deletion of tumour suppressors 
TNFAIP3/A20 and EPHA7 are associated with pathogenesis of this disease (73). A recent 
study revealed that recurrent somatic mutations in the RRAGC gene, which encodes an 
important protein in the mTOR (Mammalian target of rapamycin) complex, occurred in 17% 
of patients with FL, suggesting a possible role of these mutations in survival of the neoplastic 
B-cell clones, and also the possibility of targeting them in FL treatment (74). 
1.2.3.3 Early lesions and clonal expansion in FL: 
It was thought that the malignant FL cells are derived from transformed GC lymphocytes. 
This hypothesis was based on clinical, microscopical and molecular similarities between 
normal GC and FL cells. However, some studies suggested that FL occurs after years of slow 
growth of common precursor clones (CPCs). These clones might also be responsible for 
disease relapse after treatment (75).  
It was proposed that t(14:18) that occurs in bone marrow in the ‘pre-B’ cells is the initiating 
step in the pathogenesis of FL, rather than in the GC (76-79). Nevertheless, the observations 
that t(14:18) is present in normal individuals, and that at least one additional mutation occurs 
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in almost all FL patients, would suggest that t(14:18) is a crucial step for the pathogenesis 
of the disease, but that it is not necessarily sufficient – i.e. additional hits are required for a 
malignant transformation to commence (78, 80, 81).  
It was suggested that in early stages of FL development, AID targets genes other than IGH, 
especially proto-oncogenes involved in FL pathogenesis in a process named aberrant somatic 
hypermutation (ASHM). These genes include MYC, BCL6, PAX5, ARHH and PIM1(59, 82). 
It was also hypothesised that the origin of FL could be a group of cells named “follicular 
lymphoma in situ (FLIS)”, which express BCL2 protein found accidently in the GC, with no 
evidence of dissemination and risk of about 5% of evident FL (83). 
Another cell suggested to be the origin of FL are circulating t(14;18) positive cells, which 
are termed FL-like cells (FLLC). 
FLLCs are reported to accumulate within the GC in 14% of reactive LN specimens as non-
proliferative centrocytes (84). Molecular testing confirmed a clonal relationship between FL 
and FLLCs in some patients (69), and it was suggested that these cells may re-enter the GC 
to undergo multiple SHM reactions, increasing the chance for additional genomic hits 
required for conversion to overt FL (85). 
1.2.3.4 Ongoing mutations in FL: 
FL is a counterpart of normal GC B-cells that maintains its reactions including functional 
BCR and ongoing somatic hypermutation. Ongoing SHM leads to intraclonal variability in 
FL, and both SHM and BCR stimulation are necessary for FL viability and probably arise 
from lectins that react with IG variable regions on the surface of FL cells (86-88). 
Loeffler and colleagues studied the IGHV gene in different clones in FL by next generation 
sequencing (NGS) and confirmed the ongoing SHM process. They also suggested that a 
functional BCR and continuous AID stimulation induced ongoing IGHV mutation in 
46 
 
addition to ASHM to other important genes involved in FL pathology. This is important for 
genomic and epigenetic evolution and clonal diversity in FL (88). 
IGHV ongoing mutation was studied mainly by NGS in diagnostic, relapsed or transformed 
FL sequential samples, and it was found that relapsed or transformed FL mainly occur by 
divergent evolution from CPCs (70, 88-90).  
The first event in FL pathogenesis is suggested to be t(14;18). This is followed by acquiring 
additional mutations to make CPC population of FL precursor cells. Studies recently 
suggested that transformed FL arises from CPC by divergent evolution rather than by 
acquisition of new mutations in the same pathogenic clone (linear evolution) (Figure 1.6) 
(70). 
 
Figure 1.6: Ongoing mutation and divergent evolution of CPC clones in FL transformation and relapse. 
Ongoing SHM was studied in FL and transformed biopsies of the same patients. It was found that the branched 
divergent evolution rather than accumulation of mutations in the same clone was the principal route of relapse 
in many cases. Figure taken with permission and legend adapted from Okuson’s review (70). 
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1.2.3.5 The tumour microenvironment in FL: 
In B-cell lymphomas, the tumour microenvironment (TME) is a key player in their 
pathogenesis: this can be done by playing a role in controlling tumour cell proliferation and 
survival, helping malignant cells to escape immune surveillance and develop drug resistance 
(91). 
TME is composed of vasculature, cancer-associated fibroblasts, extracellular matrix and 
immune cells such as B and T lymphocytes, macrophages, FDCs, mast cells, neutrophils, 
and natural killer cells (92, 93). 
Chemicals released by TME cells can induce drug resistance, in addition drug therapy can 
be affected by adhesion between malignant cells to extracellular matrix or fibroblast, and 
effective malignant eradication probably can be achieved by targeting both malignant cells 
and specific TME components (92). 
The relationship between malignant cells and TME in B-cell lymphomas can involve any of 
the following three models: 
1- Re-education, as in the case of FL, where malignant cells are dependent on the 
microenvironment for growth and survival; the microenvironment here is similar both in 
arrangement and composition to normal lymphoid tissues. 
2- Recruitment, as in classical Hodgkin’s lymphoma, the malignant Reed-Sternberg cells 
recruit and get benefit from non-malignant supporting cells that are not similar in 
composition to normal lymphoid tissues. 
3- Effacement, as in Burkitt’s lymphoma and DLBCL, whereby genetic divergence, such as 
MYC translocation in malignant cells leads to self-determining, microenvironment-
independent growth and survival (94). 
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In FL, prognosis can be predicted from the composition of TME at diagnosis. Gene 
expression profiling divides TME into two immune signatures that predict survival (95). 
In addition, a correlation between different components of TME and malignant cells is 
important for predicting malignant transformation of FL to DLBCL or length of survival. 
A high percentage of tumour-infiltrating lymphocytes in FL that are PD1+ are less likely to 
undergo high-grade malignant transformation (96). Exhausted T cells in TME are also 
associated with poor survival (97). 
Time of transformation to DLBCL at diagnosis can be associated with high intrafollicular 
CD4+ T cells, CD68+ and PD-L1+ macrophage infiltration (98). 
Survival is decreased if the malignant follicles contain fewer dendritic cells and more T 
regulatory cells compared to hyperplastic lymphoid tissues (99). 
Malignant B and TME cells express programmed cell death ligand (PD-L1). This ligand 
binds to programmed cell death 1 (PD-1) of T cells. The PD-L1/PD-1 binding rescues cancer 
cells from T‑cell-mediated cellular cytotoxicity. Immune checkpoint inhibitors prevent this 
binding (100). 
Other therapeutic agents targeting the TME include chimeric antigen receptor (CAR) T-cell 
therapy, B-cell receptor signalling inhibitors and immunomodulatory drugs (91).  
1.2.4 Clinical features of FL: 
 
Painless lymphadenopathy, especially of cervical and supraclavicular nodes, is the most 
common presentation of FL, with bone marrow involvement usually occurring in about half 
of the patients at diagnosis (101). 
Involvement of retroperitoneal or mediastinal LNs can cause pressure effects on adjacent 
organs with large-sized nodes. Furthermore, dissemination of malignant FL cells to the 
circulation, bone marrow, spleen, liver and gastrointestinal tract (GIT) lymphoid tissues can 
occur (102, 103). 
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Exranodal involvement of the GIT, skin, lung, thyroid gland, ocular adnexa and other organs 
has been reported (104). 
The disease course differs among patients. Most commonly it runs an indolent course with 
multiple relapses and fluctuating lymphadenopathy over years; and about 80% of patients 
survive for about 8 years or more even without treatment (105, 106), while in others the 
disease becomes aggressive with rapid deterioration and sometimes death occurs rapidly 
(95). 
1.2.5   Laboratory features: 
1.2.5.1 Blood findings:  
In about 10% of FL patients, a high number of lymphomatous cells are found in the blood – 
i.e. a FL ‘leukaemia’ is seen (107). In the peripheral blood smear, these cells are small with 
a high degree of pleomorphism, with nuclear notches or clefts and a small rim of cytoplasm 
(108). Leukopenia, anaemia, a high erythrocyte sedimentation rate (ESR) and lactate 
dehydrogenase (LDH), are other possible serological findings associated with FL (109). 
1.2.5.2 Radiological investigations and imaging techniques: 
The simple, rapid and low cost diagnostic imaging techniques, such as conventional 
radiography and ultrasound, are yet to be frequently used in lymphoma clinical diagnostics. 
Radiological techniques mentioned below are used to check for deep nodal masses, whilst 
ultrasound is helpful for examining superficial and deep LNs in addition to abdominal 
visceral organs (110). 
The more advanced radiological techniques applied for the deeply-located masses include 
computed tomography (CT), used for both diagnostics and response to therapy assessment, 
are more commonly used compared to a decade ago (111). These also include positron 
emission tomography (PET) together with 18-F-fluorodeoxyglucose (FDG-PET) or with 
computed tomography (PET-CT). The latter techniques are regarded as the most sensitive 
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and specific imaging techniques for staging, detecting therapy response and disease 
surveillance in NHL (112). More recently, whole body magnetic resonance imaging (MRI) 
is suggested as an attractive technique for FL early diagnosis, staging and detecting bone 
marrow involvement (113-115).  
1.2.5.3 Histopathological diagnosis of FL: 
The diagnosis of FL only can be confirmed by histopathological examination of biopsied or 
excised LN; fine needle aspiration is usually not sufficient for reaching an unequivocal 
diagnosis (116). 
The biopsy should be adequate and core biopsies are only to be considered if excisional 
biopsies cannot be performed. Compared to excisional biopsies, core biopsies are less 
reliable in achieving a definitive diagnosis, and particularly for identifying the grade of the 
FL (117). 
Histopathological findings of a typical LN in FL includes: complete or partial effacement of 
the LN and replacement of its usual architecture by back-to-back atypical follicles, 
composed mainly of expanded neoplastic GC composed of large centroblasts with prominent 
nuclei and smaller centrocytes (Giemsa stain). The GCs are surrounded by an attenuated 
mantle zone (118, 119) (Figure 1.7). 
1.2.5.4 Immunohistochemical staining:  
A full or mostly partial panel of Immunohistochemical (IHC) staining in FL must be done 
to confirm the diagnosis before starting therapy. 
FL biopsies upon IHC staining are usually positive for B-cell markers (CD20 or CD79a) 
with the neoplastic cells also staining for CD10, BCL6 and BCL2. Only few CD3 positive 
T cells are seen in the GC (Figure 1.7) (93). They are negative for CD5 and CD23, 
differentiating them from chronic lymphocytic leukaemia (CLL), and for Cyclin D1, 
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differentiating them from mantle cell lymphoma (120-122). BCL2 protein is abnormally 
expressed by the neoplastic B-cells in the GCs in 65%-85% of FL cases (121-123).  
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Figure 1.7: Histopathology of FL, haematoxylin and eosin shows nodular follicles of malignant FL cells. These 
cells are positive for CD20 and BCL2 antibodies. CD3-stained T cells in the interfollicular area and a few T 
cells in the GC. Ki67 is usually used to illustrate proliferation in FL. Figure taken from and legend based on 
Coupland’s paper (93).  
1.2.5.5 Grading of FL: 
FL are categorised according to the WHO classification into three grades, FL grade 3 is 
further divided into 3A and 3B: 
Grade Histopathological microscopic criteria 
Grade 1 0-5 centroblasts per high power field (HPF) 
Grade 2 5-15 centroblasts per HPF 
Grade 3 >15 centroblasts per HPF 
Grade 3A Centrocytes are present 
Grade 3B Solid sheets of centroblasts 
Table 1.1: Grading of FL (41).  
It is recommended that at least 10 high power fields (HPF) are viewed for the grading of FL. 
Hence, it is difficult to ascertain the grade of an FL in small fine needle biopsies. 
1.2.5.6 Cytogenetics and molecular genetics:  
Investigating genetic abnormalities is performed as routine practice in diagnosing B-cell 
lymphomas: FISH can be performed on fresh or formalin-fixed paraffin-embedded (FFPE) 
tissue to confirm the presence of t(14;18). IGHV-polymerase chain reaction (PCR) may be 
undertaken to demonstrate clonality; however, due to the large number of somatic mutations, 
the primers may not bind, leading to false negative results. Further tests that may be 
undertaken, include analysis of further translocation breakpoints, microRNA profiles, gene 
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copy number variations, as well as NGS; however, these are undertaken more in the research 
area rather than for diagnostic practice (72). 
 
1.2.5.7 Next generation sequencing:  
NGS is a technique for DNA sequencing that revolutionized biology in the last decade; it 
increased speed, accuracy, diversity of genome sequencing and enabled sequencing the 
whole human genome at a cost of around $1,000 (124). 
Some advantages of NGS over older sequencing methods are, preparing NGS libraries 
instead of laborious bacterial cloning, multimillion sequencing reactions could be run at the 
same time instead of hundreds only by older sequencing techniques, and results are seen 
directly without the need for electrophoresis (125). 
However, an enormous amount of NGS data needs careful examination and analysis. For 
this reason, bioinformatics is considered an important part of the team generating NGS data, 
especially in laboratories applying NGS for clinical genetic testing (126). 
In FL, NGS research has allowed major discoveries in understanding disease pathology, and 
has enabled a better expectation of prognosis. It also facilitates understanding clonal 
evolution, disease transformation, enabling MRD detection and researching future targeted 
therapies in FL (72, 88, 127-129). 
1.2.6 Ann Arbor staging of FL: 
For the staging of FL, the Ann Arbor staging system is used (130). As shown in Table 1.2, 
this system involves the following: the number and locations of involved lymph node site as 
detected by physical examination and CT scanning, particularly of the abdomen and pelvis; 
a bone marrow aspirate and/or trephine; a complete blood picture and serological assessment 
of LDH, uric acid; and virological testing for human immunodeficiency virus (HIV), 
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hepatitis B and C virology screen. PET-CT increases the precision of staging of FL and needs 
to be used routinely (116). 
 
Stage Definition 
Stage I single LN group 
Stage II Two or more LN groups either above or below 
the diaphragm 
Stage III Involvement of lymph regions or structures on 
both sides of the diaphragm 
Stage IV Extranodal involvement 
In any stage of disease 
A No symptoms 
B Fever (>38oC), drenching sweats, weight loss of 
more than 10% of body weight within 6 months 
Table 1.2: Staging of FL (116, 130). 
1.2.7 Prognosis of FL:  
About 80% of FL patients can live with their disease for 10 years; however, some patients 
respond poorly to therapy and die early within two years (105, 106).  
Those patients with an indolent course have periods of disease progression with LN 
enlargement and systemic symptoms, and respond less well to therapy with each relapse 
(131). 
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Studies have identified several prognostic factors for FL: these include patient age and 
gender, size of tumour, extent of systemic manifestation, LDH levels, tumour stage, and β2-
microglobulin levels (132). 
Different prognostic algorithms have been proposed for FL. The most well accepted and 
widely used algorithms is the “Follicular Lymphoma International Prognostic Index” 
(FLIPI) score. It was established following a study on 4,167 patients, which took into 
account several clinical factors, including patient age, the Ann Arbor stage, LDH levels, the 
number of involved LNs, and haemoglobin level (133, 134). A revised version of the test 
called (FLIPI 2) was subsequently introduced (132), whereby different LN measurements 
were used, β2-microglobulin replaced LDH and bone marrow involvement replaced Ann 
Arbor stage III or IV (See Table 1.3). 
  
 
 
 
 
 
 
 
 
 
Table 1.3: Comparison of FLIPI1 and FLIPI2 prognostic parameters for FL. 
 
Another system, called the Groupe d’Etude des Lymphomes Folliculaires (GELF) Criteria, 
takes into account the number and size of LNs, the presence/absence of organomegaly 
Parameter FLIPI 1 FLIPI 2 
LNs  >4 LN sites Longest diameter of 
biggest LN > 6 cm 
Age >60 years >60 years 
Serum level LDH > upper normal limit β2-microglobulin > 
upper normal limit 
Haemoglobin 
concentration 
<12.0 g/d <12.0 g/d 
Clinically Ann Arbor Stage III or IV Bone marrow 
involvement 
56 
 
particularly splenomegaly, the presence/absence of B symptoms, the presence/absence of 
plural or peritoneal effusions, and the LDH or β2-microglobulin levels (116, 135). 
Recently, a scoring system based on the presence/absence of mutation in 7 genes in FL has 
been introduced, and termed (m7-FLIPI). These genes are EZH2, CREBBP, MEF2B, EP300, 
FOXO1, ARID1A and CARD11, in addition to FLIPI, The Eastern Cooperative Oncology 
Group (ECOG) demonstrated that it offers a better prediction of OS and failure-free survival 
(FFS) in FL patients receiving the first chemoimmunotherapy (129). 
1.2.8 Transformation of FL to high-grade aggressive disease: 
Transformation of FL is the histological conversion of low-grade FL (grade 1 or 2) to an 
aggressive high-grade NHL (i.e. grade 3 FL) or to DLBCL (71). DLBCL have 2 major 
subgroups, these are activated B-cell germinal centre subtype (ABC) and germinal centre B-
cell-like (GCB). The two groups are totally different in disease pathogenesis, molecular 
signature and survival rate (45, 136).   
FL transforms to DLBCL, with 80% of the cases to the GCB subtype compared to 16% of 
patients who transform to the ABC subtype (137).  
This high-grade transformation is diagnosed by histopathological examination, centrocytes 
and centroblasts are converted to irregular sheets of malignant cells with loss of follicular 
pattern. However, if no tissue is available, the transformation can be detected clinically by 
enlarging nodes or the appearance of extranodal growth, elevated LDH, B symptoms, 
hypercalcaemia or the detection of active sites by PET (59). 
Some recent genetic studies on serial or paired indolent and transformed FL found that the 
transformation clone is related to a common progenitor clone. Furthermore, a divergent 
transformation rather than a linear transformation of FL is probably a common rather than 
rare model; this was discussed earlier in Section 1.2.3.4 of this chapter (88, 138-140).   
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Pasqualucci and colleagues found that many FL transformation-associated genomic changes 
were seen in genes that are targeted by AID. She found that the mutations, deletions and 
duplications in these genes are typical for AID-induced aberrations, and these changes were 
absent before transformation, suggesting AID aberration played a role in transformation of 
FL (139). 
Loeffler and colleagues studied clonal evolution in FL, and suggested that AID and CREBBP 
genes are the key genes in co-evolution in FL (88). Correia and colleagues also observed 
that AID expression and BCL-2 mutation are correlated with higher transformation risk and 
death in FL (141). 
Further studies are needed to explore more the role of AID in FL transformation, particularly 
through inducing ASHM (71, 139). 
1.2.9 Treatment of FL: 
For the minority of patients with Ann Arbor Stages I and II disease at diagnosis, localised 
radiotherapy is used. For most patients with Stage 3 or above disease, the treatment in the 
last 3 decades has typically been anthracycline-based, with the most common protocols 
being either cyclophosphamide, vincristine and prednisone (CVP) or cyclophosphamide, 
doxorubicin, vincristine, and prednisone (CHOP) (142). 
The introduction of rituximab (R), which is an anti-CD20 antibody, in the last decade and 
adding it to chemotherapy has improved OS and response rate in FL patients in many clinical 
trials (143-145). 
1.2.9.1 Treatment options:  
There is no standard first-line nor curative treatment for FL, therapy options often rely on 
and are not limited to stage of disease, tumour burden, age and associated illness; also, 
treatment choices differ between different physicians and oncology centres (146, 147). 
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However, treatment can be divided into first-line therapy, maintenance and relapse treatment 
of patients, and in each stage of treatment, the therapy is largely dependent on stage of FL 
and tumour burden (116). 
1.2.9.1.1 First-line therapy: 
Induction treatment of FL differs according to disease stage, as follows: 
1-Stage I and II: In the case of localised disease, radiotherapy using 24 Gray is the favoured 
approach currently (148). Sometimes a ‘watch-and-wait’ approach is chosen if the patient 
declines to undergo radiotherapy, or if there is associated comorbidity (149). 
2- Stage III and IV disease: 
These represent the majority of patients, curative treatment is not yet available, and only 
symptomatic nodal and extranodal patients are treated, those with B symptoms, affected 
organ function or cytopaenia (150). 
No survival advantage of therapy over the ‘watch and wait’ approach was noted whether 
before rituximab treatment (135, 151) or during the rituximab era, despite the improved PFS 
endpoint on rituximab treatment (152). However, one study showed that for a symptomatic 
patient, rituximab induction with no maintenance decreased the life-time cost of treatment 
(153). 
So, commonly used induction treatment includes rituximab plus chemotherapy including 
either CHOP (154). 
 R with CVP, is an alternative to R-CHOP; however, a study found that R-CHOP has better 
PFS and longer time to treatment failure but still no difference in overall survival (155). 
Bendamustine with rituximab showed longer PFS and less toxic effects than R+CHOP (156) 
with quality of life being better for R and bendamustine compared to R-CHOP or R-CVP 
(157). 
1.2.9.1.2 Maintenance therapy for FL: 
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Rituximab maintenance after chemoimmunotherapy has been shown to improve PFS with 
less drug toxicities and a better tolerance (158, 159). However, in elderly patients, the PFS 
is inferior and the risk of infection is higher compared to younger people on rituximab 
maintenance (160). 
Radioimmunotherapy maintenance in FL was demonstrated to prolong PFS in one trial 
(161); however, in another trial, which compared using radioimmunotherapy after either 
CHOP or R-CHOP, it was shown that there was no difference in PFS (162). 
1.2.9.1.3 Treatment of relapsed FL: 
When relapse of disease occurs, a repeat biopsy is required to exclude transformation of FL 
to DLBCL. If the tumour burden is low on recurrence, a ‘watch and wait’ strategy is an 
option for asymptomatic patients, whilst rituximab monotherapy is advised in symptomatic 
patients.  
Using another treatment regimen is recommended to avoid the development of tumour 
resistance, and the relapsed treatment regimen administered will depend on the response to 
first-line therapy (116). 
Rituximab with bendamustine is considered to be more effective than rituximab with 
fludarabine in relapsed patients (163). 
Another recently introduced anti-CD20 antibody, Obinutuzumab, was shown to be effective 
when administered with bendamustine. This combination is followed by obinutuzumab 
maintenance showed better efficacy compared to bendumastine alone in relapsed patients 
not responding to rituximab (164). It was also shown that this antibody is effective and 
tolerable if combined with bendamustine or CHOP in induction treatment of FL followed by 
obinutuzumab maintenance (165).  
Allogeneic or autologous hematopoietic cell transplantation (HCT) in relapsed patients is 
controversial in FL (166). 
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The PI3Kδ inhibitor, Idelalisib monotherapy, was shown to have a good effect with an 
acceptable safety profile in patients with multiple FL relapses (167). 
1.2.9.2 Updated research and new approaches for treating FL: 
Drugs with different mechanisms of action against FL are under clinical trials including: 
1-Monoclonal antibodies: 
Several monoclonal antibodies are under trials, but their effects are yet to be confirmed by 
phase III trials. One of the most promising is ‘next generation’ anti-CD20 as obinutuzumab 
(168). 
Other than anti-CD20 antibodies, there are trials on many other antibodies that are given 
with rituximab; for example, Pidilizumab (anti-PD1) and rituximab (169), Epratuzumab 
(anti-CD22) +rituximab (170). 
2-Immunomodulators:  
An example of an immunomodulatory drug is lenalidomide, which acts as a tumoricidal and 
immunomodulatory agent (171). 
Many clinical trials have been performed to investigate lenalidomide performance against 
FL, either alone (172) or in a synergistic combination with rituximab, with promising results 
(173).  
3. Phosphatidylinositol 3-kinase (PI3K) inhibitors: 
The PI3K enzymes are vital for many functions, such as cellular metabolism, apoptosis, cell 
cycle regulation and DNA repair. By activating these enzymes, various intracellular 
pathways are activated, resulting in cell growth and proliferation (174). 
Idelalisib, which targets delta isoform of PI3K, showed promising results in FL patients that 
are refractory to rituximab and alkylating agents, and it was approved by the US Food and 
Drug Administration (FDA) recently as a single agent for treating relapsed FL (167, 175).  
4. Bruton tyrosin-kinase (BTK) inhibitors: 
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BTK is a vital component of B-cell receptor signalling in B-cell lymphoma (176). Ibrutinib 
irreversibly inhibits BTK, and thereby block signals for cell growth and survival. It is also 
under scrutiny in clinical trials as a monotherapy or part of combination therapies in FL 
(174). 
5- Other drugs: 
Several other drugs are under study: for example, drugs activating the immune response 
against cancer using anti-PD-1 antibodies or inhibiting EZH2 or BCL2, using CAR T cells 
etc. (177). Finally, it is important to know that not only new drugs are under investigation, 
but also new methods of administration, a study showed that subcutaneous rather than 
intravenous R administration in FL and other NHLs reduced the cost of treatment in addition 
to decreasing time required for patient hospitalization and health care professionals’ 
engagement with patients (178). 
1.2.9.3 The criteria for treatment responses: 
To assess the prognosis of patients in FL, imaging techniques using PET–CT predict poor 
prognosis with positivity in PET after chemotherapy induction (179). As mentioned above, 
FDG-PET is also found to be an important prognostic and PFS predictor (180).  
1.2.10 PACIFICO clinical trial: 
The PACIFICO (Purine-Alkylator Combination In Follicular lymphoma Immuno-
Chemotherapy for Older patients) trial is a phase III clinical trial that compares first-line R 
with cyclophosphamide, vincristine, and prednisone (R-CVP) versus R, fludarabine and 
cyclophosphamide (R-FC). Patients who achieve a complete or partial response to induction 
therapy receive maintenance therapy with rituximab for 2 years and are followed up for at 
least a minimum of 3 years from trial entry. The primary endpoint is PFS. Recruitment 
ceased on 30th April 2016 with a total of 369 patients randomised from across the UK. A 
sufficient number of primary events is expected to have accumulated to enable reporting of 
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results in October 2018. The trial is led by my Ph.D. primary supervisor (ARP). The FFPE 
tissue samples for most of the patients were stored in the trial tissue bank and were available 
for this project. Clinical and laboratory data are collected and managed by the LCTU and 
were available for analysis in this project.  
Criteria for including a patient in the trial were: 
1- Histological confirmation of FL.   
2-Ann Arbor stage II-IV.  
3-Aged 60 years or over, or aged less than 60 but anthracycline-based therapy is contra-
indicated. 
4-No systemic cancer therapy before.  
5-Acceptable haematological parameters (Haemoglobin ≥ 8.0 g/dl, Absolute neutrophil 
count (ANC) ≥ 1.5 x 109/L, Platelet count ≥ 100 x 109/L.  
6- Written informed consent. 
The objective of this trial is to explore the best treatment approach for elderly patients with 
FL, who represent the majority of patients.  
The PACIFICO trial is testing the hypothesis that R-FC may be more effective than R-CVP 
in older patients with FL without necessarily being more toxic, R-CVP being the current 
gold-standard for such patients. Only few data are currently available for tolerance and side 
effects of R-FC treatment in elderly patients with FL and other NHLs (181). 
1.3 AID: 
1.3.1 Structure and chromosomal localization:  
AID is a member of the AID/APOBEC (Apolipoprotein B mRNA Editing enzyme Catalytic 
polypeptide-like) family, which is able to deaminate cytidine, converting it to uracil in 
vertebrates; it was discovered by the Muramatsu group in 1999 (182). 
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It is encoded by its gene AID which is located on chromosome 12p13. This gene consists of 
five exons and encodes AID protein. AID protein is 24kD, and consists of 198 amino acids 
that contain the active deaminase site, and its structure is closely related to the APOBEC1 
mRNA-editing enzyme (182-184). AID consists of an N-terminal domain which is essential 
for SHM, and a C-terminal that is essential for CSR (185-187). 
AID moves between the cytoplasm and nucleus by a nuclear-localization sequence (NLS) at 
the N-terminal end and a nuclear export signal (NES) at the C-terminal end. AID also 
contains a 39-amino-acid cytidine deaminase domain and a larger APOBEC-like domain 
(about 60 amino acids) (185, 187) (Figure 1.8). 
1                                             55                                94        108                                184            198                                               
NLS Catalytic domain APOBEC-like domain NESNH2 COOH
 
Figure 1.8: Structure of AID protein, NLS; nuclear-localization sequence, NES; nuclear export signal. Figure 
based upon a review and box 1 of  Zhenming Xu and colleagues (188). 
For efficient CSR, DNA breaks require a functioning C-terminal end of AID (183). 
Due to the structural similarity of AID to APOBEC 1, it had been thought that AID was an 
RNA editing enzyme (182); however, it was later determined that it deaminates single-
stranded DNA (189). 
AID acts mainly on IGV genes. Recently, several elements were found to be responsible for 
making AID target this gene, including non-coding RNA and genomic architecture (190). 
AID-deficient mice fail to develop SHM or CSR and have large GC in LNs (191). In 
addition, mutated AID has been found in patients with hyper IgM syndrome who failed to 
develop CSR, and had high IgM level and immune deficiency (35, 192). 
1.3.2 Function of AID in normal B-cell maturation: 
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AID targets single-stranded DNA and deaminates deoxycytidine, converting it to 
deoxyuridine (193). This creates a defect in the DNA sequence, which induces subsequent 
changes through four mechanisms (Figure 1.9): 
1-A change of uridine to adenine and DNA replication with mutation (194). 
2-Uracil DNA glycosylase (UNG) removes the deoxyuridine, which is further cleared by 
apurinic-apyrimidinic endonuclease (APE) nicking the ssDNA, then it will be acted on by 
error-free replication or polymerase mediated repair to create any mutation (193). 
3-DNA mismatch repair enzymes (MMR) repair with excision of nucleotides surrounding 
the mutated one, followed by error-prone polymerases (EPP) to produce any mutation, and 
deficiency of either of those sets of enzymes affects the process of SHM (195, 196). 
4-Repair by homologous recombination if the twin chromatid template is available (197). 
                                                  AID                    C  
         UNG and APE                                             G                                                  MMR 
 
                                                                                U                                                 X X X X     
                  G                                                           G                                             
 
            G,C,T,A ?                                                                                                        EPP 
            C,G,A,T ?                                                
                                                                                                                                   G,C,T,A?       
                                                                                                                                   C,G,T,A? 
                                               HR repair                               Replication 
                                                     C                                                T 
                                                     G                                                A                                                                                               
                                                                           
                                                                                             Point mutation 
 
 
       
Figure 1.9: Consequences of AID deamination of cytidine to uridine. Either a replication of uridine occurs 
leading to point mutation, or UNG and APE remove the uridine leading to any mutation. Alternatively MMR 
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enzymes remove the mutated uridine and surrounding nucleotides causing any mutation. Finally a homologous 
recombination repair may occur. UNG; Uracil DNA glycosylase, APE: Apurinic-apyrimidinic endonuclease, 
MMR; Mismatch repair enzymes, EPP; Error-prone polymerase, HR; homologous recombination. Figure 
based on reviews by Casellas and colleagues, and Kumar and colleagues (8, 198).    
 
1.3.3 Potential role of AID in FL: 
1.3.3.1 Initiating DNA damage in B-cells and its potential roles in genomic instability: 
Transition mutation of C to T is the commonest mutation found in cancers, and cytosine 
deamination was suggested to be the possible mechanism. Thus, studies in B-cell lymphoma 
cell lines found that uracil was positively correlated with AID mRNA and protein 
expressions. In addition, it was discovered that stimulating AID expression in B-cells 
increases the genomic uracil many fold. On the other hand, knocking out AID reduces uracil 
(199).  
Additionally, AID is able to induce DNA mutations at non-IG gene loci including genes 
involved in B-cell transformation, as BCL6, MYC, BCL7A and MSH6 (200). Furthermore, 
AID induces genomic instability, gene structural lesions and translocations that are 
important in the pathogenesis of B-cell lymphoma (201). 
Single-stranded DNA in the R-loop (which is a three-strand gene structure composed of 
RNA-DNA hybrid and single stranded DNA) is particularly targeted by AID in IG and non 
IG genes, increasing mutations and is associated with DNA damage (202). 
AID is hypothesised to induce DNA double-strand breaks in both IG and MYC genes, 
allowing translocation to occur and inducing pathogenesis of Burkett’s lymphoma (203). 
To our knowledge, there are no detailed studies that have examined the role of AID in FL 
pathogenesis.  
1.3.3.2 Role of AID in ongoing IGV SHM: 
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The study of genomic clonal evolution of FL by NGS revealed a correlation between 
ongoing mutation in the IGHV gene and tumour evolution, suggesting a significant role of 
AID with disease progression (88).  
The mechanism behind ongoing mutation is suggested to be either as a result of reaction 
with self-antigens (204), or by binding of oligomannose in the tumour microenvironment to 
the variable region of BCR (205, 206), where BCR is essential for survival of B-cells (36). 
 
 
1.3.3.3 Hot motifs of AID-induced mutation: 
During CSR, it was noted that AID targets WRC/GYW motifs in the switch region of the IG 
gene (R = purine nucleotide, Y = pyrimidine nucleotide, and W = A or T base). This is called 
canonical AID induced mutation (190, 207, 208).Another hotspot for AID is the non-
canonical AID induced mutation targeting WA/TW (208-210) . 
Such motifs are more common in IGV genes compared to the whole genome (211). In SHMs, 
AID is directed to act upon these motifs in productive and non-productive alleles of the 
IGHV gene (212). While in CSR, transcription targets AID to these spots (213). 
1.3.4 Regulation of AID: 
The body can control the expression and activity of AID by the following adopted 
mechanisms. 
1.3.4.1 AID Transcription: 
Several factors play a role in controlling AID transcription. Four regions of AID DNA 
control AID expression. In region I, the gene promotor contains binding sites for NF-κB, 
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HOXC4 and Sp1 that induce AID expression by activating the promoter (214, 215).  Region 
II contains binding sites for E2f and c-Myb, and these silence AID (216).   
While AID expression is induced by IL-4 and CD40 ligation (217), E proteins (218) PAX5 
activate AID transcription (217, 219).   
Region III is a BATF-binding gene segment downstream of the AID gene, and is responsible 
for maintaining physiological AID expression by an unclear mechanism (220). 
Region IV is upstream of the AID gene and has enhancers binding NF-κB, STAT6, and 
SMAD3/4 (221). 
 
Region IV                        Region I                        Region II                 Region III                 
(Enhancer)                     (Promoter)            (Enhancer, Silencer)
NF-κB STAT6   SMAD3/4 NF-κB HOXC4   Sp1
IL-4 and CD40, E proteins 
and PAX5 (Enhancer)
E2f,  c-Myb (Silencer)  
BATF
AID gene
-9224                                            -7424       -1500                            +101        +121                  +2221         +16272      +18378
 
Figure 1.10: Binding regions for factors controlling AID transcription; distances of these regions were in base 
pair (bp) from transcription start of the gene. Figure based on review by Casali and colleagues, and other papers 
(215, 217, 219, 222). 
Further, there are miRNAs that downregulate AID, such as miR-155 and miR-181b, by 
binding to the 3′ untranslated region of AID mRNA (223, 224). It is believed that miR-181b 
downregulates AID in earlier stages, while miR-155 acts to control excessive AID 
expression and accumulation (225). 
The presence of AID splice variants inactivates SHM and CSR, suggesting it as a protective 
mechanism against mutagenic effects of AID (226). 
1.3.4.2 Post-translational modification: 
Another way of regulating AID activity is by post-translational modifications (PTM). 
Phosphorylation of many amino acids have been identified as a PTM of AID. S38 
phosphorylation in a mouse model is essential for SHM and CSR, with more than 70% 
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decrease in SHM and reduction of CSR to nearly background level in S38-mutated mice 
(227). 
Other sites of phosphorylation involved in AID regulation include S3, T27, S41, S43, T140 
and Y184 (214).Ubiquitination is another post-translational control mechanism of AID 
reducing its half-life (228). 
 
 
 
1.3.5 Cellular localization of AID: 
Although AID functions in the nucleus, it is mostly located in the cytoplasm, and it can 
shuttle in and out of the nucleus due to the NLS at its N terminal and NES at the C terminal 
(185).  
Because AID induces mutations in many genes, the cellular localization of this protein is 
strictly controlled. This includes storing of the protein in cytoplasm rather than nucleus, in 
addition to active and efficient nuclear import and export mechanisms (190). 
The NES binds to Chromosomal Maintenance 1 (CRM1) protein, directing AID out of the 
nucleus. NES is also essential for AID stabilization and CSR (229, 230). 
Sub-nuclear AID location is found in conjugation with essential cellular spliceosome and 
splicing organelle suggesting the regulation of AID function by transcription associated 
with splicing (231). 
NLS directs AID to the nucleus to be associated with CTNNBL1, nucleolin and 
nucleophosmin, and it is directed out of the nucleoli by the C-terminal end. It has been found 
that CSR is directly associated with the extent of nuclear import (232). 
1.3.6 AID targets: 
At least 236 genes have been found to be targeted by AID, using sensitive techniques (200). 
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AID targets the IG gene primarily; however, it can target and induce mutations in a large 
number of non IG genes in B-cells, including CD79A and B, BCL6, PAX5, and Myc, causing 
genomic instability (233, 234). 
Researchers have found that AID targets a larger range of tumour-associated genes than 
originally thought. It induces genomic instability and chromosomal translocations, and only 
about 25% of these mutations are protected by DNA repair mechanisms (63). 
Further ectopic AID expression in non-B-cells was found to be associated with tumour 
development (235). 
1.3.7 Correlation between AID and cancers: 
Aberrant AID activity is closely correlated to oncogenic translocations, which is the 
pathology behind many B-cell malignancies (198). Also, B-cell lymphoproliferative 
disorders of the head and neck were associated with increased AID expression and 
lymphogenesis (236).   
In DLBCL, AID expression was found to be linked to poor prognosis in patients treated with 
CHOP chemotherapy (237). 
A high level of AID is suggested to be involved in the pathogenesis of a subset of human 
lung cancers, and a positive correlation between AID mRNA level and TP53 mutation had 
been found in these tumours (238). 
Also, high AID had been found in malignant cells of oral squamous cell carcinoma (239). 
Regarding skin cancer, inflammation-associated aberrant AID expression was found to 
enhance skin cancer development, in a mechanism that is unrelated to ultraviolet light 
damage to the skin (240). 
Malaria infection has also been found to be associated with inflammation-related increase of 
AID level, leading to B-cell malignancies (37). 
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Chronic active gastritis by Helicobacter pylori infection causing chronic active gastritis was 
found to be associated with high AID expression that mutates TP53 , CDKN2B and 
CDKN2A, and promotes the development of gastric cancers (241). 
Finally, ovarian serous carcinoma was hypothesised to be linked with inflammation-induced 
aberrant AID expression (242). 
Because of the association of AID with a large diversity of cancer types, efforts are ongoing 
to investigate the possibility of targeting AID expression in a mouse model and cell lines 
(243, 244). 
 
1.3.8 Methods used for measuring levels of AID expression: 
1.3.8.1 AID mRNA level: 
Small RNA and miRNA extracted from FFPE specimens are the best material to be used for 
retrospective molecular analysis (245).  
In addition, FFPE tissue is the largest source for tissues that can preserve tissue architecture 
and allows protein-based analysis as IHC (246). Many factors affect quantity and quality of 
nucleic acids extracted from FFPE samples. These include the time period between the 
surgical extraction and fixation, the type and duration of the fixative, storage conditions and 
sample thickness (247).  
DNA and RNA are never intact in FFPE tissues compared to those in fresh samples. 
However, selected nucleic acid extraction kits may improve the quantity and quality.In 
addition, placing tissues in storage reagents gives a better yield than in FFPE blocks alone 
(248). 
1.3.8.2 AID at protein level: 
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Different methods have been used to detect AID protein expression. Pettersen and colleagues 
measured AID protein in B-cell lymphoma cell lines using western blotting and mass 
spectrometer, and found that expression is similar using both methods, and that AID protein 
was significantly positively correlated to AID mRNA expression (199). 
Cantaert and colleagues measured AID protein levels from healthy human B-cell lines by 
western blotting, and from human tissues by IHC and immunofluorescence (IF) (249).  
Antibodies specific for AID protein have been used for IHC and IF in many studies with 
FFPE tissues from B-cell lymphomas (237, 250), for western blotting using cell lysates (37, 
237, 251-253), or for immunoprecipitation of AID protein (254). 
 
1.4. Hypotheses of this thesis and approaches applied: 
1.4.1 Hypothesis: 
The level of AID activity varies between individual patients with follicular lymphoma, high 
levels of AID activity being associated with more gene mutations and adverse clinical 
features.  
1.4.2 Experimental approach: 
1.  Measure AID expression at mRNA (by qPCR) and protein (by IHC) levels. 
2.  Measure AID function as the nuclear/cytoplasmic (N/C) ratio of AID, and as total, AID-
related and ongoing IGHV mutation. 
3.  Correlate AID expression and function with clinical features and the expression of genes 
in the FL microenvironment that are associated with prognosis.  
1.4.3 Outline of thesis: 
1- Chapter 1: Introduction to thesis. 
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2- Chapter 2: Materials and methods used. 
3- Chapter 3: Optimization of RNA and DNA extraction from FFPE tissue samples of FL.  
4- Chapter 4: AID expression in FL. 
5- Chapter 5: Correlation between AID expression and ongoing IGHV mutation in 
FL.  
6- Chapter 6: Investigation of relationships between transcriptional levels of genes 
associated with T cells and macrophages and AID expression in lymph node tissue, and 
their correlations with clinical status of FL.  
7- Chapter 7: Correlations between AID expression and function against clinical outcome 
of FL. 
8- Chapter 8: General discussion. 
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Chapter 2 
 
Materials and methods 
 
 
This chapter describes the patient samples, materials and procedures used throughout this 
study.  
2.1 Tissue samples used in experiments: 
2.1.1. Patients: 
All patients included in this study had typical FL as diagnosed using the criteria of the WHO 
classification (45, 255). They were from a national clinical trial termed the “PACIFICO” 
(n=87), with the Principle Investigator being one of my supervisors (ARP). Informed written 
consents had been obtained from all patients to donate their samples for research.  
2.1.2 FFPE tissue samples from local Biobank:  
Three FL and 2 NHL, in addition to two hyperactive tonsil samples, were taken from the 
Liverpool BioInnovation Hub (LBIH) Biobank to undertake the optimization experiments 
for RNA and DNA extraction from FFPE specimens. Clinical data of the 5 samples are 
presented in Appendix Table 2. 
2.1.2.1 Storage conditions and duration: 
FFPE samples from LBIH had been prepared according to standard procedure guidelines 
(256), stored in the dark at room temperature for a period between 132 and 252 (132, 180, 
192, 240 and 252) months before being analysed. 
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2.1.3 Tissue samples from the PACIFICO trial: 
2.1.3.1 Patient consent and diagnosis criteria: 
FFPE lymph node samples from 87 patients of PACIFICO trial were used in this project.  
The clinical data of these patients at time of sampling are included in Appendix Table 1. 
2.1.3.2 Storage conditions and length: 
Samples were stored at room temperature in the dark for 1-108 months (the median being 
24 months). 
2.2 Control cell lines and tissue culturing:   
2.2.1 Raji and K562 cell lines: 
Both Raji (a B-cell line, derived from a Burkitt′s lymphoma patient) (257) and K562 (a 
myeloid cell line, derived from a chronic myeloid leukaemia clone) (258) cells were used as 
positive and negative controls, respectively, in a Real Time-quantitative Polymerase Chain 
Reaction (qPCR) study on AID mRNA expression. They were kindly provided by Dr. Chloe 
Clapham and Dr. Claire Lucas (University of Liverpool), and were cultured under conditions 
described in Section 2.2.2 (below) before being harvested for RNA extraction. Both cell 
lines were free of mycoplasma infection, as tested before and during culture by departmental 
technicians using the e-Myco TM Mycoplasma PCR Detection Kit (Intro Biotechnologies, 
Seongnam-si Gyeonggi-do, Korea). DNA of Raji cells was also used as a positive control in 
analysis of ongoing mutations in IGHV genes (Chapter 2, Section 2.4.5).  
2.2.2 Culture, passaging and quantitation of Raji and K562 cells: 
The cell lines were cultured in Roswell Park Memorial Institute medium-1640 (RPMI-1640) 
+ 10% Foetal Calf Serum, 100 U/ml penicillin, 0.1 mg/ml streptomycin and 2mM L-
Glutamine) (all obtained from Sigma Aldrich, Gillingham, UK) in vented Nunc T75 flasks 
(Thermo Fisher Scientific, Warrington, UK) in a tissue-culture incubator (Panasonic MCO-
170AICUV, Gunma, Japan) set at 37oC and supplied with 5% CO2.  
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For growth maintenance, these cells were split every three days at a ratio of 1:3 cells to pre-
warmed media in the same culture conditions. 
Cell viability and density were measured using a Cellometer TM AutoT4 cell counter 
(Nexce1om, Massachusetts, USA). Briefly, the diluted cells were mixed with 0.1% Trypan 
blue (Thermo Fisher Scientific, UK), this allowed the trypan blue to be taken into non-viable 
cells and visualised under microscope (259). Then, dead blue-stained cells and the shiny 
bright viable cells were quantified using a Cellometer counting chamber (Nexce1om, 
Massachusetts, USA), according to the manufacturer’s instructions. 1x107 cells were 
harvested after a few passages of culture, in order to produce sufficient amounts of RNA and 
DNA. 
2.2.3 RNA and DNA extraction from cell lines: 
DNA and RNA extraction from Raji and K562 cell lines was performed using an AllPrep 
DNA/RNA Mini Kit (Qiagen, Manchester, UK), following the manufacturer’s instructions. 
1x107 cells were used for each DNA/RNA column. They were transferred into 15ml 
centrifuge tubes (Greiner Bio-One, Stonehouse, UK), then centrifuged at 300 x g for 5 mins. 
With the culture medium being removed, the cells were lysed in 600µl Buffer RLT and then 
centrifuged through a Qiashredder column (Qiagen, Manchester, UK) for homogenization 
and removal of cell debris. The homogenized lysate was subsequently transferred to an 
AllPrep DNA spin column and centrifuged for 30 sec at 8000 x g. The flow-through was 
collected for RNA preparation.  
For RNA isolation, the flow-through was mixed with 350μl of 70% ethanol. Following this, 
700µl of the mixture was centrifuged through an RNeasy spin column. The column was 
washed with 700µl Buffer RW1 and 500μl Buffer RPE sequentially by centrifuge at 8000 x 
g for 15 sec. The RNeasy spin column was then placed in a new collection tube and the total 
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cellular RNA was eluted from the column with 50μl RNase-free water in a centrifuge at 8000 
x g for 1 min.  
For continuing genomic DNA preparation, 500µl Buffer AW1 was added to the AllPrep 
DNA spin column.  After centrifugation, the column was washed with 500µl Buffer AW2. 
The spin column was next put into a new collection tube, and the DNA in this column was 
finally eluted using 50µl Buffer EB twice by centrifugation after incubation at room 
temperature for 1 min.  
2.3 RT-PCR experiments: 
2.3.1 RNA extraction from FFPE tissues: 
RNA was needed to synthesize cDNA to perform qPCR for quantifying expression of AID 
and endogenous control gene (EC gene). It was also required for measuring expression of 
other genes in cells of the FL microenvironment which might correlate with expression of 
AID.  
Total cellular RNA was extracted using the RNeasy FFPE kit (Qiagen, Manchester, UK). 
The method was optimized for a starting amount of FFPE tissue as low as 2 sections of 4µm, 
instead of up to 8 sections of 10 µm in the recommended protocol. Each section was 
deparaffinized in 160μl of deparaffinization solution (Qiagen, Manchester, UK) in a separate 
microcentrifuge tube in a 56°C heating block for 3mins, 150μl Buffer PKD was added and 
centrifuged. This was followed by digestion of proteins in the RNA-containing lower phase 
with 10μl proteinase K and incubation sequentially at 56°C and at 80°C each for 15mins. 
After pooling the lower phase from the two sections into a new microcentrifuge tube, the 
RNA-containing fraction was incubated on ice for 3 mins and then centrifuged for 15 mins. 
In the same tube, the DNA was digested with 20μl DNase I and 10μl DNase I booster buffer 
at room temperature for 15 mins, before it was mixed with 320μl Buffer RBC and 700μl 
ethanol (100%).  
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700μl of the RNA-containing solution were next centrifuged through an RNeasy MinElute 
spin column at ≥10,000 rpm in a benchtop microcentrifuge. The flow-through was discarded 
and the step was repeated once for the remaining solution. In the wash step, the RNeasy 
MinElute spin column was washed twice, each with 500l of Buffer RPE and centrifugation 
at the same speed.  
After centrifugation at 14,000 rpm in the same centrifuge for 5 mins with the tube lid open, 
RNA in the RNeasy MinElute spin column was finally eluted into a fresh tube with 30l of 
RNase-free water by centrifugation at 14,000 rpm for 1 min.  
RNA isolation with deparaffinization was performed also by ReliaPrep™ FFPE Total RNA 
Miniprep System (Promega, Southampton, UK) during comparison to choose the best 
extraction kit, the steps are almost similar RNeasy FFPE kit but the deparaffinization was 
done using mineral oil rather than Qiagen depparafinization solution. 
2.3.2 Detection of RNA quantity by Qubit® 2.0 fluorometer:  
RNA and DNA quantity was measured using a Qubit® 2.0 Fluorometer instrument and a 
Qubit™ RNA BR Assay Kit for RNA detection in the range of 2-1000 ng/µl and Qubit™  
dsDNA BR Assay Kits for DNA with a scope of detection between 100 pg/µl to 1000 ng/µl. 
The instrument and both kits were obtained from (Thermo Fisher Scientific, UK). The 
concept involves using fluorescent dyes that bind specifically to RNA and DNA molecules, 
producing a fluorescent signal. It is more specific and accurate than the Nanodrop 
spectrophotometry method, which tends to overestimate RNA and DNA (260, 261). 
Working solutions were prepared by mixing Qubit® dsDNA BR Reagent with buffer in a 
ratio of 1:200. RNA BR Low and high RNA standards were supplied to obtain a standard 
curve; 10µl standards and 1µl of RNA totalled 190µl and 199µl of working solution, 
respectively; mixtures were vortexed and incubated for 2 mins, fluorescence measured and 
concentrations given in ng/µl. 
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2.3.3 Detection of RNA quality: 
RNA quality can be detected accurately using an Agilent Bioanalyzer 2100 (Agilent 
technologies, Shrewsbury, UK). We reported RNA quality by using a value termed ‘RNA 
integrity number’ (RIN). RIN ranges from 1 for totally degraded RNA to 10 for intact RNA 
(262).  
The method is based on gel electrophoresis separation of molecules according to molecular 
weight, and associated fluorescence is detected by laser; 18S and 28S ribosomal RNA peaks 
can then be visualised (262). 
The RNA 6000 Nano Kit was used, which detects RNA at a range of 25–500 ng/μl, and the 
experiment was performed according to the manufacturer’s instructions. We prepared the 
gel mix by adding 1µl of dye to 65µl of the gel, vortexing and centrifuging at 13,000 g for 
10 mins. 
Machine electrodes were cleaned using RNaseZap (Thermo Fisher Scientific) and deionised 
water. 9µl of the gel were dispensed into three gel wells in the chip, then 5µl of the marker 
was loaded into the ladder well and 12 sample wells. Finally, 1µl of denatured ladder and 
RNA samples were loaded into the chip, and this chip was placed into the machine for 
bioanalysis, and then run.  
2.3.4 Reverse transcription of mRNA to cDNA: 
In order to measure the transcriptional level of AID (as compared to that of EC gene) by 
qPCR, cDNA was initially synthesised from mRNA. This was achieved by performing 
reverse transcription in a 0.5-ml RNase-free tube (Greiner Bio-One, Gloucester, UK), 
containing 1µg of total cellular RNA and 1µl of random primers (0.5 µg/µl) (Promega, UK) 
and sterile water to make up a final volume of 13.5µl. The tube was then heated at 70°C for 
5 mins to denature the secondary structure of the RNA. After cooling it down on ice for 5 
mins, 0.5µl recombinant RNasin® Ribonuclease Inhibitor (20-40 u/µl), 4µl of 5X reverse 
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transcriptase buffer, 1µl (10mM) dNTPs and 1µl of M-MLV reverse transcriptase (all from 
Promega, UK) were added to initiate the reaction in a 37°C water bath for 1 hr, followed by 
heating at 65°C for 10 mins to inactivate the enzyme.  
2.3.5 Polymerase Chain Reaction (PCR):  
PCR was performed to detect the mRNA levels of AID, CD19 (B lymphocyte marker) and 
Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) genes in FL samples using the 
resulting cDNA prepared as described in Section 2.3.4 in this chapter. All PCRs were 
performed in 50l reaction in a 0.5-ml tube in an Eppendorf Mastercycler (Hamburg, 
Germany). A GoTaq® Flexi DNA Polymerase kit (Promega, UK) was used. The 
components in the PCR are listed in Table 2.1. The forward and reverse primers for each 
target gene are presented in Table 2.2, and the PCR amplification protocol is shown in Table 
2.3. 
 
 
 
 
 
Table 2.1: Reagents for PCR amplification of AID, GAPDH and CD19. 
Table 2.2: Primers used for PCR amplification of AID, GAPDH and CD19. 
Reagent Amount per 
sample in l 
5X PCR Buffer 10  
MgCl2 (25mM) 3  
Nuclease-free water 33.75  
Forward primers (20m) 1  
Reverse primers (20m) 1  
DNA polymerase   (5u/µl) 0.25  
cDNA 1  
 
Primer Name 
 
Primer Sequence (5’- 3’) 
Product 
size (bp) 
Source of mRNA 
sequence 
templates 
AID For (F) 5’-GAGGCAAGAAGACACTCTGGAC-3’ 406 NM_020661.2 
AID Rev  (R) 5’-TGCGGTCCT CACAGAAGTAGAG-3’  NM_020661.2 
GAPDH For 5’-ATCACCATCTTCCAGGAGCGAG-3’ 315 NM_002046.3 
GAPDH Rev 5’-GACTGTGGTCATGAGTCCTTCC-3’  NM_002046.3 
CD19 For 5’-TTC AAA GAG CCC TGG TCC TG-3’ 441 NM_001178098.1 
CD19 Rev 5’-ACT CAG CGT TGG AGA AGG AG-3’  NM_001178098.1 
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The PCR conditions had been optimised for amplification of all of the three target genes in 
the laboratory before this study, and are recorded in Table 2.3.  
 
 
 
 
 
 
Table 2.3: PCR protocol for PCR amplification of AID, GAPDH and CD19. 
 
2.3.6 Agarose gel electrophoresis: 
This is a technique that enables separation of DNA fragments. The principle is that charged 
DNA fragments with smaller size move more quickly in the agarose gel’s electrical field. 
Thus, DNA fragments with different sizes can be visualised and purified after staining (263). 
In this study we used 1-2% agarose gels for DNAs with different sizes. We prepared the gel 
by melting the desired amount of agarose (Sigma-Aldrich, Dorset, UK) in 1X TBE buffer, 
which contained 89 mM Tris-borate and 2 mM EDTA, pH 8.3 and diluted from the 10X 
stock prepared by dissolving Tris-Borate-EDTA buffer power (Sigma-Aldrich, UK) in 
distilled water. 
5μL of Midori Green Advance DNA stain (Geneflow, Lichfield, UK) were added to the 
melted agarose, which was then left to cool to room temperature before being cast. 
After solidifying, the gel was covered in the 1X TBE buffer in an electrophoresis tank. DNA 
samples with 1:5 (v/v) 6X gel-loading dye (New England BioLabs, Hitchin, UK) were 
mixed, and then loaded along with DNA size markers into slots of the gel. After 45 to 90 
mins of electrophoresis in an electrical field of 100-150 constant voltage, separated DNA 
Steps Temperature Time Number of 
cycles 
Initial denaturation 94ºC 3mins 1 
Denaturation 94ºC 30s  
29 
Annealing 58 ºC 30s 
Extension 72⁰C 30s 
Final extension 72⁰C 5mins 1 
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bands in the gel were visualised and recorded using the INGenius Imaging System (Syngene, 
Cambridge, UK). 
2.3.7 qPCR measurement of AID transcriptional level: 
Real-time PCR is a method developed to overcome the inaccuracy of conventional PCR in 
quantifying relative or total copy number of gene transcripts in cells. It records product 
signals after each cycle of PCR, and therefore enables analysis before plateau of the 
amplification. Compared with a pre-quantified standard curve or simultaneously amplified 
EC gene(s), either absolute copy number or relative level of gene transcripts can be measured 
(264). 
A LightCycler ® 480 (Roche, Hertfordshire, UK) and LightCycler ® 480 Multiwell Plate 
96, white (Roche, UK) were used to perform qPCR for quantifying AID expression.  
A Qiagen QuantiTect SYBR Green PCR master mix (Qiagen, UK) was used in the reactions. 
GAPDH was selected as an EC gene after an experimental comparison with two other EC 
(TBP and HPRT1). PCR primers are listed in Table 2.4. 
Table 2.4: Primers used for qPCR amplification of AID, GAPDH, TBP and HPRT1. 
The designed primers amplified AID product spanning exons one and two and exons four 
and five of GAPDH. 
qPCR components and protocols are listed in Tables 2.5 and 2.6. Briefly, both forward and 
reverse primers for AID or GAPDH were added to 12.5µl of PCR master mix, and 2µl of ¼ 
 
Primer Name 
 
Primer Sequence (5’- 3’) 
 
Product 
size 
(bp) 
 
Source of mRNA 
sequence templates 
AID For (F) 5’-GAGGCAAGAAGACACTCTGGAC-3’ 90 NM_020661.2 
AID Rev  (R) 5’-GCCCAGCGGACATTTTTGAATTG-3’  NM_020661.2 
GAPDH For 5’-ATCACCATCTTCCAGGAGCGAG-3’ 101 NM_002046.3 
GAPDH Rev 5’-TTCTCCATGGTGGTGAAGACGC-3’  NM_002046.3 
TBP For 5’-GCCCGAAACGCCGAATAT-3’ 73 NM_001172085.1 
TBP  Rev 5’-CCGTGGTTCGTGGCTCTCT-3’  NM_001172085.1 
HPRT1 For 5’-TGACCTTGATTTATTTTGCATACC-3’ 102 NM_000194.2 
HPRT1 Rev 5’-CGAGCAAGACGTTCAGTCCT-3’  NM_000194.2 
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diluted (v/v, in sterile water) cDNA of patients (Table 2.5.). Tests for each sample were 
performed three times, under conditions presented in Table 2.6. 
The ratio of AID/GAPDH gene transcription levels was calculated using the following 
equation: (265) 
∆Ct= Ct (AID) – Ct (GAPDH) 
∆Ct expression = 2–∆Ct 
Reagent Amount per 
sample in l  
Nuclease-free 
water 
9.5 
SYBR Green 
PCR master mix 
12.5 
Forward Primer 
(20m) 
0.5 
Reverse Primer 
(20m) 
0.5 
Diluted cDNA 2 
Total 25 
 
Table 2.5: Components of qPCR reaction. 
 
Steps Temperature Time Number of cycles 
Initial denaturation 95ºC 15mins 1 
Denaturation 95ºC 15s  
45 
Annealing 59 ºC 20s 
Extension 72⁰C 20s 
Final extension 72⁰C 5mins 1 
Table 2.6: Cycle details of qPCR reaction. 
2.4 DNA-based experiments: 
2.4.1 DNA extraction from FFPE tissues: 
DNA extraction from FFPE tissues was performed using a QIAamp DNA FFPE Tissue Kit 
(Qiagen, UK). The protocol was optimized to produce more DNA from FFPE tissue sections; 
in brief, two sections of 4µm paraffinized tissue were dissolved in 1ml xylene at room 
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temperature by vortexing for 10 sec, and centrifuged at full speed for 2 mins, followed by 
removing the liquid phase and mixing the spin-down by a brief vortex with 1ml of ethanol.  
The tube was centrifuged again for 2 mins at full speed and the ethanol was removed. The 
tube was left opened at room temperature for 10 mins to allow evaporation of remaining 
ethanol. 
Subsequently, 180µl of Buffer ATL and 20µl proteinase K were added to the tube, which 
was then vortexed and kept at 56ºC in the heating block of an Eppendorf ® Thermomixer 
(Sigma-Aldrich, UK) with shaking at 500 rpm overnight. 
The next day, 5µl proteinase K was added to the tube. After incubation under the same 
conditions for 1 hour, the tube was incubated at 90º C for 1 hour to reverse DNA 
formaldehyde modifications. Once cooled down, RNAs were digested with 2µl of RNAse-
A at room temperature for 2 mins. 
After mixing with 200µl Buffer AL and 200µl ethanol by vortex, the lysate was transferred 
onto a QIAamp MinElute column followed by centrifugation at 6000 x g for 1 min. After  
the flow through was discarded, the column was washed with 500l of Buffer AW1 and then 
500μl of Buffer AW2 sequentially by centrifuging for 1 min at 6000 x g. The column was 
dried by centrifugation at 20000 x g for 3 mins. 
Finally, 50µl of ATE buffer was loaded on the column, which was then left at room 
temperature for 5 mins, before being centrifuged at the same speed for 1 min to elute the 
DNA.  
2.4.2 Measuring concentration and purity of DNA extracted from PACIFICO FFPE 
tissues: 
The DNA quantity was measured using the Qubit™ dsDNA BR Assay Kits (life 
technologies, UK), details of which are in Section 2.3.2. 
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Purity of DNA was detected using a Nanodrop 2000 spectrophotometer (Thermo scientific, 
UK). The purity was acceptable if the ratio of spectrometric absorbance of 260 vs 280 was 
between 1.8 and 2.0. 
2.4.3 Detecting length of DNA extracted from FFPE specimens: 
In addition to purity, length is another important parameter of DNA quality. For measuring 
the quality and level of degradation of DNA, we used PCR to amplify GAPDH (DNA 
template code NC_000012.12) fragments with different sizes to measure the size of DNA 
extracted from those FFPE tissue samples. 
This was achieved by applying a consensus forward primer and 6 reverse primers designed 
to amplify 101, 206, 299, 396, 505 and 598-bp fragments of this EC gene. The details of 
these primers are listed in Table 2.7. The PCR cycle conditions are presented in Table 2.8. 
 
 
 
 
 
 
 
Table 2.7: Primers used to amplify different sizes of GAPDH PCR bands. 
 
                        
Primer name Sequences (5’- 3’) 
GAPDH For 5’-AGGTGGAGCGAGGCTAGC-3’ 
GAPDH Rev 101bp 5’-CAA GAG GAC CTC CAT AAA CC-3’ 
GAPDH Rev 206 bp 5’-AGG GGC CAT TTT GCG GTG-3’ 
GAPDH Rev 299 bp 5’-AGC CTG GCC TTT GGG GTC-3’ 
GAPDH Rev 396 bp 5’-AGG GTG CGG TGG GAG ATC-3’ 
GAPDH Rev 505 bp 5’-GGAGTGGAGCACAGGTAAG-3’ 
GAPDH Rev 598 bp 5’-GGTGGGAAGAGGGGAAGC-3’ 
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Table 2.8: PCR protocol of GAPDH PCR bands. 
 
After a pilot experiment to explore the range of DNA sizes in a number of FFPE samples, it 
was decided to amplify 206, 299, and 396 bp products, as these represented the DNA size of 
most of the samples tested. The PCR products were then semi-quantified based on their 
relative band intensity as visualized on the agarose gel (Chapter 3, Section 3.2.2.2).   
2.4.4 Full length IGHV amplification in the FFPE samples: 
Because SHM can occur anywhere across the IGHV gene, we initially attempted to amplify 
the full length of the gene by PCR, using primers annealing IGHV leader and heavy chain 
constant regions, with the expected product length being about 500 bp (Chapter 1, Figure 
1.2). 
Primers were designed in our laboratory for amplifying the IGHV gene from intact DNA, 
and conditions were optimized and published previously (266). 
Primers and all components in PCR reactions are shown in Tables 2.9 and 2.10, respectively. 
The PCR program was as follows: 
1-Initial denaturation was one cycle at 94ºC for 3 mins. 
2- (Denaturation at 94ºC for 45 sec, followed by annealing at 63ºC for 45 sec, and then 
extending at 72ºC for 45 sec) repeated twice. 
3- (Denaturation at 94ºC for 45 sec, followed by annealing at 62ºC for 45 sec, then 72ºC for 
45 sec) repeated twice. 
Steps Temperature Time Number of cycles 
Initial denaturation 94ºC 1min 1 
Denaturation 95ºC 15sec  
35 
Annealing 58 ºC 30 sec 
Extension 72⁰C 30 sec 
Final extension 72⁰C 1min 1 
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4- (Denaturation at 94ºC for 45 sec, followed by annealing at 61ºC for 45 sec, then 72ºC for 
45 sec) repeated twice. 
5- (Denaturation at 94ºC for 45 sec, followed by annealing at 60ºC for 45 sec, then 72ºC for 
45 sec) repeated 24 times. 
6- Final extension at 72ºC for 5 mins for 1 cycle. 
 
 
 
 
 
 
 
 
 
Table 2.9: Primers to amplify full length IGHV gene from leader to constant region. 
 
 
 
 
 
 
 
 
 
Table 2.10: Contents of PCR master mix to amplify full length IGHV gene from leader to constant region. 
 
Primer name Sequences (5’- 3’) 
Forward primers    
VH1 Leader 5’-CCA TGG ACT GGA CCT GGA -3’ 
VH2 Leader 5’- ATG GAC ATA CTT TGT TCC AC -3’ 
VH3 Leader 5’-CCA TGG AGT TTG GC TGA GC -3’ 
VH4 Leader 5’-ATG AAA CAC CTG TGG TTC TT -3’ 
VH5 Leader 5’- ATG GGG TCA ACC GCC ATC CT -3’ 
VH6 Leader 5’-ATG TCT GTC TCC TTC CTC AT -3’ 
Reverse primers  
IgA   5’- GAG GCT CAG CGG GAA GAC CTT -3’ 
IgG   5’-GGG GAA GTA GTC CTT GAC CAG -3’ 
IgM   5’- CAG GAG AAA GTG ATG GAG TCG -3’ 
Reagent Amount per reaction in µl 
Nuclease free water 33.25 
dNTP(10mM) 0.5 
5X Taq Buffer 10 
MgCl2 (25mM) 3 
GoTaq® DNA polymerase (Promega) 0.25 
Forward primers (20m) 1 
Reverse primers (20m) 1 
cDNA 1 
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However, as expected from degraded DNA that is extracted from FFPE, we could not 
amplify the full length of the gene. So, we tried the BIOMED-2 protocol to amplify a 
shorter length of the IGHV gene. 
2.4.5 BIOMED-2 protocol for study of IGHV clonality by multiplex PCR: 
BIOMED-2 is a PCR-based technique to test clonality of the immunoglobulin gene 
receptor that aids in diagnosis of B-cell malignancies, including FL (11). This technique 
was used to amplify the IGHV gene for cloning study on ongoing mutations of the same 
sample by comparing this gene nucleotides between different clones.  
2.4.5.1 PCR amplification of IGHV genes in families: 
In total, there are more than 52 functional VH segments; these have been divided into 6 
families that have similar structure, and can be amplified by PCR using the same primers 
(11). 
The protocol allowed us to use primers to start the amplification from FR1, FR2 or FR3 to 
the junction (Chapter 1, Figure 1.2). Owing to limited size of the DNA in FFPE specimens, 
we could not amplify the IGHV genes with a combination of primers targeting leader and 
constant regions. But with modification of the PCR conditions, we successfully amplified 
the rearranged IGHV genes between their FR1 and junction regions, which were long enough 
to provide information about the clonality and ongoing mutations.  
So, the first round of PCR was used to apply primers of all families to detect B-cell 
clonality of the lymphoma. In the second round, the family with productive results was re-
amplified in order to purify templates for Sanger sequencing. 
A Thermo-Start DNA polymerase kit (Life technologies, UK) was used for PCR, which was 
performed in a TC512 Techne PCR thermal cycler (Bibby Scientific™, Staffordshire, UK). 
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As mentioned above, we modified the BIOMED-2 protocol in order to amplify the large 
region of this gene. Thus, 5µl Mgcl2 (2.5 mM) instead of 3µl (1.5 mM), as suggested by 
BIOMED-2, was used in the 50l reactions; and the number of PCR cycles was increased 
from 35 to 38. Tables 2.11, 2.12 and 2.13 show details of primers used, components in the 
reaction and PCR cycle conditions. 
Primer name Sequences (5’- 3’) 
VH1-FR1 5’-GGCCTCAGTGAAGGTCTCCTGCAAG-3’ 
VH2-FR1 5’-GTCTGGTCCTACGCTGGTGAAACCC-3’ 
VH3-FR1 5’-CTGGGGGGTCCCTGAGACTCTCCTG-3’ 
VH4-FR1 5’-CTTCGGAGACCCTGTCCCTCACCTG-3’ 
VH5-FR1 5’-CGGGGAGTCTCTGAAGATCTCCTGT-3’ 
VH6-FR1 5’-TCGCAGACCCTCTCACTCACCTGTG-3’ 
  
VH1-FR2 5’-CTGGGTGCGACAGGCCCCTGGACAA-3’ 
VH2-FR2 5’-TGGATCCGTCAGCCCCCAGGGAAGG-3’ 
VH3-FR2 5’-GGTCCGCCAGGCTCCAGGGAA-3’ 
VH4-FR2 5’-TGGATCCGCCAGCCCCCAGGGAAGG-3’ 
VH5-FR2 5’-GGGYGCGCCAGATGCCCGGGAAAGG-3’ 
VH6-FR2 5’-TGGATCAGGCAGTCCCCATCGAGAG-3’ 
VH7-FR2 5’-TTGGGTGCGACAGGCCCCTGGACAA-3’ 
  
VH1-FR3 5’-TGGAGCTGAGCAGCCTGAGATCTGA-3’ 
VH2-FR3 5’-CAATGACCAACATGGACCCTGTGGA-3’ 
VH3-FR3 5’-TCTGCAAATGAACAGCCTGAGAGCC-3’ 
VH4-FR3 5’-GAGCTCTGTGACCGCCGCGGACACG-3’ 
VH5-FR3 5’-CAGCACCGCCTACCTGCAGTGGAGC-3’ 
VH6-FR3 5’-GTTCTCCCTGCAGCTGAACTCTGTG-3’ 
VH7-FR3 5’-CAGCACGGCATATCTGCAGATCAG-3’ 
  
JH consensus 5’-CCAGTGGCAGAGGAGTCCATTC-3’ 
Table 2.11: BIOMED-2 primers (11). 
 
 
 
 
Table 2.12: BIOMED-2 PCR components.             
Reagents Amount 
PCR buffer (10X) 5µl 
Mgcl2 (25mM) 5µl 
dNTP (10mM) 2µl 
Thermo-Start DNA 
Polymerase (5U/µl) 
 
0.2µl 
DNA 50ng 
Nuclease-free water Add to complete volume to 50µl 
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Steps Temperature Time Number of cycles 
Initial denaturation 95ºC 7mins 1 
Denaturation 95ºC 30 sec  
38 
Annealing 60 ºC 30 sec 
Extension 70⁰C 50 sec 
Final extension 72⁰C 10mins 1 
 
Table 2.13: BIOMED-2 PCR protocol.   
 
2.4.5.2 Agarose gel electrophoresis and PCR purification of IGHV gene: 
In order to study ongoing mutations of IGHV in FL clones by Sanger sequencing, we needed 
to subclone the PCR product of the clonal IGHV into a plasmid vector. Thus, an agarose 
electrophoresis gel was run, in order to identify and purify PCR products from such clones. 
To do so, 400µl of IGHV PCR product (details in Section 2.4.5.1) were loaded into slots of 
a 2% agarose gel (details of agarose gel preparation and running is described in Section 
2.3.6).  DNA bands were visualised and cut out under UV light using a blade. Next, DNA 
from the agarose gel was purified using a Wizard® SV Gel and PCR Clean-Up System 
(Promega, UK) according to the manufacturer’s instructions. 
In brief, the gel slice was covered with membrane binding solution provided (each 10mg of 
gel in 10μl of solution) and then incubated for 10 mins at 65°C until all gel was thoroughly 
dissolved. The dissolved gel mixture was then transferred onto the SV minicolumn 
connecting to a collection tube and incubated at room temperature for 1 min. Then, the SV 
minicolumn was centrifuged at 16,000 × g for 1 min and the ‘flow through’ was discarded; 
the column was washed twice, first with 700µl and then 500µl using membrane wash 
solution and centrifugation at 16,000 × g for 1 min in the first wash and 5 mins in the second 
one. 
Another centrifugation of the minicolumn was done for 1 min with the lid off to allow 
ethanol to evaporate, then we added 50µl of nuclease-free water to the Minicolumn and left 
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it at room temperature for 1 min. Finally, the purified DNA was eluted into a fresh tube by 
centrifugation at 16,000 × g for 1 min. The concentration of DNA was measured by using a 
Qubit™ dsDNA BR Assay Kit (Life Technologies, UK) and method as in Section 2.3.2. of 
this chapter. 
2.4.5.3 Cloning of IGHV DNA: 
To study the ongoing mutations of IGHV in FL, we subcloned IGHV PCR products into a 
pGEM-T-easy Vector system (Promega, UK), according to the manufacturer’s 
recommendations. Following this, the recombinant vector was transformed into JM109 
competent cells. According to the manufacturer, we made 10µl of ligation in a micro tube 
containing the following components: 
2x ligation buffer                           5.0µL 
T-easy vector (50ng/µl)                 1µL  
T4 ligase                                        1.0µL 
Then, 15ng PCR products were added at a 3:1 ratio to the amount of vector as determined in 
the pilot experiment. The required 15ng of DNA in PCR products was calculated as follows:  
ng of vector x kb size of insert     
                                                      x insert: vector molar ratio = ng of insert 
          kb size of vector 
(50ng vector × 0.3kb insert)/3 × 3/1 = 15ng of DNA. This is followed by adding nuclease 
free water to a final volume of 10µL. Following the ligation reaction in 4°C overnight, the 
transformation reaction was performed in a 1.5ml microcentrifuge tube, which contained      
2µl of the ligated product and 50µl of JM109 competent cells (Promega, UK).  Contents 
were flicked to mix, put on ice for 20 mins and then into a 42°C water bath for 45-50 sec;  
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the tube was then transferred onto ice for 2 mins. Then, 950µl of Super Optimal broth with 
Catabolite repression (SOC) medium (Thermo scientific, UK) were added followed by 
incubation at 37°C with shaking at 150 rpm for 1.5 hours. 
200µl of the transformation culture was plated onto duplicate Luria-Bertani agar 
(LB)/ampicillin/ isopropylethio-ß-D galactoside (IPTG)/X-Gal plates and then incubated at 
37°C for 16-24 hours. LB/ampicillin/IPTG (Sigma Aldrich, UK) and X-gal (Promega, UK) 
plates had been prepared as follows: after melting LB agar tablets in distilled water, we 
added Ampicillin to the LB agar when it was cooled to 55°C or less, to be at a concentration 
of 100µg/ml. When the LB agar had set in the petri dishes (Thermo Fisher Scientific), 5µl 
of stock IPTG (200mg/ml) and 40µl of X-gal (20mg/ml) were spread on the agar an hour 
before the transformed bacteria were inoculated onto the plates. 
2.4.5.4 Clonal selection: 
Following incubation, white clones that contained the DNA insert were distinguished from 
blue clones that had no DNA insert. At least 15 white clones were selected for each sample. 
Each clone was cultured overnight in a falcon tube that contained 1ml of LB agar at 37°C. 
Then, the clones were sent for DNA to be prepared from these clones and sequenced with 
Sanger sequencing as commercial services provided by Genewiz company, UK. 
2.4.5.5 Analysis of IGHV gene sequences: 
Using IMGT/V-QUEST software (the international ImMunoGeneTics information system), 
we were able to align our IGHV gene sequences against their germline counterparts, and 
identify somatic mutations in them (267). After applying the sequence results to IMGT/V-
QUEST software, the obtained sequence was aligned to the closest Ig germline. Further, our 
junction segment was translated into amino acids: first, sequences of junction segments of 
all IGHV subclones were compared, and only those with identical junction segment 
sequences as originated from the same clone were considered. 
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Then, an excel file was used to record mutations in each codon manually (for example, GCA 
to GAA), and then these mutations were translated into amino acids (Alanine to Glutamine) 
to determine whether the mutation changed the amino acid or not.  Next, it was identified 
whether each mutation was related to AID activities, by analysis of AID hotspots, as 
suggested in previous publications (198, 208). 
2.5 Protein-based experiments: 
2.5.1 Immunohistochemical detection of AID protein: 
2.5.1.1 IHC staining of AID:   
To detect the protein level of AID in FL, 4µm FFPE tissue sections were cut and placed on       
X-tra® slides (Leica Biosystems); these slides were dried at 40°C overnight and 
subsequently stained using mouse anti-human monoclonal antibody against AID protein 
clone: ZA001, (Thermo scientific, UK). 
Heat-induced deparaffinization, rehydration and antigen retrieval was performed using a 
DAKO PT-Link machine. IHC was undertaken using a Dako autostainer and Dako Flex 
System kit for FFPE tissues, both from Dako UK Ltd (Cambridgeshire, UK). 
With each batch of slides stained, a positive control (hyperplastic tonsil) and a negative 
control (hyperplastic tonsil with added mouse IgG1 isotype-specific negative control) (Dako 
UK Ltd, UK) were included. The steps of AID staining by IHC are shown in Figure 2.1.  
 
Dako Autostainer
that performs 
automatic staining 
for up to 48 slides
Put in PT-link for pre-
treatment process of 
deparaffinization, 
rehydration and epitope 
retrieval of tissue slides 
Scoring of AID
Cutting of sections 
from FFPE tissues
Figure 2.1: Workflow experiment for AID staining by IHC. 
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2.5.1.1.1 PT link epitope retrieval: 
Antigen retrieval was undertaken using the PT link solution by adding 30ml of Envision 
Flex target retrieval solution high pH (50x) (Dako UK Ltd, UK) to 1.5 L of distilled water. 
The PT-link was heated to 65°C, and the slides were placed in PT link; the temperature was 
raised to 96ºC and then reduced to 65ºC, when the slides were removed, washed using 
EnVision™ FLEX Wash (Dako UK Ltd, UK) 3 times, and then moved to the DAKO 
autostainer (Dako UK Ltd, UK). 
2.5.1.1.2 Staining slides with AID antibody using Dako autostainer:  
The DAKO Autostainer is capable of undertaking automatic IHC staining of up to 48 tissue 
slides in each run.  
It requires FLEX Wash Buffer, which is composed of Tris buffered saline (TBS) with Tween 
pH 7.6 (50mM Tris, 150mM sodium chloride, 0.05% Tween). Hence, 60.6 gm of Tris 
(Hydroxymethyle-methylamine) (VWR 271195Y) and 80.9 gm of sodium chloride (VWR 
27800.291), 34ml of hydrochloric acid sp.gr. 1.18 (VWR 28507AE), and Tween 20 
(polyoxyethelyne (20) sorbitan monolaurate) (VWR 663684B) 5ml was added to 10L 
distilled water and the pH adjusted to 7.6 using sodium hydroxide and hydrochloric acid. 
The slide number was entered and the appropriate reagents were used as per software 
instructions. Envision-Flex block, which blocks nonspecific antibody binding sites was 
added for 5 mins, then AID antibodies (1/500 dilution in Phosphate buffered saline (PBS)) 
applied for 30 mins, followed by the mouse linker that amplifies the signal of primary 
antibody, for 15 mins, Horseradish Peroxidase (HRP) enzyme was added for 15 mins: this 
converts diaminobenzidine (DAB) in the presence of hydrogen peroxide (H202) into a brown 
pigment; DAB was added for 20 mins.  
Slides were washed by Envision-Flex buffer and rinsed in distilled water; subsequently 
slides were transferred to filtered haematoxylin solution for 30 sec to stain the nucleus, and 
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placed into a rack under a running tap water bath until the water ran clear.  
The slides were dipped in acid alcohol to remove excess stain, and then put in Scott’s tap 
water/ammonia water for 30 sec to change the pH to alkaline, and change the nucleus stain 
to blue. Then slides were put into a rack and placed into a running tap water bath for 1 min. 
Subsequently, the slides were dehydrated in a series of 5 times IMS (Industrial Methylated 
Spirits) and 2 times xylene (both from Sigma Aldrich, UK), before one drop of mountant 
was added to a coverslip, and covered the stained section. 
2.5.1.2 Scoring system for AID quantification: 
The protein expression of AID was scored separately by two individuals (myself and 
Professor Sarah E. Coupland (a haematopathologist)); if there was any discordance of scores, 
at a combined meeting the slides were re-reviewed and consensus obtained. 
The scoring was undertaken according to the number and intensity of stained cells, which is 
the general scoring method used in IHC as follows: percentage of lymphocytes stained: 0% 
Negative, 1-24% scored 1, 25-49% scored 2, 50-74% scored 3, and more than 75% scored 4  
Intensity: Negative scored zero, weak scored one, moderate scored 2 and strong scored 3. 
The final score was decided by multiplying percentage score X intensity score, with a 
minimum score being 0 and a maximum being 12 (268-270).   
2.5.2 Immunofluorescent double staining of AID with CD3, CD20 or CD68:  
The protocol for double staining of each of the antibody combinations was optimised. 
Two protocols were followed: either the 2 antibodies were mixed together followed by AID 
secondary antibody, then a mixture of fluorescent detection dyes of 2 colours; or a complete 
protocol for staining of one antibody was followed by the staining of the other antibody. 
The concentration of AID in all experiments was 1/50 dilution in PBS.  
95 
 
For the fluorescent dyes, Alexa Fluor 555 (Red) (Thermo Fisher Scientific, UK) was applied 
in a concentration of 1/200 to visualize CD3, CD20 and CD68. For AID, the secondary 
biotinylated Goat Anti-Mouse IgG Antibody was used, and the green colour DyLight 488 
Streptavidin, both of Vector Laboratories Ltd (Peterborough, UK), were added to accelerate 
the signal diluted in PBS in a 1/200 concentration.  
For the double staining of AID with CD3 (Rabbit polyclonal anti-human CD3, Agilent 
Technologies, UK), the antibodies were applied ‘one after the other’ whilst for the 
combination of CD20 and CD68, the antibodies were mixed together at a concentration of 
1/50 for AID with 1/100 PBS dilution of Rabbit Monoclonal antibody to human CD20 (AMS 
Biotechnology (Europe) Ltd, Abingdon, U.K) and 1/50 PBS diluted Rabbit polyclonal IgG 
to human CD68 Antibody (Santa Cruz Biotechnology, Heidelberg, Germany). 
Prior to the immunofluorescence staining, the slides were put into a DAKO PT Link system 
for antigen retrieval (see details in Section 2.6.1.1.1), and the blocking reagent was added to 
prevent nonspecific binding of AID antibody to other proteins; the blocking reagent used 
was 10% Normal Goat Serum in PBS (Vector Laboratories Ltd, UK) with 1% bovine serum 
albumin (BSA) for 1 hour at room temperature. The slides were then incubated with ready 
to use CD3 antibody for 1 hour (in the case of AID and CD3 double staining), then goat anti-
rabbit Alexa fluor 555 (Red). Monoclonal mouse AID antibody was then added followed by 
Biotinylated Goat Anti-Mouse IgG Antibody for 1 hour, then DyLight 488 Streptavidin 
(green) in 1/200 PBS dilution for 30 min. 
In the case of double staining of AID with CD20 and CD68, AID was mixed with CD20 or 
CD68, then incubated for 1 hour at room temperature; then washed three times each for 3 
mins in FLEX wash buffer (preparation details in Section 2.6.1.1.2 of this chapter). 
Then, biotinylated Goat Anti-Mouse IgG Antibody was placed on the slides for 1 hour, and 
then goat anti-rabbit Alexa fluor 555 (Red) and DyLight 488 (Green) were added, both at 
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1/200 PBS dilution in the dark at room temperature for 30 mins. Subsequent to this, they 
were washed and mounted in Cygel mountant (Biostatus, Leicestershire, UK). Positive- 
(hyperplastic tonsil) and negative controls (hyperplastic tonsil with added monoclonal 
mouse IgG1 antibody 1/50 dilution) were included in all experiments. 
The slides were visualised using an Olympus BX61 microscope (Olympus, Tokyo, Japan). 
Steps involved for AID immunofluorescent co-expression with CD3, CD20 or CD68 are 
shown in Figure 2.2. 
 
FFPE 
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sections 
on slides 
CD3 
blocking 
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PT-link 
Pre-treatment
AID secondary 
Ab (Biotinylated 
goat anti mouse)
AID 
mAb
Alexa fluor 555 
dye
Dylight
488
AID mAb + 
CD20 or 
CD68 
AID secondary Ab 
(Biotinylated goat 
anti mouse)
Alexa fluor 555 
dye
+
Dylight 488
Figure 2.2: Workflow for Immunofluorescent double staining of AID with CD3, CD20 or CD68 experiments. 
 
2.5.3 Subcellular localization of AID by immunofluorescence: 
2.5.3.1 Protocol for immunofluorescent staining and confocal microscopy visualization: 
To identify the subcellular localization of AID protein by immunofluorescent expression, 
4µm sections from FFPE tissues were cut and placed on super frost plus slides (Thermo 
Fisher Scientific). The slides were stained with nuclear stain and AID stain to identify 
nuclear co-expression of AID; the same protocol as in Section 2.6.2 (above) was applied. 
Initially, antigen retrieval using the DAKO PT Link system was performed and then a 
blocking reagent was added, followed by the AID Monoclonal Antibody at 1/50 dilution. 
Subsequently, a secondary biotinylated goat anti-mouse IgG antibody was added with a 
1/100 dilution (Vector Laboratories Ltd, UK) to amplify the signal. This was followed by 
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1/200 PBS diluted DyLight 488 Streptavidin (Vector Laboratories Ltd, UK). Finally, 
Hoechst 33258 Fluorescent Stain (Thermo Fisher Scientific, UK) in 1/200 dilution for 15 
mins was added. The slides were coverslipped using 10µl of Cygel mountant (Biostatus, 
Leicestershire, UK). 
The slides were visualised using an LSM 710 confocal microscope (Carl Zeiss Vision UK 
Ltd, Cambridge, UK), using a 10x lens first to identify the GCs that are closest to 12, 3, 6, 
and 9 o’clock directions and the centre itself. A higher power (25x objective) was used to 
identify upper and lower parts of the GC, and then the 40x objective to ultimately take the 
images.  
2.5.3.2 Analysis of immunofluorescent images: 
To analyse the subcellular localization of AID, we modified a previously-published method 
(271, 272). Image j1x software was used to measure the nuclear intensity:  
The colours were changed into the grey scale, because of the better appearance and contrast 
in Image j1x by (Image> Color> channel tools> grey scale), and then the image was split 
into 2 images (Image> color> split channels): one having the nuclear stain and the other with 
the AID stain. The command (Image > Adjust > Threshold) was used to focus on the nuclear 
stain image to identify nuclei, then (Edit > Selection > Create Selection) was used to select 
nuclei only. Following this, the AID positive image was focused on and selected [Edit > 
Selection > Restore Selection] and then ‘m’ was pressed to measure the region. This is for 
the nuclear measurement. 
Using [Edit > Selection > Select None] the area was ‘de-selected’, and the command ‘m’ 
given to measure the whole image. A total measurement was obtained. Finally, 5 different 
areas that were free of fluorescence were used to calibrate for (and remove) background 
staining. 
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The corrected total cell fluorescence (CTCF) was then calculated according to the 
following equation:  
CTCF = Integrated Density – (Area of selected cell X Mean fluorescence of background 
readings) (271, 272).  
The ratio of nuclear to total AID was calculated using the following equation: 
= (Nuclear CTCF / (nuclear + cytoplasmic CTCF)) X 100 (Figure 2.3)  
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colour recognition
Splitting images into nuclear and 
AID stain images
Nuclear fluorescence                             AID fluorescence  
Opening fluorescent images using 
Image j1x software
Identifying nuclei from the image Selecting nuclei  
nuclei was selected copy the selection to AID fluorescence image 
Select five areas of no flourescence to
subtract background
Measure background, nuclear and total 
fluorescence
Calculate corrected total fluorescence 
using equation in 2.6.3.2 
Total
  
Figure 2.3: Calculating nuclear cytoplasmic/AID ratio using Image j1x software. The flow of arrows between 
the screenshots explains the technique used to quantify and calculate the intensity of staining.  
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2.6 qPCR quantification of genes associated with microenvironment in FL: 
2.6.1 Optimizing qPCR protocol: 
This experiment was done to explore the correlation between AID and expression signature 
of genes involved in tumour microenvironment in FL that had been proven to correlate with 
disease outcome (95). 
To quantify expression of these genes as shown in Table 2.13, we optimized a method of 
qPCR using Taqman primers (Thermo Fisher Scientific, UK), published by Byers and 
colleagues (273). 
Because of limited time we had for this last chapter, also, due to the limited availability of 
remaining cDNA of the PACIFICO samples, we only included six out of 66 candidate genes 
in this study. Three of the six genes (STAT4, LEF1 and CD2) were selected as they were 
associated with good prognosis and related to T cells, while the other three (C3AR1, LGM 
and MAPK1), were associated with bad prognosis. The details of these six genes are listed 
in Table 2.14. 
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Table 2.14: FL microenvironment-related genes studied in this thesis. 
* Information about pathways these genes are involved in was taken from GeneCards 
(http://www.genecards.org/) and Byers and colleagues’ paper (273). 
 
 
Taqman Primer 
Probe Set 
 
Cell marker  
 
Pathway* 
 
Prognosis 
 
Taqman primers 
catalogue number 
 
MAPK1(Mitogen-
activated protein 
kinase 1) 
 
Many mammalian 
cells 
proliferation, 
differentiation, 
transcription regulation 
and development 
 
 
Bad 
 
 
(Hs01046830_M1) 
 
C3AR1 
 
Macrophage and 
dendritic cells 
Signalling by GPCR, 
complement and 
coagulation cascades. 
 
Bad 
 
 
(Hs00269693_s1) 
 
 
 
LGMN 
 
 
Macrophage and 
dendritic cells 
processing of bacterial 
peptides and 
endogenous proteins for 
MHC (Major 
histocompatibility 
complex class) II 
 
 
 
Bad 
 
 
 
(Hs00271599_m1) 
 
CD2 
 
T cell 
Adhesion and 
costimulatory molecule 
 
Good 
 
(Hs00233515_m1) 
 
LEF1 
 
T cell 
 
transcription factor 
 
Good 
 
(Hs01547250_m1) 
 
STAT4 
 
T cell 
 
transcription factor 
 
Good 
 
(Hs01028017_m1) 
 
GAPDH 
 
All mammalian cells 
 
EC gene 
  
(HS02758991_G1) 
 
ACTB 
 
All mammalian cells 
 
EC gene 
  
(HS01060665_G1) 
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20µl qPCR reaction was composed of 10µl of Taqman ® Universal PCR Master Mix 
(Thermo Fisher Scientific, UK), 8µl water, 1µl cDNA and 1µl of Taqman assay which 
includes primers and a specific probe. The qPCR was conducted in a LightCycler ® 480 and 
LightCycler ® 480 Multiwell Plate 96 (Roche, UK) with a programme detailed in Table 
2.15. 
 
Step Temperature Time Cycle 
Initial denaturation 95ºC 10 min 1 
Denaturation 94ºC 40 sec  
 
40 Annealing 56 ºC 30 sec 
Extension 72⁰C 1 min 
Final extension 72⁰C 1 mins 1 
Table 2.15: qPCR protocol used for Taqman reaction. 
 
2.6.2 Selection of cell lines to be used as a control for expression of these genes: 
To amplify genes representing TME in PACIFICO samples, we needed to choose positive 
control cell lines for the qPCR reaction; to do that, we ran the qPCR reaction for six 
malignant cell lines available at the department: those are Raji cell line (Burkett’s 
lymphoma) (257), Karpas 422 cell line (DLBCL) (274), Daudy cell line (Burkett’s 
lymphoma) (275) and Jurkat cell line (Acute T cell Leukaemia) (276). We found that genes 
MAPK1, C3AR1 and LGMN were expressed in the Daudy cell line, while LEF1, CD2 and 
STAT4 were best expressed in Jurkat cell lines, so these cell lines were used as a positive 
control for those genes. Each qPCR measurement was repeated three times (technical 
repeats) (Table 2.16). 
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        Gene Cell line Average qPCR cycle 
threshold 
MAPK1 Daudy 18.29 
C3AR1 Daudy 21.89 
LGMN Daudy 23.85 
LEF1 Jurkat 22.94 
CD2 Jurkat 26.74 
STAT4 Jurkat 30.34 
 
Table 2.16: Shows cell lines amplifying TME genes that are used as a positive control for these genes’ 
expression in PACIFICO samples. 
 
RNA was extracted and cDNA were prepared from these cell lines in the same way as 
described in Sections 2.2.3 and 2.3.4, respectively, and the cDNA was then used in the 
optimized qPCR reaction. 
2.7 Statistical analysis: 
Statistical analyses were performed using IBM SPSS 22 software. A P value of 0.05 or less 
was regarded as statistically significant. Details of tests used and explanations can be found 
in relevant results sections. 
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Chapter 3 
 
 
Optimization of RNA and DNA extraction from FFPE 
tissue samples of FL  
 
3.1 Introduction:  
The golden age of molecular cancer research began with the discovery of DNA’s structure 
(277). This led us to understand many aspects of cancer development and progression. We 
began to understand the relationship between gene mutations and cancer, and this 
knowledge, in turn, increased our chances of developing cancer therapies. For example, 
discovery of defects in DNA repair mechanisms in cancer cells enabled us to understand 
how cancers can be initiated, and how we can target tumour cells (277).  
With respect to RNA, it was considered for a long time to be merely involved in the 
translation from DNA to protein. However, scientists have recently established that it has 
another functional importance, with the discovery of non-coding RNAs. Scientists have 
shown that expression of both forms of RNA (coding and non-coding) are closely related to 
the formation, progression and metastasis of cancer (278). 
One of the most significant advances in molecular biology during the last decade has been 
the application of NGS in sequencing DNA to unprecedented depths, to reveal further 
astonishing knowledge of the human genome. Initially NGS was performed on fresh tissue 
material or fluids. For decades, however, surgical biopsies and post-mortem tissues had been 
preserved using formaldehyde followed by tissue dehydration and paraffin embedding. 
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These FFPE tissues with the associated clinical data represent a major resource for DNA and 
RNA that can be used for molecular testing. Such preservation prevents tissue from 
degradation to keep tissue structures as close as possible to a living state (4). However, 
nucleic acids are often partially degraded in those FFPE tissues, compared to fresh or frozen 
tissues (279).  
Many factors affect the integrity of nucleic acid in FFPE samples, these include the time 
interval between surgical procedure/sampling and fixation, size of the tissue and storage 
conditions (247). 
Additionally, formaldehyde fixation of FFPE tissues is associated with cross-linking of RNA 
and DNA with proteins and with each other. Moreover, the current methods of nucleic acid 
extraction from FFPE samples affects the integrity of DNA and RNA. Therefore, use of 
better, less aggressive extraction methods is required to improve the quality of nucleic acid 
extracted from FFPE samples (280, 281). 
One of the aims of this thesis was to determine whether the AID level at diagnosis of FL is 
important in FL diagnostics and/or predicting its progression. For that purpose, it was 
important to examine AID at mRNA and protein levels, as well as its sub-cellular 
localization. It was also important to determine the correlation of AID with ongoing IGHV 
mutation in FL, and its associations with mutations in other genes detected by NGS in a 
parallel study that may play a role in FL pathogenesis. 
With the exception of AID protein expression that was examined by IHC and IF in tissue 
sections, all other experiments for this thesis were undertaken using DNA and RNA. 
As stated in the General Introduction, we used tissue samples from the PACIFICO trial in 
this study. Since materials for this study were limited, we show our efforts in this chapter to 
optimize conditions of RNA and DNA extraction from FFPE tissue samples, with the aim 
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of obtaining higher quantity and better quality of nucleic acids for molecular testing in this 
study. 
3.2. Procedures and Results: 
3.2.1 Optimization of RNA extraction from FFPE samples: 
3.2.1.1 Choosing the best kit for extraction of RNA from FFPE tissues: 
As described in the literature, multiple kits are commercially available for RNA extraction 
from FFPE samples, including the RNeasy FFPE kit (Qiagen, Valencia, CA, U.S.A.), 
RecoverAll™ Total Nucleic Acid Isolation Kit for FFPE tissues (Ambion, Austin TX), 
ReliaPrep™ FFPE Total RNA Miniprep System (Promega, UK), PureLink FFPE Total RNA 
Isolation Kit (Invitrogen, Carlsbad, CA) Absolutely RNA® FFPE Kit (Stratagene, La Jolla, 
CA), high Pure RNA paraffin kit (Roche Diagnostics, Mannheim, Germany), and Agencourt 
FormaPure (Beckman Coulter, Beverly, MA). 
The most commonly used kits, RNeasy FFPE kit of Qiagen and ReliaPrep™ FFPE Total 
RNA Miniprep System of Promega were chosen in the following experiments, to compare 
the quantity and quality of the resulting RNA. 
These two kits were used to extract RNA from FFPE tissue samples of three cases with FL 
and two with NHL stored in the LBIH according to the manufactures’ instructions, and three 
individual experiments were performed for each sample. 
It was found that the Qiagen RNeasy FFPE kit produced higher concentrations of RNA in 
the same elution volume (20l) from the same amount of tissue (two sections of 4µm 
thickness) compared to the Promega ReliaPrep™ FFPE kit in most experiments (13/15) 
using samples from five cases (Figure 3.1). Thus, the averages in all of the five cases were 
higher with the former kit. Using the paired t test, this difference was statistically significant 
(P= 0.003). No noticeable change was found between the two kits in the remaining single 
experiments in two cases as presented in red and blue, and in both patients the average was 
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better when applying the Qiagen kit compared to the Promega kit (average: 128 ng/µl vs 83 
ng/µl for the brown and 130 ng/µl vs 124 ng/µl for the red case for the Qiagen and Promega 
kits, respectively). The Qiagen kit was therefore used for RNA extraction in all subsequent 
experiments, as detailed in Chapter 2, Section 2.3.1. 
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Figure 3.1: Comparison of yields of total cellular RNA extracted from FFPE samples with two different kits. 
RNA was extracted from FFPE tissue samples of five patients with NHL (two sections of 4µm thickness) in 
three independent experiments with ReliaPrep™ FFPE Total RNA Miniprep System of Promega and RNeasy 
FFPE kit of Qiagen. Concentration of the RNA in the same volume was compared using a paired t test. 
Experiments on the sample of each of the five patients are colourised.  
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3.2.1.2 Thickness of FFPE tissue sections used for RNA extraction: 
Because the yield of RNA amount depends on many factors, including the size of tissue 
material in the FFPE block, a large variation of RNA yield was found between the examined 
cases (0.3-24 µg).  
Moreover, the kit manufacturer stated that too much starting material reduces RNA yield, 
due to overloading the spin column. For each extraction, the RNeasy FFPE kit handbook 
suggested to use a maximum of four sections per FFPE sample, each with a thickness of 
10µm. However, there was no suggestion of a minimum amount to be used.   
Given that the use of thick sections not only reduces nucleic acid yield as suggested in the 
manufacturer’s protocol, but also wastes precious FFPE tissue blocks, RNA from only two 
sections of 4µm per sample was extracted. In an experiment using samples from three FL 
cases, it was established that the RNA yield was 2.25-3 µg, which is sufficient for the 
planned experiments. Consequently, this amount of starting material was used in all 
subsequent RNA extractions. 
3.2.1.3 RNA degradation in FFPE samples during storage:  
To examine the effects of FFPE block storage time on tissue RNA quality, three FFPE 
samples stored for six months or less, two samples stored for about one year, and four 
samples stored for 10 years or more, were compared. All samples had been stored in the dark 
at room temperature.  
The RIN was determined using a 2100 bioanalyzer instrument, with the RIN ranges being 
between one and 10 representing highly degraded and intact RNA, respectively. Examples 
of degraded RNA measured by 2100 bioanalyzer are shown in Figure 3.2.  
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We found that there was no difference in RNA integrity between samples stored for about 
one year and those stored for 10 years or longer (P= 0.438) (Mann-Whitney U test). 
However, FFPE samples stored for six months had much better RNA quality compared to 
both groups of tissues stored for one year or more (P < 0.024) (Mann-Whitney U test) (Figure 
3.3). 
 
RIN      Ladder         5.2           2.8            1.9    
Marker                18s         28s
Marker                      18s         28s
Ladder                                                                                          RIN 5.2  
Marker
RIN 2.8                                                                                          RIN 1.8  
a
dc
bDCBA
nt
nt nt
nt
28s
18s
 
Figure 3.2: Examples of RNA degradation measured by 2100 bioanalyzer. The RNA ladder as shown in gel 
image (A) and electropherogram (a); RNA extracted from a FFPE sample with RIN of 5.2 as shown (B) and 
(b); RNA from a FFPE tissue sample with RIN of 2.8 as shown in (C) and (c); and RNA from a FFPE sample 
with RIN of 1.9 as shown in (D) and (d). 
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Figure 3.3: Comparison of RIN of RNA extracted from FFPE samples stored for different periods of time. 
Results are presented as mean  SE measured in triplicate, Mann-Whitney U test was used.  
 
3.2.2. Optimization of DNA extraction from FFPE tissues: 
It is well known that DNA is more stable than RNA (282, 283). This is because compared 
to de-oxy ribose in DNA, the RNA contains an additional OH group in 2', which reduces its 
stability making RNA more prone to hydrolysis (284). In order to examine our study 
hypothesis presented in Chapter 1, we needed DNA to: 
1. Explore the role of AID in ongoing mutations in FL. 
2. Identify the correlation between AID levels and the mutation of other important genes in 
the pathogenesis of FL using NGS. 
Efforts were made initially to isolate better quality and higher quantity of DNA from the 
least amount of tissues of precious PACIFICO clinical trial FFPE specimens. To select the 
best kit for DNA extraction from FFPE samples, a literature review established that the 
QIAamp DNA FFPE Tissue Kit (Qiagen) had proven to be one of the best kits that yielded 
the highest amount and the best quality of DNA from FFPE tissues among all commercially 
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available kits (285-287). Hence, we decided to use this kit for DNA extraction in all of the 
planned experiments requiring DNA. 
3.2.2.1 Optimizing DNA extraction kit to obtain higher quality and quantity of DNA: 
In order to optimize the protocol for obtaining more DNA from the FFPE samples, DNA 
yields achieved with different duration of protein digestion were compared. In experiments 
using 3 FL and 2 NHL samples stored in the LBIH in addition to one of the PACIFICO trial 
FL samples, proteins in one section of 4µm thickness of FFPE tissues was digested for one 
hour and overnight before extraction of gDNA, as described in Chapter 2, Section 2.4.1.  
Each experiment was repeated twice. The DNA yield (presented as concentration in the same 
volume) was greater with the overnight digestion in 11 out of the 12 experiments. In only 
one case, DNA showed a lower concentration as compared to the shorter digestion. 
However, the average level of the two experiments for this case was almost the same (63 
versus 61.5) (brown in Figure 3.4.). Taken together, the overnight treatment was associated 
with an increase in the DNA extracted (Figure 3.4) (P= 0.017, Paired t-test). This was also 
seen when six sections from each of the six cases were tested (data not shown). 
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Figure 3.4: Comparison of DNA yield (presented as the concentration of DNA in the same volume of eluent) 
extracted from FFPE samples after protein digestion for different durations. The FFPE tissue sample sections 
from each of the six patients with FL were incubated with proteinase K for one hour and overnight. This 
procedure was repeated twice in different experiments as colourised (biological repeats). The paired t-test was 
employed to compare the difference between the two digestion durations.  
 
The quality of extracted DNA can be determined by examining the length of gene sequences 
amplifiable in PCR. In order to do this, about 100-bp, 200-bp, 300-bp, 400-bp and 500-bp 
PCR products within the EC gene GAPDH were amplified using DNA extracted from the 
FFPE samples treated with proteinase K, for one hour and overnight.  
It was found that 100bp PCR fragments were produced in all of the six samples. In 4/6 
patient samples, sharper bands were obtained from DNA prepared by overnight incubation 
with proteinase K (Table 3.1). This suggested the prolonged treatment allowed more time 
for reversal of protein-DNA crosslinking in FFPE tissues, and consequently released an 
increased amount of DNA with good amplifiable quality. This can be seen in Figure 3.5 
below: compared to one-hour treatment, the stronger and/or larger PCR bands are presented 
in samples of three cases incubated overnight with proteinase K (Figure 3.5). 
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Hence, it was decided to use overnight incubation with proteinase K at 56°C for all of the 
samples in the planned experiments. 
 
 
 
LTB Samples
One hour proteinase k 
(PCR product size (bp))
Overnight proteinase k
(PCR product size (bp))
100 200 300 400 500 100 200 300 400 500
Patient (217) ++ +++ ++ ++ + +++ ++++ ++++ ++++ ++
Patient 
(T247/99)
++ ++ + + - ++ ++ + + -
Patient 
(T15/98)
++ +++ +++ +++ + ++ ++++ +++ +++ ++
Patient 
(T106/93 )
++ +++ +++ ++ - ++ +++ ++ ++ -
Patient 
(T305/03)
+ ++ + + + + +++ ++ + -
Patient 
(T54/94 )
++ +++ +++ +++ + +++ +++ +++ +++ +++
 
Table 3.1: Comparison of PCR products of GAPDH between FFPE samples with protein digestion for one 
hour and overnight.   -: no product; +, ++, +++ and ++++: PCR product band intensity change from weak to 
strong.  
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DNA ladder
500 bp
400 bp
300 bp
200 bp
100 bp
100 200    300     400    500    600                                                 100    200     300     400   500 600
GAPDH PCR product (bp)                                                            GAPDH PCR product (bp)  
DNA 
ladder
500 bp
400 bp
300 bp
200 bp
100 bp
100 200        300     400        500                                                         100        200        300 400         500 
GAPDH PCR product (bp)                                                                         GAPDH PCR product (bp)  
Overnight  proteinase K 
incubation 
Patient 1
One hour
DNA ladder
500 bp
400 bp
300 bp
200 bp
100 bp
Patient 217
Patient T247/99
a
b
Patient T15/98 Patient T15/98
Patient T247/99
DNA
ladder
500 bp
400 bp
300 bp
200 bp
100 bp
DNA
ladder
500 bp
400 bp
300 bp
200 bp
100 bp
100 200       300  400      500                                   100       200      300      400       500 
GAPDH PCR product (bp)                                                 GAPDH PCR product (bp)  
c
One hour proteinase K 
incubation
Patient  217
 
Figure 3.5: Comparison of length of GAPDH gene fragments amplified using gDNA extracted from FFPE 
tissue samples pre-treated with proteinase K for different periods of time. FFPE tissues from three FL 
patients, (a, b and c) were incubated with proteinase K for one hour (left) and overnight (right) before DNA 
extraction. The PCR products amplified with primer sets designed for 100- to 500-bp gDNA fragments of 
GAPDH were visualised on agarose gels following electrophoresis.  
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3.2.2.2 Adaption of a system to measure DNA integrity: 
The quality of DNA is important for selecting the best samples for ongoing mutation analysis 
of IGHV and NGS experiments. Since we needed DNA templates between 200-400 bp in 
subsequent experiments, we designed PCR primers that amplify about 200-bp, 300-bp and 
400-bp DNA fragments of GAPDH, and used them to detect DNA integrity in all samples. 
Intact DNA prepared from the Karpas 422 cell line (DLBCL) was used as a positive control. 
Its PCR band intensity was scored as ++++, whereas the bands representing partially 
degraded DNA were scored as +++, ++ or +.  A negative score was given to any PCR that 
failed to amplify the gene fragment (Figure 3.6). 
 
Expected size of PCR products (bp) and intensity scores
DNA
ladder
500 bp
400 bp
300 bp
200 bp
100 bp
200         300   400  200       300   400   200  300    400
++           +           - +++       +++       +++     ++++    ++++     ++++  
Patient 1    Patient 2        Karpas cell line
 
Figure 3.6: PCR primers to amplify GAPDH gene at 200, 300 and 400 bp were designed to detect DNA 
quality from FFPE tissues of PACIFICO samples, intact DNA of Karpas 422 cell line was scored (++++), 
partially degraded DNA were scored as +++, ++ or +. 
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In total, DNA from all 87 samples originating from the PACIFICO trial was extracted, with 
an average DNA amount of 18.8 µg (range, 0.15 and 101g), and the DNA yield was high 
enough for NGS ( 0.5μg) in 79 (91%) of the 87 cases. A sufficient quality of DNA was 
able to be obtained for most of the samples to analyse ongoing mutations (Table 3.2).  
 
Table 3.2: The number (%) of DNA samples with different length and amount as estimated with PCR 
amplified GAPDH gene fragments.   
 
3.3 Discussion: 
In this Chapter, the extraction procedures for both RNA and DNA from initial test samples 
were able to be optimised. The DNA and RNA required for the main study are from FFPE 
tissues with all of the associated limitations of formaldehyde and paraffin embedding  
With respect to RNA degradation during the storage in FFPE, it was established that samples 
that were stored for up to six months were associated with a significantly better RNA quality 
than those stored for up to one year. However, there was no difference in the RIN for those 
samples stored for one year and >1 year (up to 19 years) (Figure 3.2). These results are in 
agreement with Ahlfen and colleagues, who found a similar RNA integrity between a series 
of FFPE samples stored for > 1-10 years under the same storage conditions (288).  
Regarding DNA extraction from FFPE samples, we found that overnight incubation with 
proteinase K at 56°C improved both the quantity and quality of DNA compared to one hour 
Band intensity 
Product size 
- + ++ +++ ++++ Total 
% of PCR 
positive 
samples 
200bp 0 14 27 36 10 87 100.00% 
300bp 7 24 25 25 6 87 91.95% 
400bp 23 29 20 13 2 87 73.56% 
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incubation at the same temperature (Figures 3.4 and 3.5). Proteinase K digestion is a critical 
step for proper isolation of the largest possible amount of DNA from FFPE tissues with 
commonly used commercial kits (289). In this step, both concentration of proteinase K and 
duration of treatment are important factors to optimize (290). 
When comparing proteinase K incubation durations of 39, 68 and 116 hours, Hassani and 
colleagues found that 68 hours yielded the largest DNA fragments (290). While Sengüven 
and co-authors found that 72 hours’ incubation yielded better quality and quantity of DNA 
compared to overnight incubation (286). These protein digestions were longer than those 
used in our study. However, the temperature was one degree lower than ours (55°C versus 
56°C). It is difficult to conclude which procedure was better for DNA extraction from the 
FFPE tissue samples.  
Nevertheless, it became a general practice to prolong incubation time with proteinase K to 
improve DNA yield from FFPE samples (291). In fact, other people also prolonged the 
protein digestion to overnight or longer either using the same (292) or different extraction 
kits (293). 
We used PCR amplification of an EC gene to estimate the integrity of DNA extracted from 
FFPE samples (Figure 3.6). This is a commonly used quality control technique by many 
research groups to detect DNA quality (294-297).  
We achieved a 100% amplification for DNA product sized 200 bp. This was greater than 
that reported by Lin and colleagues, who achieved successful DNA amplification in 97% 
(range: 88–100%) of samples only for a PCR product (using the beta actin gene rather than 
the GAPDH that we used). This was probably because the optimizations performed in our 
work improved the quality and quantity of DNA extracted from FFPE tissues (298). Thus, 
our results of DNA extraction from the FFPE samples were comparable to achievements by 
others. For example, Hassani and colleagues, with conditions of DNA extraction optimised, 
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managed to have all DNA samples amplified for a 104-bp PCR product, 50% of samples a 
351-bp (20% faint bands) and 20% of samples a 560-bp products (290). 
In conclusion, suitable kits were selected and conditions optimized for extracting higher 
amount and better quality of RNA and DNA with the less starting material of FFPE 
specimen. These optimised methods were applied in subsequent studies in this project, 
outlined in the following chapters. 
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   Chapter 4 
 
 
AID expression in FL  
 
4.1 Introduction: 
 
The AID enzyme is well known for inducing IGHV mutations in SHM and CSR (198). These 
are physiological processes required to produce highly specific antibodies against antigens, 
as illustrated previously in Chapter 1 (Figures 1.2 and 1.3). 
Strict control of AID is important for preventing mutations affecting genes other than IGHV. 
However, molecular biological techniques have revealed that AID targets other genes 
involved in pathogenesis of lymphomas (198). 
Measuring AID expression is an attractive approach for studying its roles in B-cell 
malignancies. Unfortunately, this is hampered by technical difficulties in extracting good 
quantity and quality of nucleic acids and proteins from FFPE tissue samples. 
Different methods for AID expression in cancers have been used. For AID mRNA 
expression, qPCR was measured either using SYBR Green (299) or Taqman primers and 
reagents (300).  
To detect AID protein levels, different techniques have been employed, including FACS 
analysis, western blotting (37, 299), IHC (141) and immunofluorescence (301).  
However, to our knowledge, no publication to date has provided data concerning AID 
expression at the levels of mRNA, IHC, IF and subcellular localization in FL for one cohort 
of patients.  
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To identify AID expression at all of these levels, we undertook all of the optimizations 
required to make a reliable measurement of AID level from partially degraded FFPE as the 
starting material.  
4.2 Patients and Methods:  
87 patients diagnosed with FL and recruited in the PACIFICO clinical trial were included in 
this study. Most patients had advanced disease at trial entry: Stage I, n=0 patients; stage II, 
n=11; stage III, n=40; stage IV, n=36. Clinical data of patients were blinded until completion 
of experimental work and the commencement of thesis writing.  
4.2.1 AID mRNA expression using qPCR: 
We optimized RNA extraction methods from FFPE to obtain more RNA; details are 
described in Chapter 2, Section 3.2.1. 
4.2.1.1 Quality and quantity of RNA extracted from FFPE: 
Before starting qPCR experiments for AID expression of FL, we wanted to establish a cut-
off level of RNA quality that can be reliably used in our experiments. To detect the quantity 
of RNA extracted from FFPE, we used the Qubit fluorometer 2. To analyse the integrity and 
quality of RNA, we used the 2100 Bioanalyzer instrument of Agilent. 
In 83 out of 87 (95%) PACIFICO FFPE samples, RIN values ranged between one and 5.2 
with an average of 2.2. Four samples had a RIN value of ‘NA’ (not available), which is 
usually an indication of highly degraded RNA. The total RNA extracted from FFPE tissue 
ranged between 0.225-36 µg, with the average being 7.36 µg.  
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4.2.1.2 Storage conditions and duration of PACIFICO FFPE tissues: 
PACIFICO FFPE tissues used in our work were stored in the dark at room temperature. 
The age of the 87 FFPE samples ranged between 1-108 months in paraffin, with a median 
of 24 months. We explored the correlation of sample age and the RIN of all samples. We 
established a weak but significant negative correlation between sample age and RIN, with 
poor RNA quality being associated with increasing duration of FFPE samples storage,         
(r= - 0.265, P= 0.016) (Spearman’s correlation), (Figure 4.1 (a)) 
In addition, there was a statistically significant difference between RIN of samples aged 12 
months or less compared to those stored for more than one year (Figure 4.1(b)) (P= 0.02), 
(Mann-Whitney U test). 
 
 
1 year or shorter
(n= 28)
longer than 1 year
(n= 55)
Storage time of FFPE tissues 
ba P = 0.02 
Storage time of FFPE tissues (months)  
r= - 0.265
P = 0.016
Y=2.47-8.11E-3*x
n=  83
R
IN
 
R
IN
 
 
Figure 4.1: RNA integrity was reduced during storage of FFPE samples. (a) A negative correlation between 
RNA integrity as presented as RIN quantified with Bioanalyser measurement and duration of sample storage. 
This was identified amongts the 83 samples with the Spearman’s correlation analysis ( r = - 0.265, P= 0.016); 
(b) A significantly lower level of RIN in FFPE samples stored more than one year compared to those stored 
for one year or less (P= 0.02), (Mann-Whitney U test). 
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To identify whether we could use the RNA extracted from FFPE to amplify AID, an EC gene 
(GAPDH) and one of germinal B-cell markers (CD19) were evaluated. 
As a positive control, we used cDNA from a CLL patient blood sample, which was known 
to express AID protein.  
We reversed transcribed RNA extracted from two FFPE tissues of the LBIH that were stored 
for a period >10 years, and then performed PCR using primers to amplify 300-400 base pairs 
for the three genes. We repeated this experiment twice, with method details being described 
in Chapter 2, Section 2.3.5 (Figure 4.2). 
We did not obtain PCR products of GAPDH, AID or CD19 on agarose gel analysis in both 
LBIH samples. This was expected to be due to degradation of RNA extracted from the FFPE 
tissue, so we subsequently optimized RNA extraction and designed primers to amplify 
smaller PCR products. 
 
DNA 
ladder
1000
500   
400  
300  
200   
100  
Water      LBIH Patient 1 (RIN=2) LBIH  Patient 2 (RIN 1.9)                CLL patient blood  Water                                    
GAPDH GAPDH CD19      AID GAPDH    CD19     AID GAPDH      CD19          AID AID
 
Figure 4.2: No amplification of genes from RNA of FFPE when primers amplifying large PCR products 
were used. AID, GAPDH and CD19 could not be amplified in two old FFPE samples when PCR primers of 
300-400 bp were used (orange and yellow), The fresh blood CLL sample amplified all three genes (blue); In 
each of the three different samples used, the experiment was technically repeated twice.   
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4.2.1.3 Checking the quality of RNA required for reliable qPCR results: 
Fixation and paraffin embedding degrades RNA in FFPE tissues. To determine the degree 
of RNA degradation that would still allow us to use the sample for AID expression, we 
needed to compare expression of AID to the EC gene in fresh and degraded counterparts of 
the same sample. Unfortunately, this could not be done on our FFPE tissues, as we did not 
have the respective fresh frozen biopsy of the sample. 
Hence, we decided to grow a B-cell lymphoma cell line that is known to express AID. We 
then extracted RNA and degraded it by heating for differing time periods. This allowed us 
to measure the qPCR expression ratio of AID to EC gene in fresh and degraded series of 
RNAs from the same cell line. Subsequently, we compared qPCR expression in intact and 
degraded series, with determine to what degree of degradation it was still possible to use the 
RNA.  
For the above, we chose the Raji cell line (Burkitt's lymphoma cell line), which is known for 
high expression of AID (302, 303) . We degraded the cell line by heating at 95°C in batches 
from 3-30 minutes; this led to a degraded RNA series with RIN ranging from 9.1-NA, with 
NA being an indication of severely degraded RNA (Figure 4.3 (a)).      
To understand the effect of RNA degradation on AID expression by qPCR, we used the 
qPCR reaction that was optimized by our research group (Chapter 2, Section 2.3.7).  
For further optimization for detecting suitable quality of RNA for qPCR, we compared oligo-
dt primers and random primers to amplify AID and GAPDH in the series of degraded Raji 
RNA samples (RIN from 9.1 - NA) to produce small (90 bp versus 101 bp)  
and large (386 bp versus 315 bp) AID and GAPDH PCR products, respectively, random 
primers amplified mRNA products in the above samples.  
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We also saw that cDNA derived from RNA samples with RIN of 2.6 produced the same 
qPCR ratio of AID/GAPDH to the intact RNA; however, this ratio was not the same for 
samples of RIN of 1.9. 
So, we further degraded two batches of samples to obtain RNA samples with RIN of 2.4 and 
2.1. We found that the ratio of AID/GAPDH genes was achieved in degraded samples down 
to RIN of 2.1 was close to the intact RNA.  
Each experiment was performed at least twice and each time three qPCR readings were taken 
(n=6).  
The AID/GAPDH mRNA ratio in an intact sample is statistically significantly different from 
samples with RIN of 1.9 (P= 0.028) (Wilcoxon signed-rank test). None of the other ratios 
from 8.1 – 2.1 were statistically different from the intact RNA (Figure 4.3(b)). 
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Figure 4.3: RNA RIN ≥2.1 produced reliable AID/GAPDH qPCR results. (a) We degraded RNA extracted 
from a Raji cell line by heating at 95°C for 3-30 mins. RIN measured by a bioanalyzer 2100 ranged from 9.1 
– NA, NA usually results from severely degraded RNA; (c) Only small products of random primers can produce 
a ratio of AID/GAPDH in degraded RNA down to 2.1 that does not statistically differ from the ratio produced 
by intact RNA. A significantly lower ratio of AID/GAPDH was found for RNA RIN of 1.9 compared to intact 
RNA (P= 0.028) (Wilcoxon signed-rank test) (mean ± SD, n=6). 
 
 
Hence, as a result of these experiments, we used random primers in RNA reverse 
transcription reactions and PCR primers that amplify products less than 101 bp. The suitable 
samples for mRNA expression of AID were only those with RNA of RIN ≥ 2.1. In our cohort 
of patients, out of 87 patients, 59 samples had a RIN of 2.1 or more (≈68%).   
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4.2.1.4 Selecting the best EC gene for qPCR reaction of AID gene: 
The AID transcriptional level was measured as its ratio to an EC gene in qPCR. To do so, 
we needed firstly to determine what EC gene is most homogeneously expressing among 
different patients with FL, and therefore whether it was suitable to be used to as an internal 
control.  
A review of the literature showed that other authors used the following genes as endogenous 
controls in FL: GAPDH, HPRT1 and TBP (273, 304-306). 
We used the same primers as in the above papers and performed our qPCR expression using 
our optimized protocol (Chapter 2, Section 2.3.7) of all three genes in nine cases of FL from 
the PACIFICO trial. Each experiment was repeated technically three times using our 
optimized qPCR protocol. 
In comparison to transcriptional levels, as presented by the threshold of PCR cycles (Ct), a 
significant positive correlation was observed between any two of the three EC genes (Figure 
4.4). 
However, the slope in the linear regression and the correlation efficient (r) between GAPDH 
and HPRT1or TBP was closer to one (Figure 4.4. A and B) than those between HPRT1and 
TBP (Figure 4.4. C), suggesting that the variation of GAPDH expression among FL patients 
is smallest among the three EC genes. In addition, the Ct of GAPDH was smaller than 30 in 
eight out of the nine patient samples, with the Ct for the remaining one being closer to 32.5, 
whereas it was bigger than 30 in four, or all, patients for HPRT1and TBP, respectively 
(Figure 4.4). This indicated that the measurement of GAPDH mRNA in this qPCR was more 
reliable as compared to the other two EC genes tested. So, we subsequently used GAPDH as 
an EC gene in our qPCR to quantify AID transcriptional levels. 
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Figure 4.4: Comparison between different EC genes to choose the most suitable gene to produce the AID/EC 
gene ratio. Nine FL cases were used to explore this issue: we found a significantly positive correlation between 
all three genes. However, the linear regression slope and r value were closer to one between GAPDH against 
HPRT1 and TBP (a and b) than between the latter two genes (c) (n= 9).  
 
To recap, at this stage, the selection criteria for RNA quality to give reliable qPCR results 
was completed, the best EC genes were selected, and the qPCR reaction for estimation of 
AID mRNA by qPCR was optimised. 
Our total cohort was 87 cases, 28 samples (≈ 32%) (≈ is approximately equal) had a RIN 
less than 2.1, and so we performed AID mRNA expression by qPCR in 59 out of 87 samples 
(≈ 68%).   
As mentioned above, the Raji cell line (Burkitt’s lymphoma) was used as a positive control 
(302, 303), and the K562 Chronic Myeloid Leukemia (CML) cell line as a negative control 
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(307, 308) for AID qPCR expression (details of methods provided in Chapter 2, Section 
2.3.7). 
The AID qPCR products were sent for sequencing in forward and reverse directions, and we 
established that the qPCR sequence of AID was consistent with the primer design. The qPCR 
ratio of AID/GAPDH varied widely in the 59 cohort samples, ranging between 0.0001- 0.72; 
the median was 0.02. Each experiment was repeated technically twice (Figure 4.7).  
4.2.2 AID protein expression by IHC: 
To elucidate the role of AID in FL pathogenesis, we wanted to identify total protein 
expression of AID by IHC. Details of this protocol are provided in Chapter 2, Section 2.6.1.1. 
To determine the best concentration of AID antibody to be used for IHC, we tried different 
dilutions of the AID monoclonal antibody (mAb). We found that a 1/500 dilution of AID in 
antibody diluent was the most suitable.  
We used hyperplastic tonsil tissue that was stained by AID as a positive control, and IgG1 
as an isotype control (Figure 4.5).  
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a b
c d
Figure 4.5: Hyperplastic tonsil was used as a positive and negative controls for AID protein expression by 
IHC. (a) Hyperactive tonsil stained with IgG1 isotype control (c) is a magnified image of the same stained 
tissue in (a); (b) The same tonsil was stained by AID mAb (d) is a magnified part of the image in (b). In (a) 
and (b) the scale bar is 3mm, in (c) and (d) it is 100µm.  
We then stained all of our 87 patient cohort samples with the AID mAb; examples for 
different levels of AID protein expression by IHC can be seen in Figure 4.6. 
c
200 µm200 µm
b
200 µm
a
 
Figure 4.6: Different FL LNs stained with AID mAb using IHC technique, (a) LN scored 1, (b) LN scored 4, 
(c) LN scored 9. 
 
We scored the slide sections according to the number of stained cells and intensity of staining 
using the following formula:  % of lymphocytes stained X Intensity (Table 4.1) This scoring 
system is widely used to identify IHC score of a protein in lymphoma and other cancers 
(268-270, 309-312). 
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Table 4.1: Scoring system used to score IHC slides stained with AID mAb. 
 
The scoring of the slides was performed by two observers (myself and a specialist 
pathologist, Prof. Sarah E. Coupland). All of the 87 slides were scored. The AID score 
ranged from 1-9 with a median of 2. 
4.2.3. AID mRNA and protein expression profiles in the cohort of patients with FL 
studied: 
AID/GAPDH mRNA expression and AID IHC expression varied widely among FL 
PACIFICO patients (Figure 4.7). 
AID IHC expression was calculated in all cases. AID/GAPDH mRNA expression was 
measured in about 2/3 of patients (59 out of 87) and 18/20 cases of nuclear to cytoplasmic 
(N/C) ratio of AID have AID/GAPDH mRNA data   
Lymphocytes Intensity of stain Final score 
Percentage Score Degree Score  
 
 
= % of lymphocytes stained X Intensity 
0 0 Negative 0 
1-24 1 Weak 1 
25-49 2 Moderate 2 
50-74 3 Strong 3 
>75 4   
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Figure 4.7: Expression of AID is variable among FL cases (a) Variable expression of AID/GAPDH mRNA, 
and (b) AID protein in PACIFICO FL cases.   
 
4.3 Correlation between AID protein and AID mRNA expression: 
We were able to obtain sufficient quality of RNA to perform qPCR in about 68% of our 
samples (59 out of 87). 
When we divided IHC into 2 groups based on the median, we found a significantly higher 
ratio of AID/GAPDH mRNA in patients with high AID protein (P= 0.001) (Mann-Whitney 
U-test) (Figure 4.8). 
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Figure 4.8: A positive significant correlation was obtained by comparing mRNA and protein level of AID. We 
devided AID into high and low groups, the ratio of AID/GAPDH in mRNA was significantly higher in pateints 
with high AID protein by IHC (P= 0.001, Mann-Whiteney U test).   
 
4.4 Immunofluorescent expression of AID: 
Total AID protein expression was determined using IHC. We wanted next to explore AID 
expression by immunofluorescence (IF). This was undertaken to identify exactly which cells 
of the GC were expressing AID, and to quantify the nuclear/cytoplasmic (N/C) ratio of AID. 
4.4.1 Immunofluorescent co-expression of AID with CD3, CD20 and CD68: 
In order to identify cells expressing AID in FL LNs, we undertook an immunofluorescent 
co-expression of AID protein with markers of common cells in GC.  
We performed dual-immunostaining of AID with CD3 (T cells), CD20 (B-cells) and CD68 
(macrophages). The method details are outlined in Chapter 2, Section 2.6.2.  
When FL GC were stained with AID and CD3 immunofluorescence, we established that 
there was no co-expression of AID and CD3 on the same cells, i.e. on T-lymphocytes. This 
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was the same with CD68, i.e on macrophages. However, when we performed the dual 
staining of AID with CD20, we found that the colour became yellow in most GC cells, due 
to co-expression of AID (green) and CD20 (red), i.e. on the B-lymphocytes. We did this 
experiment in two cases expressing high AID and in hyperplastic tonsil tissue, and the results 
were the same (Figure 4.9).  
 
 
 
B cells
AID stain (green) Cell marker (red) Merged
T cells
Macro
-phages
10  µm 10  µm
10  µm10  µm
 
Figure 4.9: AID is expressed in B-cells of the GC, and not T cells or macrophages. CD20 is the B-cell marker 
used, CD3 is (T cell marker) and CD68 (Macrophage marker). Only CD20 is co-expressed with AID in the 
same cells giving an orange colour (upper right).  
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4.4.2 Subcellular localization of AID: 
AID protein is synthesized and stored in a stable form in the cytoplasm, but shuttles to and 
from the nucleus where it functions (198). Hence, we wanted to determine the N/C ratio of 
AID in patients with high and low total AID expression. Our aim was to better explore 
functional AID. This is because total AID represents the stored and functional AID, while 
nuclear AID probably represents more the active AID. 
To do this, three nuclear immunofluorescent stains (TO-PRO-3, 7-AAD and Hoechst 33258) 
were tested. In addition, different antibodies dilutions and protocols for double 
immunostaining with AID were used. The Hoechst 33258 antibody gave the best images, so 
it was employed in all IF slide staining. The method details are given in Chapter 2, Section 
2.6.3.1 (Figure 4.10). 
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Figure 4.10: Three different nuclear stains were tried (red) in co-expression with AID (green) (a) Hoechst 
nuclear stain (red) (b) AID (green) (c) Hoechst and AID (d) TO-PRO-3 (red) (e) AID (green) (f) TO-PRO-3 
and AID (g) 7-AAD (red) (h) AID (i) 7-AAD and AID. 
 
Ten cases of FL with high AID protein by IHC and another ten cases of FL with low AID 
were selected. The slides were stained and visualised by confocal microscopy. After 
obtaining AID and nuclear co-expression IF images, a review of the literature was 
undertaken to identify a way of measuring N/C ratio of AID.  
Published methods using Image j1x software were modified to analyse nuclear and 
cytoplasmic portions of AID (271, 313, 314). 
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Image j1x software was used to measure the ratio of N/C AID expression. This was done by 
removing the background IF stain. Then, an automatic selection of the nuclei was performed, 
followed by measurements of the nuclear AID expression. Cytoplasmic AID in the image 
was finally calculated by excluding the nuclear AID. The method details are supplied in 
Chapter 2, Section 2.6.3.2.    
The positive control was a hyperactive tonsil, and the negative control was the IgG1 isotype 
staining of the hyperactive tonsil (Figure 4.11). 
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Figure 4.11: Positive and negative controls for subcellular AID IF. (a, b and c) are hyperactive tonsil positive 
controls (a) Hoechst nuclear stain (red) (b) is AID antibody stain (green) showing nuclear and cytoplasmic 
AID (c) is co-expression of both stains; (d, e and f) are IgG1 isotype control staining of hyperactive tonsil; (d) 
is the nuclear stain (red); (e) IgG1 stain (no AID) and (f) is a combination of both. 
 
To identify the GCs under the IF microscope, a low magnification was initially used (10x). 
Five GCs were then selected: these were closest to 12, 3, 6 and 9 o’clock positions, in 
addition to one central GC within the LN. This is to take a representative GC from each 
region of LN because it was very difficult, time consuming and costly to take all or the 
majority of GCs (Figure 4.12). 
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Figure 4.12: To study subcellular localization of AID in FL we needed to take a good representative areas of 
LN, so we took from five different GCs by choosing closest GC to areas 12, 3, 6 and 9 o’clock positions in 
addition to the middle of LN. 
 
Within each GC selected, it was attempted to examine two immunofluorescent images if 
possible in the upper and lower parts of the GC, so that the number of images for each sample 
ranged between “6-15”, with an average of nine. 
To carry out the subcellular localization of AID in FL, ten cases were selected with high 
AID protein by IHC (≥3), the range was 3 - 9 and ten cases with low AID. The N/C ratio of 
AID in the 20 cases ranged between 46.91 and 70.69; the median of N/C AID ratio  
was 60.13%. The expression of N/C ratio of AID is shown in Figure 4.13. 
138 
 
 
N
/C
 A
ID
 r
a
ti
o
PACIFICO trial FL cases
0
10
20
30
40
50
60
70
80
84 55 187 42 202 142 118 237 256 3 242 269 59 233 76 196 11 120 33 267
 
Figure 4.13: Expression of N/C ratio of AID protein in 20 cases of the PACIFICO trial FL. We divided 
patients into two groups, these were low and high N/C ratio of AID using the median as a cut-off point. 
 
 
 
The AID/GAPDH mRNA expression data were available for 18/20 cases with subcellular 
AID staining. A significant positive correlation was found between the N/C ratio of AID and 
AID/GAPDH mRNA (r=0.513, P= 0.025) (Spearman’s correlation). 
The same observation was made when we examined the correlation between N/C ratio of 
AID compared to total AID protein. We found a significantly higher N/C ratio of AID in the 
group of high AID protein score measured by IHC (P= 0.023) (Mann-Whitney U test).   
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Figure 4.14: A significantly higher N/C AID ratio was found in cases with higher AID total protein by IHC 
(P= 0.023) (Mann-Whitney U test). 
 
4.5: Correlation between clinical data at diagnosis and AID level: 
We were able to obtain some clinical and diagnostic data from the LCTU. These data 
included the age, sex, number of enlarged LNs (patients were divided into two groups, five 
or less nodes in one group and six or more LNs is the second group), LDH levels, histological 
grade, anatomical stage and FLIPI prognostic score.  
Details of correlations between AID/GAPDH mRNA expression, total AID protein and N/C 
ratio of AID and clinical data are found in Tables 4.2, 4.3 and 4.4, respectively.  
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Table 4.2: Correlation between AID/GAPDH mRNA expression and clinical data of patients. 
                               
 
 
Parameter 
 
Range 
AID/GAPDH    
mRNA 
Mean ± SD 
 
AID/GAPDH  mRNA 
P value Statistical 
test 
 
Age 
 
57- 89 
 
0.053 ± 0.103 
 
0.786 
(r= 0.036) 
Spearman's 
correlation 
 
 
Sex 
Male 
 
34 (57.62%) 
 
0.07 ± 0.132 
 
 
 
0.407 
 
 
Mann-
Whitney U 
test 
Female 
 
25 (42.37%) 
 
0.028 ± 0.027 
 
 
 
Number of LN 
1 – 5 
 
22 (37.29%) 
 
0.041 ± 0.048 
 
 
 
0.402 
 
 
 
Mann-
Whitney U 
test 
≥ 6 
 
37 (62.71%) 
 
0.059 ± 0.126 
 
 
 
 LDH (U/L) 
 
156 – 862 
 
 
0.053 ± 0.103 
 
0.108 
(r= - 0.213) 
 
Spearman's 
correlation 
 
 
 
 
Histological grade 
1 
 
14 (23.73%) 
 
0.038 ± 0.048 
 
 
 
 
0.966 
 
 
 
 
Kruskal -
Wallis test 
2 
 
29 (49.15%) 
 
0.07 ± 0.1418 
3 
 
16 (27.12) 
 
0.035 ± 0.032 
 
 
 
Ann Arber stage 
2 
 
8 (13.56%) 
 
0.018 ± 0.011 
 
 
 
 
0.429 
 
 
 
Kruskal -
Wallis test 
3 
 
26 (44.06%) 
0.065 ± 0.141 
4 
25 (42.37%) 
0.051 ± 0.068 
 
 
 
FLIPI score 
0                                
5 (8.47%) 
 
0.03 ± 0.032 
 
 
 
0.73 
 
 
Kruskal -
Wallis test 
1 
13 (22.03%) 
 
0.046 ± 0.059 
2 
41 (69.49) 
 
0.057 ± 0.12 
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Table 4.3: Relation between total AID protein expression and clinical data of the patients. 
 
   
 
Parameter 
 
Range 
AID total 
protein 
Mean ± SD 
AID total protein by IHC 
2 groups: 
≤2 (55 patients (63.21%)) 
>2 (32 patients (36.78%)) 
P value Statistical test 
 
Age 
 
54 - 89 
 
3.25 ± 2.73 
 
0.888 
 
Mann-Whitney U test 
 
 
Sex 
Male 
46 (52.87%) 
 
3 ± 2.76 
 
 
 
0.35 
 
 
Chi-square test 
Female 
41 (47.12%) 
 
3.63 ± 2.83 
 
 
Number of LN 
1 – 5 
32 (36.78%) 
 
3.67 ± 2.92 
 
 
0.49 
 
 
Chi-square test ≥ 6 
55 (63.22%) 
 
2.91 ± 2.66 
  
LDH (U/L) 
 
109 – 862 
 
    
3.25 ± 2.73 
 
0.398 
 
Mann-Whitney U test 
 
 
 
Histological grade                                 
1 
23 (26.44 %) 
 
3 ± 4 
 
 
       
    0.17 
 
 
 
 
Chi-square 
test 
2 
42 (48.28%)
 
2.91 ± 2.02 
3 
22 (25.29%) 
 
4.2 ± 3.42 
 
 
 
FLIPI score  
0 
9 (10.34%) 
 
1.33 ± 1.32 
 
 
0.077 
 
 
Fisher-Freeman-
Halton exact test 
1 
20 (22.99 %) 
 
2.3 ± 2.36 
2 
58 (66.66) 
 
2.64 ± 2.15 
142 
 
 
Table 4.4: Correlation between N/C AID ratio expression and clinical data of PACIFICO patients. 
No statistically significant correlations were found between AID expression at all levels and 
any of the clinical parameters. However, when we compared patients with N/C AID protein 
ratio against stage of disease, a tendency towards higher N/C ratio of AID in patients with 
advanced stages of disease, (P= 0.089) (Fisher Exact test). Note that stage IV was compared 
to stages II and III: this was because, in agreement with the fact that most patients with FL 
present advanced disease at time of diagnosis (315), and particularly at entrance to the 
 
 
 
 
Parameter 
 
 
Range 
N/C  ratio of 
AID 
Mean ± SD 
             N/C  ratio of AID  
 
 2 groups’ ≤ 60.13 (11 patients 
(55%)) 
                    > 60.13 (9 patients 
(45 %)) 
P value Statistical test 
 
Age 
 
57 - 84 
59.56 ± 6.69  
0.28 
 
Mann-Whitney U 
test 
 
 
Sex 
Male 
 
12 (60%)  
 
58.12 ± 6.48 
 
 
 
0.169 
 
 
     
  Fisher Exact test Female 
 
8 (40%)  
 
61.71 ± 6.83 
 
 
Number of LN 
1 – 5 
 
9 (45%)  
 
58.26 ± 7.09 
 
 
1 
 
 
Fisher Exact test 
≥ 6 
 
11 (55%)  
 
60.62 ± 6.48 
  
LDH (U/L) 
 
109 – 830 
 
     
 59.56 ± 6.69 
 
0.971 
 
Mann-Whitney U 
test 
 
 
 
    Histological grade                                 
1 
4 (20%) 
 
56.62 ± 7.25 
 
 
 
0.6 
 
 
 
Fisher Exact test 
2 
11 (55%) 
 
60.81 ± 7.05 
3 
5 (25%) 
 
59.14 ± 5.98 
 
 
 
            FLIPI score 
0 
3 (15%) 
 
58.83 ± 6.31 
 
 
 
0.533 
 
 
 
Kruskal -Wallis test 
1 
3 (15%) 
 
56.29 ± 9.26 
2 
14 (70%) 
 
60.41 ±  6.53 
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clinical trials, 18 of the 20 (90%) cases studied were at stages III (n = 9) or IV (n = 9), with 
the remaining two being at stage II (Table 4.5). 
Also, there is a non-significant positive association between AID total protein expression 
and FLIPI score (P= 0.077) 
 
 
 
Stage 
 
N/C ratio of AID 
 
≤ median* > median 
II or III 8 3 
IV 2 7 
 
Table 4.5: Comparison of frequency of stage IV FL between patients with high and low N/C ratio of AID 
protein by IF.* The median of N/C ratio of AID protein was 60.13. 
 
 
 
4.6 Discussion: 
 
Using gene mRNA expression by qPCR is one of the key technologies for biomarker 
discovery and clinical research to date (316). However, it is well known that intact RNA in 
fresh frozen tissues are preferred for qPCR mRNA levels. Unfortunately, these samples are 
usually of limited availability in research centres, in contrast to FFPE tissues that are stored 
for decades in most clinical centres and pathology departments (317).    
The aim of this chapter was to measure AID expression in FL at the levels of mRNA, total 
protein by IHC and subcellular localization of AID protein. This can be used to correlate 
AID expression to clinical data, and to my knowledge, there is no publication which includes 
these three levels of AID expression in FL. 
As discussed in Chapter 3 previously, RNA is degraded in FFPE tissues that are available 
for our research project. We wanted first to explore the effect of time storage of FFPE on 
RNA quality. It was found that the longer the time storage, the worse was the quality of 
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RNA. In addition, a significant difference was found in RNA quality between samples stored 
for less than or more than one year (Figure 4.1). 
In contrast to our results, Bradley and colleagues found that the storage time of FFPE 
samples was not correlated with RNA quality for samples stored up to 3 years (318). This 
contradiction to our results was probably due to their small cohort of samples (18 compared 
to our 87 samples). Furthermore, they did not publish the storage time of each sample; 
probably the majority of their samples were in one of the categories of less than or more than 
one year and yielded no statistically significant correlation between RNA quality and sample 
age. In addition, this difference may also have resulted from other factors known to affect 
RNA quality such as fixation process or storage conditions (319, 320). 
Subsequent to this, we tried to amplify large PCR products of AID and GAPDH genes 
(between 300-400 bp) from cDNA that was reversed transcribed from RNA of FFPE tissues 
of FL patients. Unfortunately, we did not obtain PCR products, mostly due to RNA 
degradation (Figure 4.2).  
These findings were similar to many other studies: for example, Mathieson and colleagues 
used FFPE tissue samples for PCR amplification (321). They were able to amplify PCR in 
all samples when they used 65bp. However, by using primers to amplify 265bp products, 
only about half of samples were amplified (321). Belder and colleagues failed to amplify 
fragments longer than 150 bp from cDNA derived from FFPE tissues RNA (322). Similarly, 
Kong and co-workers found a poor PCR amplification efficiency and reliability for products 
around 200bp size (317). 
For this reason, we tried next to identify a cut-off point of RNA degradation that produce a 
reliable results for AID/GAPDH ratio in qPCR reaction. To do this, we degraded a series of 
Raji cell line RNA by heating at 95°C for 3-30 mins (Figure 4.3 a), then synthesised cDNA 
and performed qPCR; after that, we compared qPCR ratios across all samples. 
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In comparison to our method of artificial RNA degradation, different procedures were used 
in these publications. Examples of these techniques include adding RNAse enzymes (323, 
324) or RNA hydrolysis by incubating RNA with high pH alkaline buffer (325). Other 
mechanisms for RNA degradation are exposing nucleic acid to ultraviolet light for extended 
time periods (326) or heating RNA in a thermal block using different temperatures and times, 
and this method was used in our experiment (327).  
However for FFPE tissues, the common method for estimating degradation of RNA was by 
comparing the samples stored for different time periods (288). So, we used the heating 
method in RNA extracted from cell lines because we did not have enough time to wait for 
our FFPE tissue samples to degrade. 
To determine the most suitable primers for reverse transcription reactions, a comparison was 
carried out between using random primers and oligo-dt primers in RT qPCR reactions. It 
was found that random primers produced better results (Figure 4.3 b). This could be due to 
RNA degradation in FFPE tissue samples. As a result, the poly A tail of mRNA is degraded 
in many templates and oligo-dt primers cannot start reverse transcription. This is in contrast 
to random primers, which can start reverse transcription from any segment of the gene. So, 
although Oligo-dt primers are more specific and preferred in two-step PCR reactions, 
random primers are the best option for degraded RNA in FFPE tissues and produce a large 
amount of cDNA (328, 329). Some researchers prefer using a combination of oligo-dt 
primers and random primers in the same reverse transcription reaction to obtain the benefits 
of both types. Examples include Olsen et al. (330), Yao et al. (331), Vuong et al. (332) and 
Medimegh et al. (333).  
In our study, it was shown that short PCR products were more suitable and produce reliable 
and consistent results for qPCR performed on nucleic acid of FFPE (Figure 4.3 b). Recent 
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studies also used short amplicons around 100bp for amplifying PCR from FFPE tissues (334, 
335). This is in agreement with Zeka et al. (336), and Kocjan et al. (337).  
In order to determine which EC gene should be targeted for our qPCR expression of AID, 
we undertook qPCR expression of three most commonly used genes in FL. It was found that 
GAPDH is the most suitable (Figure 4.4). In agreement with us, Walter and colleagues found 
that GAPDH and not HPRT1 was the best reference gene in FFPE tissue gene expression 
experiments (338). In addition, GAPDH is still being used by the most well-known research 
groups involved in FL as a reference gene for qPCR reactions in FL (339-343). However, in 
contrast, B de Kok and colleagues found that HPRT was a better EC gene than GAPDH 
(344). Further, lso Lossos and co-workers noted that PRKG1 and/or TBP were also better 
than GAPDH as an EC gene in lymphoma (345). This is probably because of the use of intact 
RNA in those two studies (frozen tissues) compared to our degraded tissues using TBP and 
HPRT1, which appeared to be more degraded and found in later cycles of qPCR. 
After we performed AID expression at both mRNA and protein level, we found that there 
was a significant positive correlation between mRNA and protein levels of AID in FL 
(Figure 4.8). These results were in agreement with Rush et al. (346), who also noted a 
positive correlation between AID mRNA and protein level in GC B-cells.  
In this study, it was observed that only B-cells but neither T cells nor macrophages of GC 
expressed AID (Figure 4.9). This was in agreement with Cattoretti and colleagues. These 
authors discovered that AID was expressed in B-cells and not T cells or FDCs. In addition, 
they found that AID positive B-cells were in contact with T cells or FDCs (347). However, 
in the presence of chronic inflammation, FDCs start to form follicular structures that are 
similar to GC. It has been noted that these cells may express AID, and this was observed in 
FDCs of rheumatoid arthritis synovium (348) and Sjogren’s Syndrome (349). In T cells, 
although less than 1% of T cells express AID at any given time point, Qin and co-workers 
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found that in mouse LNs, a small subset of T cells may express AID, and these cells increase 
with age; the authors suggest that these cells are connected to long-term immunity (350). 
It was observed in this study that AID was present in the nucleus and those cells with high 
AID mRNA and high AID total protein have high N/C AID ratio (Figure 4.14).  
Excess AID in the nucleus is mutagenic and different molecular mechanisms to prevent 
nuclear damage by the additional AID were elucidated. For instance, Methot and colleagues 
found that AID was kept out of the nucleus by two mechanisms: (1) AID cytoplasmic 
sequestration by eukaryotic elongation factor 1 α (eEF1A), and (2) CRM1-mediated AID 
nuclear export (351). Hu and colleagues discovered the C-terminal region of AID includes 
a nuclear-export signal which is responsible for AID’s nuclear cytoplasmic (232). 
In addition, (ubiquitin-dependent) proteosomal degradation pathways also prevent AID 
nuclear damage (228, 352, 353). 
We used Image j1x software to measure N/C ratio of AID in FL FFPE tissue sections; 
however, we faced some difficulties with these samples. This is because of the nature of 
cells in FL that are tightly packed close to each other, with the nucleus appearing to extend 
into the cytoplasm of the same cells and even into that of nearby cells. Consequently, this 
made automatic nuclear selection problematic.  
When AID expression was compared to all of the clinical data at entry to clinical trial, it was 
found that there was no direct correlation between AID expression and clinical outcome of 
patients. This was with the exception of a tendency towards higher N/C ratio of AID in 
patients with more advanced stage of disease. This could be explained by the following 
factors: 
1- Most patients reached advanced disease. In stage II disease, we had 11 FL patients 
only compared to 40 patients in stage III, and 36 patients in stage IV. So, the patient 
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cohort was skewed with most patients having advanced disease. This may have led to 
no clear changes between AID expression and clinical data. 
 
2- Although the cohort of patients was low in N/C AID ratio (20 patients), we still 
observed tendency toward higher AID N/C protein ratio with advanced stage of 
disease. This may indicate that the function of AID correlates better with disease 
progression than AID mRNA or protein expression. However, a larger cohort of 
patients is required to validate our results and provide a robust conclusion. 
In agreement with our findings, Willenbrock and colleagues found that total AID protein 
expression by IHC was not related to prognosis and stage in FL (354). 
Further support for our results comes from very recent data from Kawamura and co-workers. 
They found that in contrast to diffuse large B-cell lymphomas, there was no correlation 
between AID expression at RNA and protein levels with disease stage and prognosis in FL 
(237). 
In summary, in this chapter an optimization of methods for AID expression at the levels of 
mRNA, protein and N/C AID expression was carried out. Further, it was established that 
AID expression at the mRNA, total and N/C protein levels were correlated to each other. A 
tendency towards higher N/C ratio of AID and stage of disease was observed. Consequently, 
this study was further extended to explore the correlation between AID expression and the 
number of ongoing mutations in FL: this work is to be found in the next chapter. This process 
of ongoing mutation of the IGHV gene is of relevance as it is associated with formation of 
subclones, relapse and progression of disease in addition to resistance to chemotherapy. 
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Chapter 5 
 
 
Correlation between AID expression and ongoing IGHV 
mutation in FL  
 
5.1 Introduction: 
This thesis is focused on studying the role of AID in pathology and pathogenesis of FL. FL 
FFPE tissue samples were used to identify AID expression, which was then correlated with 
various biological and clinical parameters of patients. 
In this chapter, the relationship between AID expression and ongoing IGHV mutation in FL 
is explored, with the relationship being connected to disease progression and transformation 
(78). 
5.1.1 Background: 
FL is predominantly a monoclonal proliferation of neoplastic B-cells. However, the IGHV 
gene which encodes an important component of the BCR, has been found to carry significant 
varying SHM in the tumour cells within a single tumour. In addition, the SHM process is 
ongoing, so that each malignant subclone may have a slightly different IGHV gene sequence 
(355). 
Continuing AID activation in the SHM throughout tumour progression was suggested to be 
a possible mechanism for ongoing mutations occurring in the GC. Continuous evolutionary 
changes at genomic and epigenomic levels in FL were suggested to be associated with AID 
activities producing continuous GC reaction and mutations in IGHV and other genes. (88, 
356). 
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Ongoing AID activity is also associated with the acquisition and loss of genetic material, 
intraclonal heterogeneity and drug resistance in FL (357, 358).  
The mutational status of the IGHV gene could be used as an indication for disease prognosis 
in FL (359). Because of the importance of ongoing mutations, researchers have started to 
investigate ongoing mutation in IGHV and other genes in FL using recently developed 
techniques, including next generation sequencing (360).  
5.1.2: Aims: 
To explore the relationship between ongoing mutations of IGHV that represent AID function 
and clinical parameters of FL. 
5.1.3: Hypothesis: 
We hypothesised that high ongoing IGHV mutations represents AID function and this 
ongoing mutational process is associated with advanced disease and clinical outcome in FL. 
5.2: Approaches to study ongoing IGHV mutation in FL: 
To test our hypothesis, the ongoing mutation status was studied in two cohorts of patients: 
the first group were those with high levels of AID expression (at both AID protein assessed 
by IHC and mRNA by qPCR), whilst the second group were cases with low levels of AID 
expression.  
5.3 Materials and methods:  
5.3.1 Patients and samples: 
In this Chapter, 20 of 87 FL samples from patients enrolled in the PACIFICO clinical trial 
were selected, in which the AID protein expression in the FFPE tissue samples had been 
successfully assessed with IHC (see Chapter 4, Section 4.2.2).  
Based on material availability and to exclude those with intermediate levels, ten samples at 
the low-level end and ten at the high-level end of the profile of AID protein expression were 
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selected for study in this chapter. The group with low levels of AID protein had IHC scores 
of one (with the exception of one case which had an AID IHC score of 2. This case was then 
removed from analysis due to failure of cloning). The group with high level of AID protein 
scored between 4 and 9. 
Selection of samples in each cohort was undertaken according to the following: 
1-Possibility of having high or low both AID total protein and mRNA in the same sample. 
2-The presence of sufficient DNA materials.  
3-Better quality of DNA. 
 
Details of samples, AID expression levels both at mRNA by qPCR and protein levels by 
IHC, amount and quality of DNA of samples used can be found in Table 5.1.  
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Table 5.1: Samples used for analysis of correlation between AID expression and ongoing mutation, there are 
ten cases with high AID total protein by IHC and ten cases with low AID; cases 234 and 105 failed to produce 
IGHV and IGK clones and were removed from the analysis. DNA ranges from negative for no gel bands to 4+ 
for strong bands. 
 
5.3.1.1 Clinical data of cases: 
Clinical data of the PACIFICO patients at time of diagnosis were stored at the LCTU and 
became available by request. 
 
Patient 
ID 
Total 
cellular 
AID 
protein 
(IHC 
score) 
AID 
mRNA 
(by 
qPCR) 
DNA 
available 
(µg) 
Length of DNA (by PCR) 
200 bp 300 bp 400 bp 
142 9 0.0978 78.4  +++  +++  +++ 
233 9 0.02 9.75 +++ + - 
120 6 0.2052 3 + + - 
269 6 0.2946 2.668  +++  +  + 
200 6 0.0037 25.2  +++  ++  + 
182 4 0.0001 7.8 ++++ ++++ ++ 
11 4 0.0948 5.5  ++ + + 
267 4 0.094 46.8 +++ ++ - 
48 4 0.1015 15.25 +++ ++ + 
42 4 0.0421 2.2 ++ + - 
              
187 1 0.0065 66.8 ++++ ++++ ++++ 
202 1 0.004 20 ++++ ++++ + 
33 1 0.0057 11.25 ++ ++ + 
237 1 0.0012 10.2 +++ +++ + 
221 1 0.0098 24.15 +++ +++ ++ 
118 1 0.0102 14.25  +++  +++  ++ 
56 1 0.0091 10.25  ++ + + 
46 1 
  
4.8 +++ +++ ++ 
234 1 0.0336 35.42  ++  ++ + 
105 2 0.0387 0.5 +++  ++ + 
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5.3.2 Technical approaches to study SHM in IGH gene: 
DNA was first extracted from FFPE tissues (as discussed in Chapter 2, Section 2.4.1), and 
then IGHV PCR amplification was performed. Next, PCR products were run on agarose gel 
and PCR products were extracted from gel bands. 
The PCR products were cloned in E. coli bacteria and clones were grown on agar. Fifteen 
bacterial clones were selected and sent for sequencing to Genewiz Company using T7P 
primer (Figure 5.1). Cloning method details are outlined in Chapter 2, Section 2.4.5.3. 
In the case of IGHV of non-clonal B-cells being sequenced, more colonies were screened 
until 15 clones were successfully sequenced for each sample. 
 
 
 
DNA extraction from FFPE IGHV PCR amplification                PCR products gel extraction
Sanger sequencing            Select multiple transformed colonies    Cloning
Subclones (ongoing mutation)
 
Figure 5.1: Platform of work to identify ongoing IGHV mutation in FL, starting with DNA extraction from 
FFPE to pedigree clone screening. 
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5.3.3: PCR amplification of clonal IGH in the FFPE samples using BIOMED-2 
protocol: 
Van Dongen and colleagues designed primers and optimized PCR conditions for detecting 
clonality in immunoglobulin and T-cell receptor genes in lymphoproliferative diseases. In 
combination with a junction primer, primers designed to anneal FR1, FR2 and FR3 produce 
a 310 – 350bp, 250 – 295bp and 100 – 170bp PCR band, respectively. This strategy is 
particularly useful for amplification of IGHV fragments from degraded DNA, such as those 
prepared from FFPE samples. Details are given in Chapter 2, Section 2.4.5.1. In the case of 
no amplification by FR1 primers, FR2 or FR3 primers can be used. IGK primers were also 
used to amplify IGK genes in two-tube PCR in our study using a Raji cell line (positive 
control). IGK amplification was performed to be used in samples failing to produce IGHV 
amplification. The expected sizes of IGK in tube A is 120-160bp and in tube B IGK is 270-
300bp (Figure 5.2) (11). 
The first step was to put one set of primers for each of the 6 FR1 families into an individual 
PCR tube (six PCR tubes in total) to determine which FR1 family was amplified. 
Then, the positive IGHV gene family was reamplified in a 400µl PCR reaction performed in 
eight tubes to obtain enough PCR product for subsequent experiments. The PCR products 
were then extracted from agarose gel before being used for subcloning to detect ongoing 
mutation in IGHV (Method provided in Section 2.4.5).  
5.3.3.1: Optimizations for BIOMED-2 protocol for IGHV amplification: 
With the BIOMED-2 protocol, we obtained IGHV bands. However, the bands were faint, so 
we tried the following optimizations to improve PCR bands from BIOMED-2 reactions: 
1-MgCl2 was tried in different concentrations between 1.5mM to 2.5 mM (3-5 µl). 
2-Annealing temperature was increased gradually from 55-60°C. 
3-PCR cycle number was increased gradually from 35 to 40.  
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4. dNTP (10mM) was increased from 2 to 3 µl. 
5-DNA input was increased from 50ng to 100 ng. 
6- Thermo-Start DNA Polymerase (5U/µL) was increased from 0.2 to 0.5 µl.  
5.3.3.2: Investigating the faint bands resulted from BIOMED-2 PCR amplification: 
In half of the samples (ten out of 20 cases), we obtained a prominent PCR band in one IGHV 
family in addition to a faint band in another family. 
So, we decided to investigate the origin of the faint band. To do this, we chose one of the 
samples (Patient 221) with an additional faint band, then performed six tubes of PCR for 
each family to identify the positive IGHV gene family. Then, we cloned the PCR product 
from that family in E. coli, and then compared the IGHV sequences from the predominant 
and faint PCR bands. 
5.3.4 SHM analysis:  
5.3.4.1 Database used: 
The international ImMunoGeneTics information systemR (IMGTR) has been the most 
commonly used reference software for analysis of the IGHV gene for over 28 years now 
(267). 
The IMGTR consists of seven databases and 17 online tools to study the complicated 
diversity of immunoglobulin and T cell receptor major histocompatibility genes (267). 
IMGT/V-QUEST program version: 3.4.2  was used for studying the IGHV gene; this 
software is able to align and analyse our IGHV gene in comparison to its closest germline 
counterpart. 
PCR sequences between the two ends of the vector were used to run in IMGT/V-QUEST 
using the (http://www.imgt.org/IMGT_vquest/share/textes/) website. After inserting our 
cloned PCR sequence, we chose human species and IG gene type, then ran the software. In 
this software, we also obtained the percentage of IGHV mutation.  
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5.3.5: Strategy to identify ongoing mutations: 
To identify the degree of clonal evolution as reflected by ongoing IGHV mutation, the first 
step was to identify clonality of these multiple IGHV sequences. We considered all cloned 
sequences with the same VDJ junction segment being derived from a B-cell malignant clone, 
as discussed in various publications (361-363). 
Details of IGHV mutational analysis were discussed in Section 2.4.5.5. 
To study ongoing mutation, we used the following parameters: 
1-Number of subclones with ongoing mutation activity identified among the 15 IGHV 
sequences for each case using phylogenetic tree analysis software (364). 
2-Ongoing mutation was analysed using a commonly used calculation in publications. It was 
determined by dividing the cumulative number of mutations occurring in a single clone and 
in more than one clone (but not in all of the 15 clones) with the number of artificial mutations 
resulting from DNA polymerase-induced error in PCR (358, 365).   
Error rate mutation was calculated with the expected DNA Polymerase-induced rate of error, 
which is 2.28 x 10-5 per base per PCR cycle for the Thermo-Start DNA Polymerase used in 
this study (366-368). 
5.3.6 Identifying clone branching: 
Performing a phylogenetic tree and its branching can be used as a read out of ongoing 
mutation (364).  
To identify the phylogenetic tree of the resultant clones, the NCBI nucleotide blast website 
was used for aligning nucleotide sequences of the 15 clones 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=MegaBlast&PROGRAM=blastn&BLAST
_PROGRAMS=megaBlast&PAGE_TYPE=BlastSearch&BLAST_SPEC=blast2seq&DAT
ABASE=n/a&QUERY=&SUBJECTS=). We then stored the aligned sequences in FASTA 
form. 
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Phylogeny.fr software was then used for creating the phylogenetic tree. 
This was done by using software on the appropriate website (http://www.phylogeny.fr/); 
then we clicked on Phylogeny analysis one click mode which is the simplest mode, loaded 
our aligned nucleotides sequences in FASTA form and clicked submit to obtain our 
phylogenetic tree (369). 
5.3.7 AID hotspot mutation in IGHV gene analysis: 
AID is known to target specific sequences of nucleotides in the IGHV gene; these sequences 
are called AID hotspots. AID targets WA/TW sequences, in addition to WRC/GYW 
sequences, W is either (A or T), R is (A or G) and Y is (T or C) (209, 210). 
WRC/GYW sequences produced by the action of AID while WA/TW mutation is produced 
by error prone DNA polymerase as a result of DNA repair following AID action (207, 370). 
WRC/GYW mutations are called canonical AID induced mutations, while WA/TW were 
named non-canonical AID mutations (208). 
5.3.8 Statistical analysis:  
Statistical analysis was undertaken by using IBM SPSS statistics v22. Spearman’s 
correlation, Mann-Whitney U test, Kruskal-Wallis test and Fisher exact test were used to 
examine the correlation between AID hotspots, percentage (%) of SHM and ongoing 
mutation with patient clinical parameters. Statistical significance was defined as P< 0.05.  
5.4 Results: 
5.4.1 Optimizations of SHM identification in IGHV gene: 
5.4.1.1 Successful IGHV gene amplification using BIOMED-2 PCR reaction: 
Full IGHV gene amplification failed using primers from leader to constant regions in four 
FL FFPE samples. The positive control (Raji cell line) successfully amplified the gene, and 
each experiment of the four FFPE samples was repeated three times. 
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For shorter segments of the IGHV gene from FR1 to VDJ junction, BIOMED-2 PCR 
amplification was successful; however, PCR bands were not strong enough in some samples. 
The weak PCR bands appeared on using Mgcl2
 concentration of 1.5mM and 35 cycles of the 
PCR reaction. 
5.4.1.2: Optimizations for BIOMED-2 PCR reaction: 
Optimizations to improve PCR efficiency were carried out using the Raji cell line that was 
also used as a positive control for IGHV amplification. 
We found that increasing Mgcl2 concentration from 1.5mM to 2.5 mM and increasing the 
PCR cycles from 35 to 38 produced the strongest specific bands. We therefore used these 
optimized BIOMED-2 PCR conditions to amplify the IGHV gene in our study cohort of 20 
cases with FL in this chapter (Figure 5.2). 
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Figure 5.2: Optimization of PCR conditions harmonising BIOMED-2 protocol to amplify IGHV in Raji cell 
line (329 bp in size). (a) increasing the PCR cycles from 35 to 38 or Mgcl2 concentration from 1.5mM to 2.5 
mM, improved intensity of PCR products; (b) Successful PCR amplification of Raji IGHV gene using modified 
BIOMED-2 protocol from FR1 (product = 329 bp), FR2 (≈250 bp) or FR3 (≈150 bp) to VDJ junction segment; 
(c) Raji IGK gene amplification in two-tube PCR (products in tubes A and B were ≈150 and ≈280 bp, 
respectively). All PCR gel bands sizes were similar to that expected from primer design and to other 
publications (371-373). 
5.4.2 Investigating the extra faint bands generated in BIOMED-2 PCR reactions for 
amplifying IGHV gene of PACIFICO trial samples: 
B-cell monoclonality is a feature of FL (374); however, in half of the cases we found a faint 
band in addition to the main PCR band of monoclonal B-cells. The prominent and faint bands 
in one of the FL patients (Sample 221) had been cloned and sequenced. It was found that the 
prominent PCR band produced clones with the same VDJ junction segment, although some 
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of them had different mutations within the IGHV gene fragment compared to others. On the 
other hand, on cloning the faint band, 11 clones was successfully sequenced. Nine out of the 
11 clones derived from the faint PCR band had different IGHV gene and different VDJ 
junction segments from each other. Another two clones had the same IGHV gene and the 
same VDJ segment, but one of them was 100% similar to the wild type gene and the other 
one had an additional single mutation. We concluded that the faint bands represented the 
background IGHV expression in non-clonal normal B-cells, and that they had wild type 
IGHV genes with different junction segments for individual clones (Figure 5.3). 
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Figure 5.3: PCR faint bands in IGHV gene amplification are background normal B-cells. (a) Main and faint 
PCR bands of BIOMED-2 protocol to amplify DNA of IGHV gene in sample (221) PCR products on agarose 
gel (b) reamplifiable main PCR products in family 3 and then weak PCR in family 4 for cloning (c) ongoing 
mutation detected in different subclones of the same malignant clone as defined using criteria described in 
Section 5.3.5 above (d) background B-cells identified by different VDJ junction segment between different 
clones and low degree of mutation compared to FL samples. Circles of the same colour have similar VDJ 
segment of the IGHV gene. 
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5.4.3 Performing BIOMED-2 reaction, cloning and analysing FL cohort:  
Biomed-2 PCR reaction and cloning was successful in 10 patients with high and eight out of 
10 patients with low AID protein. Unfortunately, in the low AID cohort, two cases (patients 
234 and 105) failed to produce clones, so they were excluded from further analysis. 
After cloning, we sent clones for sequencing and ensured that we had 15 clone sequences 
for each patient. The cloned PCR sequences in all clones of all patients were clean, and 
sequences were analysed using IMGT/V-QUEST software as discussed in Section 5.3.4.1. 
An example of the clean PCR sequences and IMGT software use are shown in Figure 5.4. 
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FL patient (mutation)
a
b
118
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Figure 5.4: (a) A representative Sanger sequence of a part of an IGHV gene cloned shows a clean sequence 
and a clear point mutation; (b) An example of IGHV sequence analysis in one of the clones of sample 48, the 
nucleotide sequence in the purple box is the cloned sequence compared to the closest germline sequence in the 
green box (Homsap IGHV3-30*03 F, or Homsap IGHV3-30*18 F or Homsap IGHV3-30-5*01 F). The 
sequence identity to the germline counterpart is 89.24% (199/223 nt). Identical nucleotides are represented by 
hyphens. 
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5.4.4 Percentage of SHM:  
In all 18 samples, the percentage of mutation ranged between 2.89 and 19.22, with an 
average of 14.86 (Figure 5.5). 
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Figure 5.5: Percentage of IGHV mutations in the 18 patients studied. Red line represents the mean of mutations 
(14.86%).  
 
5.4.5 Divergence of ongoing IGHV mutation:  
In addition to percentage mutations in IGHV, there is a large difference in the intraclonal 
variation among the cohort of patients. For example, all of the 15 cloned IGHV in patient 
(118) shared the same sequence, while patient (269) had 12 different subclone sequences 
due to ongoing mutation. The number of different subclones derived from the original clone 
ranged from (0 to 12) with a median of eight. An example of ongoing mutation in one of 
these patients is shown as intraclonal variation in Figure 5.6. 
 
165 
 
               FR1-IMGT->_______CDR1-IMGT _______<------------------FR2-IMGT  
 
AB019439      TGCAGCCTCTGGATTCACCTTCAGTAGCTATAGCATGAACTGGGTCCGCCAGGCTCCAGG 
1             TGAAGTTTCTGGGTTCGACTTCAGTATCTATTACATAAATTGGGTCCGCCAGACTCCAGA 
2             TGAAATTTCTGGGTTCGACTTCAGTATCTATTACATAAATTGAGTCCGCCAGACTCCAGA 
3             TGAAGTTTCTGGGTTCGACTTCAGTATCTATTACATAAATTGGGTCCGCCAGACTCCAGA 
4             TGAAGTTTCTGGGTTCGACTTCAGTATCTATTACATAAATTGGGTCCGCCAGACTCCAGA 
5             TGAAGTTTCTGGGTTCGACTTCAGTATCTATTACATAAATTGGGTCCGCCAGACTCCAGA 
6             TGAAATTTCTGGGTTCGACTTCAGTATCTATTACATAAATTGAGTCCGCCAGACTCCAGA 
7             TGAAATTTCTGGGTTCGACTTCAGTATCTATTACATAAATTGAGTCCGCCAGACTCCAGA 
8             TGAAGTTTCTGGGTTCGACTTCAGTATTTATTACATAAATTGGGTCCGCCAGACTCCAGA 
9             TGAAGTTTCTGGGTTCGACTTCAGTATCTATTACATAAATTGGGTCCGCCAGACTCCAGA 
10            TGAAGTTTCTGGGTTCGACTTCAGTATCTATTACATAAATTGGGTCCGCCAGACTCCAGA 
11            -GAAGTTTCTGGGTTCGACTTCAGTATCTATTACATAAATTGGGTCCGCCAGACTCCAGA 
12            TGAAGTTTCTGGGTTCGACTTCAGTATCTATTACATAAATTGGGTCCGCCAGACTCCAGA 
13            TGAAGTTTCTGGGTTCGACTTCAGTATCTATTACATAAATTGGGTCCGCCAGACTCCAGA 
14            TGAAGTTTCTGGGTTCGACTTCAGTATCTATTACATAAATTGGGTCCGCCAGACTCCAGA 
15            TGAAGTTTCTGGGTTCGACTTCAGTATCTATTACATAAATTGGGTCCGCCAGACTCCAGA 
               * *   ***** ***  ********  ***  *** ** ** ********* ******  
 
                                      ------------------------------------------------>________ CDR2-IMGT___________<------------------- 
 
AB019439      GAAGGGGCTGGAGTGGGTCTCATCCATTAGTAGTAGTAGTAGTTACATATACTACGCAGA 
1             GAAGGGGCTGGAGTGCGTCTCATACATTAACCCTCGTGGAAATCACATATCATATGCAGC 
2             GAAGGGGCTGGAGTGCATCTCATACATTAATCCTCGTGGAAATCACATATCATATGCAGC 
3             GAAGGGGCTGGAGTGCATCTCATACATTAATCCTCGTGGAAATCACATATCATGTGCAGC 
4             GAAGGGGCTGGAGTGCATCTCATACATTAATCCTCGTGGAAATCACATATCATGTGCAGC 
5             GAAGGGGCTGGAGTGCATCTCATACATTAATCCTCGTGGAAATCACATATCGTATGTAGC 
6             GAAGGGGCTGGAGTACGTCTCATACATTAACCCTCGTGGAAATCACATATCATATGCAGC 
7             GAAGGGGCTGGAGTACGTCTCATACATTAACCCTCGTGGAAATCACATATCATATGCAGC 
8             GAAGGGGCTGGAATGCGTCTCATACATTAATCCTCGTGGAAATCACATATCATATGCAGC 
9             GAAGGGGCTGGAGTGCGTCTCATACATTAACCCTCGTGGAAATCACATATCATATGCAGC 
10            GAAGGGGCTGGAATGCGTCTCATACATTAATCCTCGTGGAAATCACATATCATATGCAGC 
11            GAAGGGGCTGGAATGCGTCTCATACATTAATCCTCGTGGAAATCACATATCATATGCAGC 
12            GAAGGGGCTGGAATGCGTCTCATACATTAATCCTCGTGGAAATCACATATCATATGCAGC 
13            GAAGGGGCTGGAATGCGTCTCATACATTAATCCTCGTGGAAATCACATATCATATGCAGC 
14            GAAGGGGCTGGAATGCGTCTCATACATTAATCCTCGTGGAAATCACATATCATATACAGC 
15            GAAGGGGCTGGAATGCGTCTCATACATTAATCCTCGTGGAAATCACATATCATATGCAGC 
              ************ *   ****** *****    * ** * * * ******  *    **  
 
 
              ------------------------------------------------------------ FR3-IMGT-------------------------------------------  
  
AB019439      CTCGATGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACTCACTGTATCTGCA 
1             CTCAATGACGGGCCGATTCATCGTCTCCACAGACAATGCCGATAATTCACTTAATCTCCA 
2             CTCAATGACGGGCCGATTCATCGTCTCCAGAGACAATGCCAATAATTCACTTAATCTCCA 
3             CTCAATGACGGGCCGATTCATCGTCTCCAGAGACAATGCCAATAATTCACTTAATCTCCA 
4             CTCAATGACGGGCCGATTCATCGTCTCCAGAGACAATGCCAATAATTCACTTAATCTCCA 
5             CTCAATGACGGGCCGATTCATCGTCTCCAGAGACAATGCCAATAATTCACTTAATCTCCA 
6             CTCAATGACGGGCCGATTCATCGTCTCCAGAGACAATGCCAATAATTCACTTAATCTCCA 
7             CTCAATGACGGGCCGATTCATCGTCTCCAGAGACAATGCCAATAATTCACTTAATCTCCA 
8             CTCAATGACGGGCCGATTCATCGTCTCCAGAGACAATGCTAATAATTCACTTAATCTCCA 
9             CTCAATGACGGGCCGATTCATCGTCTCCAGAGACAATGCCAATAATTCACTTAATCTCCA 
10            CTCAATGACGGGCCGATTCATCGTCTCCAGAGACAATGCCAATAATCCACTTAATCTCCA 
11            CTCAATGACGGGCCGATTCATCGTCTCCAGAGACAATGCCAATAATTCACTTAATCTCCA 
12            CTCAATGACGGGCCGATTCATCGTCTCCAGAGACAATGCCAATAATTCACTTAATCTCCA 
13            CTCAATGACGGGCCGATTCATCGTCTCCAGAGACAATGCCAATAATTCACTTAATCTCCA 
14            CTCAATGACGGGCCGATTCATCGTCTCCAGAGACAATGCCAATAATTCACTTAATCTCCA 
15            CTCAATGACGGGCCGATTCATCGTCTCCAGAGACAATGCCAATAATTCACTTAATCTCCA 
              *** **** *********** * ****** ****** **  * **  ****  **** **  
Figure 5.6: An example of ongoing mutations shown in IGHV sequences of different subclones originating 
from one original clone. The yellow lines represent mutations shared by all clones that are different from the 
closest IGHV germline in the first raw data, while the red coloured nucleotides represent single nucleotide or 
partial mutation across different clones. The sequence on top is that of germline counterpart. 
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5.4.6 Number of subclonal generations:  
A phylogenetic tree of IGHV clones for each sample clone was produced using the 
phylogene.fr software. The range of generations derived from parental clones was between 
zero and four with a median of two in the 18 patients. 
An example of phylogenetic tree generation is illustrated in Figure 5.7.  
 
 
 
Sample 42 (3 generations)                Sample 120 (4 generations)
Sample 233 (1 generation)
c
a
b
 
Figure 5.7: Phylogenetic tree of three different patients produced by phylogeny.fr software. This was used to 
estimate generation of FL subclones based on ongoing mutation in IGHV for all of the 18 patients studied.   
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5.4.7: Types of mutations in IGHV: 
We performed an analysis of different types of mutations in ten cases of high AID and eight 
cases with low AID. 
Replacement mutations were more common than silent mutations in both CDR and FR 
regions; however, replacement to silent mutations were more in CDR than FR regions. (R/S 
mutations =7/1.5 median in CDR compared to 13/7 median in FR region) (Table 5.2). 
All mutations in all of 15 clones of 18 patients were point mutations with the exception of 
the following: 
1- One nucleotide insertion in one of the clones in sample 142. 
2- Three nucleotides inserted and one deleted in one of sample 200 clones. 
3- Three nucleotides inserted in one of the clones of sample 120. 
4- Deleted one nucleotide in one of the clones of sample 182. 
5- All clones with insertion or deletion mutations were from samples with high AID 
protein by IHC.  
Ongoing mutations were identified in 17 out of 18 cases in our cohort. The ongoing 
mutations were measured using techniques described earlier in Section 5.3.5 of this chapter. 
The percentage of IGHV mutation range was (2.89 - 19.22). The number of subclones 
derived from 15 clones analysed in each patient was between (0 and 12). The ongoing 
analysis measured by excluding PCR error rate from unique and partially shared mutations 
was between (0 and 16.37) (Table 5.3). 
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Pt ID Close IGHV Germline
No. of 
mut.
CDR1 and CDR2 FR1,FR2 and FR3
R S TR TV C to T R S TR TV C to T
142 IGHV3-7*02 F, or -7*03 F 39 4 1 2 6 1 13 10 17 14 7
233 IGHV3-30*03 F, or -30*18 F or 30-5*01 F 25 8 2 6 7 0 8 2 5 6 1
120 IGHV3-21*01 F or 21*02 F 42 9 1 6 8 0 17 7 16 12 4
269 IGHV3-21*01 F, or *02 F 42 9 1 7 7 0 20 6 15 12 7
200
IGHV3-23*01 F, or23*04 F or 23D*01 F or -
23D*02 F 38 8 1 8 5 0 12 8 20 4 9
182 Homsap IGHV3-48*02 F 37 5 2 10 2 3 14 7 13 11 4
11 Homsap IGHV3-69-1*02 P 38 7 2 7 5 0 17 7 14 12 8
267 IGHV3-48*03 F 43 8 2 5 10 0 17 7 17 11 8
48
Homsap IGHV3-23*01 F, or*04 F or IGHV3-
23D*01 F or *02 F 7 2 0 0 2 0 3 0 0 4 0
42 IGHV3-21*01 F, or 21*02 F or 48*03 F 42 9 1 7 7 0 17 7.5 15.5 12 8
Average 35.3 6.9 1.3 5.8 5.9 0.4 13.8 6.15 13.25 9.8 5.6
187
IGHV3-23*01 F, or23*04 F or 23D*01 F or23D*02 
F 38 7 2 9 6 2 12 7 19 4 10
202 IGHV3-69-1*02 P 41 8 2 7 8 1 17 6 14 11 8
33 Homsap IGHV3-21*03 F 42 9 1 7 7 0 18 7 16 12 8
237
Homsap IGHV3-23*01 F, or23*04 F or 23D*01 F 
or 23D*02 F 21 5 2 5 5 1 6.5 3 5 5 3
221 IGHV3-21*01 F, or *02 F 23 7 1 6 5 1 6 3 7.5 5 2
118 IGHV3-30*03 F, or *18 F or5*01 F 26 7 2 6 7 1 8 2 6 7 2
56 IGHV3-23*01 F, or-23*04 F or 23D*01 F 38 6 3 9 5 1 13 7 19 5 9
46 IGHV3-23*05 F 26 6 1 3 7 1 9 3 9 7 0
Average 31.88 6.88 1.75 6.5 6.25 1 11.19 4.75 11.94 7 5.25
 
Table 5.2: Data derived from ongoing mutation analysis in 10 samples with high total AID protein by IHC (red colour) and 8 samples with low AID protein (blue). Pt, patient; 
mut, mutation; R, replacement mutation; S, silent mutation; TR, Transition mutation; TV, Transversion mutation. 
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Sample 
ID 
AID 
protein 
(IHC 
score) 
AID/ GAPDH  
mRNA 
(qPCR) 
Average 
num. of 
nucleotide 
* PCR 
error 
Unique  
mut.s 
Partially 
Shared 
mut.s 
**Total 
PCR 
error 
*** 
Ongoing 
mutation 
No of 
subclones 
Average 
% of 
mut. 
142 9 0.0978 226.6 0.013 9 9 2.95 6.11 10 17.42 
233 9 0.02 233 0.013 2 1 3.03 0.99 3 10.79 
120 6 0.2051 225.36 0.013 15 34 2.93 16.73 10 18.45 
269 6 0.2946 223 0.013 9 39 2.90 16.56 12 19.06 
200 6 0.0037 235.86 0.013 9 7 3.07 5.22 12 16.529 
182 4 0.0001 230.86 0.013 3 2 3.00 1.67 4 15.42 
11 4 0.0948 221.64 0.013 2 6 2.88 2.78 4 18.266 
267 4 0.094 230.4 0.013 7 10 3.00 5.68 12 18.19 
48 4 0.1015 232.86 0.013 11 0 3.03 3.63 8 2.89 
42 4 0.0421 223 0.013 7 14 2.90 7.24 10 19.22 
            
187 1 0.0065 225.43 0.013 8 15 2.93 7.85 9 16.69 
202 1 0.004 218.67 0.013 4 3 2.84 2.46 8 18.06 
33 1 0.0057 229.67 0.013 6 5 2.99 3.68 5 18.08 
237 1 0.0012 225.07 0.013 4 1 2.93 1.71 5 8.96 
221 1 0.0097 223.79 0.013 7 4 2.91 3.78 8 10.49 
118 1 0.0102 223 0.013 0 0 2.90 0.00 0 10.76 
56 1 0.0091 226.36 0.013 1 0 2.94 0.34 2 16.93 
46 1  226.14 0.013 7 4 2.94 3.74 8 11.33 
Table 5.3: AID expression and ongoing mutation in FL, *Total PCR error= PCR enzyme error (2.28 x 10-5) X 
38 PCR cycles X 15 clones per sample; mut, mutation; nuc, nucleotides.**                                                                    
Total PCR error= PCR error X Average number of total nucleotides; Ongoing mutation= (Unique mutations 
+Partially shared mutations)/Total PCR error. 
 
5.4.8: AID-induced IGHV mutations: 
The types of mutations induced by AID are either canonical or non-canonical, as discussed 
in Section 5.3.7. In order to accurately identify the percentage of AID induced mutations 
among the total nucleotides in the 15 clones of each patient, we used the following formula: 
= (Number of AID induced mutations/Total number of nucleotides in the 15 clones) X 100 
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The percentage of AID induced mutation among the total nucleotides ranged between (1.38 
% and 6.67 %). The mean for all cases was 4.22. 
Canonical AID mutation ranged between (0.92% - 4.51%), while non canonical mutations 
ranged between (0 - 3.08%). 
5.4.9 Correlation of AID expression with different parameters tested in this chapter: 
To explore the relationship between AID expression and ongoing mutations in IGHV, 
statistical analyses were conducted in following subsections. 
5.4.9.1 Relation between AID/GAPDH mRNA expression and ongoing mutation: 
The correlation between AID expression levels and ongoing mutation in FL was explored. 
A suggestive of a trend if a larger sample size could be analysed in future between higher 
AID/GAPDH mRNA and bigger % of IGHV mutation (r= 0.419, P= 0.094) (Spearman’s 
correlation). A very similar positive trend (very close to statistical significance) was 
determined between AID/GAPDH mRNA and ongoing mutation (r= 0.483, P= 0.05) 
(Spearman’s correlation).  
No correlation was identified between AID/GAPDH mRNA and % of AID induced 
mutations (canonical and non-canonical) among total nucleotides (Table 5.4). 
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Table 5.4: Correlations between AID/GAPDH mRNA and % of IGHV mutation, AID induced mutations and 
measures of ongoing mutation.  
 
Furthermore, out of 15 clones in each patient, the cases were divided by the median number 
of subclones (8) into two groups (≤8 and >8). We also found a positive but non-significant 
trend of higher number of subclones in patients with higher AID/GAPDH mRNA (P= 0.133) 
(Mann-Whitney U test) (Figure 5.8).      
 
Parameter 
AID/GAPDH  
mRNA 
Range 
AID/GAPDH  
mRNA 
Mean ± SD 
AID/GAPDH  mRNA 
P value Statistical test 
 
Percentage of  IGHV 
mutation 
 
 
0.00012 - 0.295 
 
 
0.0589 ± 0.0834 
 
0.094 
(r= 0.419) 
 
Spearman's 
correlation 
 
 
 
Number of subclones 
(≤8) 
0.0001- 0.102 
 
0.0257 ± 0.0387 
 
 
0.133 
 
Mann-Whitney 
U test (>8) 
0.0037 - 0.295 
 
0.1063 ± 0.1081 
 
Ongoing mutation 
 
0.00012 - 0.295 
 
0.0589 ± 0.0834 
0.05 
(r= 0.483) 
Spearman's 
correlation 
% of AID induced 
mutations among 
total nucleotides 
 
0.00012 - 0.295 
 
0.0589 ± 0.0834 
 
0.225 
(r= 0.386) 
Spearman's 
correlation 
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Figure 5.8: Examining the relationship between AID/GAPDH mRNA and number of subclones (P= 0.133) 
(Mann-Whitney U test). Subclones were divided into high and low by the median of subclones (8) in all cases. 
 
5.4.9.2 Correlation between total AID protein expression and ongoing mutation: 
Ongoing mutations were compared to AID total protein. Two groups of AID protein 
expression were used. Eight samples with low AID protein (IHC score =1) and ten cases 
with high AID (≥4).   
When the % of IGHV mutations between high and low AID IHC groups was compared, the 
high level group showed a larger % of mutations, although the difference was not statistically 
significant (P= 0.146) (Mann-Whitney U test) (Figure 5.9). 
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Figure 5.9: Examining the relationship between AID total protein IHC level and percentage of mutation (P= 
0.146) (Mann-Whitney U test).  
 
Also, when the subclones were divided into two groups by the median (8), a tendency 
towards higher AID IHC score and more number of subclones was observed (P= 0.066) 
(Fisher exact test) (Table 5.5). Thus, six of the ten (60%) patients with a high level of AID 
protein had > 8 mutated IGHV subclones, while only one of the eight (13%) cases with a 
low level had a similar number of the subclones. 
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 Table 5.5: Comparison of number of subclones between patients with high and low total AID protein by IHC 
(P= 0.066) (Fisher exact test). 
                                   
The correlation between AID IHC and ongoing mutations was explored, (P= 0.173) (Mann-
Whitney U test) (Figure 5.10). 
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Figure 5.10: Examining the relationship of ongoing mutation in the group of patients with low and high total 
AID protein by IHC score (P= 0.173) (Mann-Whitney U test).  
 
 
 
Number of subclones (Median is 8) 
 
 Total AID IHC score 
 
1 ≥ 4 
≤ 8 7 4 
>8 1 6 
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When the percentages of AID induced mutations among total nucleotides was explored in 
the two groups of low and high AID, no difference in the % of AID-induced mutations was 
noted between the two groups (P= 0.897) (Mann-Whitney U test).  
Ratio of N/C AID was available for 12/18 cases cloned. No association was identified 
between ongoing mutation and N/C ratio of AID (r= 0.056, P= 0.863) (Spearman’s 
correlation). 
5.4.10: Correlation between clinical parameters of FL at time of entry to clinical trial 
and parameters tested in this chapter: 
We compared AID induced mutations, analysing the % of IGHV mutation and ongoing 
mutation against clinical data at time of enrolling the patients to the clinical trial. 
5.4.10.1 Relation between percent of AID induced mutations and FL clinical data: 
The correlation between percentage of AID induced mutations and FL clinical data at time 
of entry to the clinical trial was explored. 
No correlation was found between % of AID induced mutations and age (P= 0.408, r= 0.208) 
(Spearman's correlation) and sex (P= 0.503) (Mann-Whitney U test) of patients (Table 5.6). 
Furthermore, it was found that there was no relation between % of AID induced mutations 
and number of LNs (P= 0.211) (Mann-Whitney U test). 
Additionally, no correlation was identified between % of AID induced mutation and LDH 
level (P= 0.462, r= - 0.191) (Spearman's correlation), histological grade of patients (P= 
0.244) (Kruskal -Wallis test) and Ann Arbor stage (P= 0.914) (Table 5.6).  
Also no relation was identified between % of AID induced mutation and FLIPI score (P= 
0.939) (Kruskal -Wallis test). 
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Table 5.6: Correlation between percent of AID induced mutations and clinical features of FL at time of entry 
to clinical trial. 
 
 
5.4.10.1 Correlation of percentage of IGHV mutation with FL clinical data: 
 
 
 
Parameter 
 
Range or 
number and 
% of total 
% of AID 
induced 
mutations 
(Mean ± SD) 
% of AID induced mutations 
 
P value 
 
Statistical test 
 
Age 
 
57- 78 
 
4.22 ± 1.63 
 
0.408 
(r = 0.208) 
Spearman's 
correlation 
 
 
Sex 
Male 
 
13 (72%) 
 
4.21 ± 1.61 
 
 
 
0.503 
 
 
Mann-Whitney 
U test Female 
 
5 (28%) 
 
4.25 ± 1.89 
 
 
 
Number of LN 
1 – 5 
 
7 (39%) 
 
3.81 ± 1.92 
 
 
 
0.211 
 
 
 
Mann-Whitney 
U test 
≥ 6 
 
11 (61 %) 
 
4.49 ± 1.46 
 
LDH (U/L) 
 
 
109 – 862 
 
 
 
4.22 ± 1.63 
 
0.462 
(r = - 
0.191) 
 
Spearman's 
correlation 
 
 
 
 
Histological grade 
1 
 
3 (17%) 
 
3.1 ± 1.34 
 
 
 
 
0.244 
 
 
 
 
Kruskal -Wallis 
test 
2 
 
10 (56%) 
 
4.66 ± 1.79 
3 
 
5 (28%) 
 
4.04 ± 1.344 
 
 
 
Ann Arber stage 
II+III 
 
11 (61%) 
 
4.42 ± 1.54 
 
 
0.914 
 
 
Mann-Whitney 
U test IV 
 7 (39%) 
 
3.92 ± 1.85 
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The range of percentage of IGHV mutation in all 18 patients in our cohort was 2.89% – 
19.22%, and the average was 14.86%. Although we did not find a significant difference in 
any of the clinical variables (including age, sex, number of lymph nodes, LDH level and 
Ann Arbor stage) recorded at time of trial entry (Table 5.7), a non-significant positive trend 
probably is present between percentage of IGHV mutation and histological grade of the 
disease in the 18 patient cohort. But no relation was noted between % of IGHV mutation and 
FLIPI score (P= 0.945) (Kruskal -Wallis test). 
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 Table 5.7: Results of statistical analyses for relations between percentage of IGHV gene mutation and clinical 
parameters of FL patients at time of entry to the clinical trial. 
5.4.10.2 Relationship between number of subclones and FL clinical data: 
The number of subclones in all patients ranged between (0 and 12) with an average of 7.22 
and a median of 8. Patients were divided by the median into two groups. The first group 
consisted of 11 patients and the other group had seven patients. Differences in clinical 
variables were compared between the two groups of patients. 
 
 
 
 
              Parameter 
 
Range  or 
number and % of 
total 
 
Mean ± SD of 
IGHV percentage 
mutation  
 
Percentage of IGHV mutation 
 
P value 
 
Statistical test 
 
Age  
 
57- 78 
 
14.86 ± 4.56 
 
 
 
0.672 
(r =  0.111) 
Spearman's 
correlation 
 
 
Sex 
Male 
 
13 (72%) 
 
15.31 ± 4.79 
 
 
 
0.566 
 
 
Mann-Whitney 
U test Female 
 
5 (28%) 
 
13.7 ± 4.14 
 
 
 
Number of LN 
1 – 5 
 
7 (39%) 
 
15.48  ±  4  
 
 
 
0.93 
 
 
 
Mann-Whitney 
U test 
≥ 6 
 
11 (61%) 
 
14.47 ± 5.034 
 
 
   LDH (U/L) 
 
109 – 862 
 
 
14.86 ± 4.56 
 
 
0.462 
(r = - 0.191) 
 
Spearman's 
correlation 
 
 
 
 
Histological grade 
1 
 
3 (17%) 
 
10.17 ± 1.05 
 
 
 
 
0.116 
 
 
 
 
Kruskal -Wallis 
test 
2 
 
10 (56%) 
 
15.23 ± 5.3544 
3 
 
5 (28%) 
 
16.95 ± 1.04 
 
 
Ann Arber stage 
II+III 
11 (61%) 
 
14.99 ± 3.81  
 
 
0.775 
 
 
Kruskal -Wallis 
test 
IV 
 7 (39%) 
 
14.66 ± 5.88  
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The correlation between number of subclones and age of the patients was first examined. No 
difference in age was identified between the two groups (P= 0.285) (Mann-Whitney U test) 
Similarly, no difference in LDH level was seen between the groups of low and high 
subclones (P= 0.364) (Mann-Whitney U test) (Table 5.8). 
 
 
Table 5.8: Correlation between age and LDH level against the two groups of low and high number of subclone. 
 
 
The correlation between sex of patients and the 2 groups of subclones was tested. No 
relationship was identified (P= 0.59) (Fisher exact test) (Table 5.9). 
 
 
 
 
 
 
Table 5.9: No correlation between sex of patients and number of subclones (P= 0.59) (Fisher exact test). 
 
 
 
Parameter 
 
Range  
 
Mean ± SD for 
number of 
subclones 
            Number of subclones 
 
 2 groups’ ≤ 8 (11 patients 
(61.11%)) 
                > 8 (7 patients 
(38.88%)) 
P value Statistical test 
 
Age 
 
57 - 84 
 
     7.22 ± 3.64 
 
0.285 
 
Mann-Whitney U 
test 
  
LDH  (U/L) 
 
109 – 830 
 
     
     7.22 ± 3.64 
 
0.364 
 
Mann-Whitney U 
test 
 
 
Number of 
subclones (Median 
is 8) 
 
Sex of patient 
 
Male Female 
≤ 8 (n=11) 7 4 
>8 (n=7) 6 1 
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At entry to clinical trial, the actual number of enlarged LNs was noted if there were five or 
less. If six or more LNs were enlarged, the patients was given the number six. So, we divided 
patients into two groups, those with five or less enlarged LNs (seven patients) vs those with 
six or more LNs (11 patients). No correlation was found between number of enlarged lymph 
nodes and the groups of low and high subclones (P= 1) (Fisher exact test) (Table 5.10).   
 
 
 
 
Table 5.10: No relationship between 
number of LNs and subclones of mutated IGHV (P= 1) (Fisher exact test) 
 
No difference was found in the histological grade of disease between the groups of low and 
high subclones (P= 0.358) (Fisher-Freeman-Halton exact test) (Table 5.11).   
 
 
 
 
 
Table 5.11: No Correlation was found between grade of disease and subclones of mutated IGHV (P= 0.358) 
(Fisher-Freeman-Halton exact test). 
 
 
 
Number of 
subclones 
(Median is 8) 
 
Grade of disease  
 
2 3 4 
≤ 8 (n=11) 2 7 2 
>8 (n=7) 0 2 5 
 
 
Number of 
subclones (Median 
is 8) 
 
Number of LNs 
 
LNs < 6 LNs ≥ 6 
≤ 8 (n=11) 4 7 
>8 (n=7) 3 4 
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Then, we compared the difference in the stage of disease among the groups of patients with 
low and high number of subclones. As mentioned in Chapter 4, Section 4.5, 18 of the 20 
cases studied were at stage III (n = 9) or IV (n = 9), with only two cases being at stage II. 
So, we combined stages II and III into one group against stage IV disease in the other group 
(Table 4.6).  
A significant positive correlation was identified between patients advanced stage of disease 
(stage IV) and number of subclones (P= 0.049) (Fisher exact test) (Table 5.12). 
Thus, nine of the 11 (82%) patients with less advanced disease had ≤ 8 mutated IGHV 
subclones, while only two of the seven (29%) cases with stage 4 disease had a similar number 
of the subclones. 
 
 
 
 
 
Table 5.12: A positive significant correlation was identified between number of subclones in mutated IGHV 
and Ann Arbor stage (P= 0.049) (Fisher exact test). 
 
Finally, when we compared the number of subclones with FLIPI score, we found that there 
was no correlation between the two (P= 0.81) (Fisher-Freeman-Halton exact test). 
5.4.10.3 Correlation of ongoing mutation with FL clinical data: 
Following the above analyses, the ongoing IGHV mutation was measured by dividing the 
sum of unique mutations and partially shared mutations with PCR error rate (Section 5.3.5 
of this chapter). The range of ongoing mutations was between (0-16.37) with a mean of 5. 
 
 
 
Number of 
subclones (Median 
is 8) 
 
Stage of disease (Ann Arber staging) 
 
II+III IV 
≤ 8 (n=11) 9 2 
>8 (n=7) 2 5 
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The relationship between age of patients and ongoing mutation was first explored. It was 
found that there was no correlation between the two, (P= 0.371) (r= 0.224) (Spearman's 
correlation) (Table 5.13).  
Next, we wanted to determine whether there was a difference in ongoing mutation between 
males and females. No difference of ongoing mutation was identified between the two sexes 
(P= 0.246) (Mann-Whitney U test). 
Also no difference in the ongoing mutation was found between patients with high or low 
number of enlarged LNs (P= 0.375) (Mann-Whitney U test). 
No correlation was found between LDH level and the degree of ongoing mutation (P= 0.127) 
(r = - 0.385) (Spearman's correlation). Also, no association was identified between ongoing 
mutation and FLIPI score (P=0.9) (Kruskal -Wallis test) (Table 5.13).. 
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Table 5.13: Correlation between ongoing mutations analysed by method from published papers and clinical 
parameters of FL at entry to clinical trial. 
 
 
Parameter 
Range or 
number and 
percentage of 
total 
Ongoing  
mutation 
Mean ± SD  
Ongoing  mutation 
 
P value 
 
Statistical test 
 
Age 
 
57- 78 
 
4.76 ± 4.54 
 
0.371 
(r = 0.224) 
Spearman's 
correlation 
 
 
Sex 
Male 
 
13 (72%) 
 
5.62 ± 4.98 
 
 
 
0.246 
 
 
Mann-Whitney 
U test Female 
 
5 (28%) 
 
2.51 ± 2.14 
 
 
 
Number of LN 
1 – 5 
 
7 (39%) 
 
5.62 ± 4.98 
 
 
 
0.375 
 
 
 
Mann-Whitney 
U test 
≥ 6 
 
11 (61 %) 
 
4.21 ± 4.40 
 
 
LDH (U/L) 
 
 
109 – 862 
 
 
 
4.76 ± 4.54 
 
0.127 
(r = - 0.385 ) 
 
Spearman's 
correlation 
 
 
 
 
Histological grade 
1 
 
3 (17%) 
 
0.86 ± 0.82  
 
 
 
 
0.037 
 
 
 
 
Kruskal -Wallis 
test 
2 
 
10 (56%) 
 
6.53 ± 5.05 
3 
 
5 (28%) 
 
3.56 ± 2.98 
 
 
 
Ann Arber stage 
II+III 
 
11 (61%) 
 
2.9 ± 2.11 
 
 
0.069 
 
 
Mann-Whitney 
U test IV 
7 (39%) 
 
7.69 ± 5.89 
 
 
 
 
FLIPI score 
0 
3 (15%) 
 
6.62 ± 8.04 
 
 
 
 
0.9 
 
 
 
 
Kruskal -Wallis 
test 
1 
4 (20%) 
 
3.9 ± 1.35 
2 
14 (65%) 
 
4.57 ± 4.5 
184 
 
Ongoing mutation was compared among the histological grades of FL in our cohort of 18 
patients. It was found that the ongoing mutation in patients with histological grade 2 FL 
significantly increased by more than two fold as compared to patients with grade 1.  
In cases with grade 3, although slightly lower than that in grade 2, it still nearly doubled 
compared to that in the group with grade 1 (P= 0.037) (Kruskal -Wallis test) (Figure 5.11). 
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Figure 5.11: A positive significant correlation between ongoing mutations with advanced disease grade (P= 
0.037) (Kruskal -Wallis test). 
Furthermore, the average ongoing mutation level in patients at stage IV was nearly twice 
as high in cases at stage II and III. This showed a tendency towards increase in ongoing 
IGHV mutation in advanced FL (P= 0.069) (Mann-Whitney U test) (Figure 5.12). 
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Figure 5.12: Difference in ongoing IGHV mutation between FL patients at different disease stages as 
analysed with a Mann-Whitney U test.  
 
Discussion: 
The aims of our work in this chapter were: (1) to explore the correlation between AID 
expression and ongoing IGHV mutations, and (2) to determine whether there was a 
relationship between the ongoing mutation and clinical variables in FL at time of patient 
enrolment in the clinical trial. 
Although lacking a statistical significance, a positive trend was observed between both AID 
mRNA and protein expression with ongoing mutation in IGHV of the patients studied.  
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With the optimised protocols for DNA preparation and PCR in combining with BIOMED-2 
primers, the IGHV gene was successfully amplified from 90% (18/20) of patient FFPE 
samples, and all of these PCR products were successfully subcloned and sequenced. The 
success rate was markedly higher than those previously reported (between 35% (375) and 
79.7% (376)) in studies using similar FFPE samples from patients with FL. 
The improvement made in this thesis was probably due to the following reasons: 
1-Our optimizations of DNA extraction from FFPE tissue samples produced a very good 
quality of DNA. All of our samples produced at least a PCR band with a size of 200 bp or 
more (details given in Chapter 3, Section 3.2.2.2)  
2-Optimizations of BIOMED-2 PCR conditions by increasing the Mgcl2 concentration from 
1.5-2.5 mM or increasing the number of PCR reaction cycles to 38 rather than 35. The Berget 
group found also that increasing PCR cycles to 38 produced better results (376), and this 
may explain better results of IGHV clonality detection of this group compared to the 
HALLDO´ RSDO´ TTIR paper (79.7% compared to 35%) (375). 
So, it can be concluded that optimizing the BIOMED-2 PCR reaction is important for 
avoiding false negative cases associated with clonality detection in clinical services. 
We followed the same analysis and also found the positive trend between AID mRNA 
expression and ongoing mutation reported by Hardianti et al. (358). 
In agreement with Bose and colleagues, Loeffler and co-workers, and Jackson and 
colleagues, the number of mutations are more in FR regions because it covers a larger area 
of the IGHV gene (377, 378).  
Although we found a trend of higher AID expression with ongoing mutation, However, 
Takata and colleagues and Smit and co-workers found that there was no correlation between 
AID expression, particularly at the mRNA level, with percentage of IGHV mutation and 
ongoing mutation in FL (365, 379). This is probably due to different tissues used (duodenal 
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rather than nodal FL) in the first paper or different method for ongoing mutation detection 
in the second publication. Willenbrock and colleagues and Kawamura and co-workers found 
that there was no correlation between AID expression and stage of disease in FL (237, 354).  
In conclusion, we found a positive correlation between ongoing IGHV mutation and both 
histological grade and Ann Arbor stage of FL.  
Again, and similar to findings in the previous chapter, function of AID rather than expression 
level was correlated better with clinical parameters. However, increasing the size of the 
cohort of patients is necessary to prove the relationship between the functional readout of 
AID (N/C  ratio of AID and ongoing mutation) with FL clinical features.  
Finally, in agreement with Rebhandl and colleagues, our results suggest the possible role of 
AID not only in malignant transformation as thought earlier, but also in clonal evolution of 
B-cell malignancies (380).  
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Chapter 6 
 
Investigation of relationships between transcriptional levels of 
genes associated with T cells and macrophages and AID 
expression in lymph node tissue, and their correlations with 
clinical status of FL  
 
6.1 Introduction: 
The tissue microenvironment plays a vital role in lymphoma pathogenesis. It helps malignant 
cells to grow, survive and escape the immune system (94). We can predict the prognosis of 
FL more accurately from knowledge of TME composition than from features of neoplastic 
B-cells (95). 
In addition to its role in pathogenesis, the TME protects some lymphoma cells from 
destruction by therapeutic drugs. Malignant cell clones that are resistant to particular 
therapies are able to proliferate, resulting in disease relapse. Furthermore, with the help of 
the TME, resistant malignant lymphocytes can acquire further mutations and genomic 
instability that may lead in turn to the development of aggressive, complex and drug-resistant 
malignant clones (381). 
The TME of FL contains different types of cells: most of them have been reported to be 
associated with disease outcome, and some of them are known to be associated with 
malignant transformation (94). TME cells in FL include reactive T lymphocytes of differing 
subtypes (helper T cells, tumour-infiltrating CD8+ T cells and follicular regulatory T cells). 
Other TME cells include macrophages, mast cells, FDCs, and fibroblastic reticular cells 
(382).  
The different types of TME cells have varying correlations with FL prognosis: for example,  
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macrophages are associated with a bad prognosis in FL patients not treated with rituximab, 
and a good prognosis if patients were treated with rituximab (382). 
Neoplastic follicles with lower dendritic cell densities and higher T regulatory cells are found 
to be associated with a decreased overall survival. This is probably caused by the inhibition 
of other beneficial T-cell types from proliferating within the FL TME; these other T-cell 
types would otherwise destroy the malignant lymphocytes (99). 
Although gene expression profiling studies have provided clues relating TME gene 
expression to FL prognosis, IHC studies examining T-cell subsets and macrophages on FFPE 
tissues and correlating these IHC data to clinical outcome have been inconsistent, and hence 
have yet to be translated into clinical practice (73). 
The process of SHM in FL is important for producing N-glycosylation sites for BCR in 
malignant FL cells (383), and the process of ongoing SHM favours maintaining these 
mannose molecules (384). The BCR mannose is capable of binding to mannose-binding 
lectins on bacteria, dendritic cells and macrophages, and commonly supporting survival of 
malignant lymphoma cells (87, 385). The correlation between AID expression and TME was 
studied in some other B-cell malignancies such as CLL. In CLL, it was found that in the 
group of patients with bad prognosis, AID levels were high. This high AID expression was 
associated with ongoing CSR and the expression was affected by TME signals (386). 
However, we did not find studies exploring the relationship between AID expression and 
TME in FL in the literature. 
So, we wanted to explore the correlation between several genes expressed in TME and both 
AID expression (as a readout of SHM) and the process of ongoing SHM. The selected list 
of genes and number of samples were affected by the amount and quality of RNA available 
for our study.  
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6.1.1 Aim and hypothesis: 
The aim of Chapter 6 was to examine the correlation of AID expression and function at 
diagnosis of FL with TME gene expression.  
This is because it was found that in other B-cell malignancies, active TME induced AID 
expression (386). Also, cytokines secreted by inflammatory cells such as TNF, IL-1β, IL-4, 
IL-13 and TGFβ were found to be associated with ectopic expression of AID, inducing 
genomic instability and cancer development (387). We wanted to explore whether there is a 
relationship between AID and genes predicting prognosis and representing TME cells. Thus, 
AID expression or function can probably be added to TME to predict prognosis of disease. 
6.2 Materials and methods: 
6.2.1 Samples used for qPCR measurement of TME gene expression: 
To carry out cDNA synthesis for qPCR gene expression, only cases with good RNA amount 
and quality (RIN ≥ 2.1) were used. Therefore, of the 87 cases from the PACIFICO trial 
included in this thesis, only 31 samples met such criteria, and were therefore used for 
research in this chapter. Seventeen of these cases had low AID protein expression (IHC 
score=1) and 14 high AID (IHC score of ≥4). 
6.2.2 Approaches to identify genes expression of TME in FL: 
mRNA expression of  6 genes in the TME that predicts prognosis in FL were explored (see 
below for details). The transcription level of these genes to EC gene (GAPDH) by qPCR was 
measured in the same way, and using the same equation, as presented in Chapter 2, Section 
2.3.7.  
6.2.3 Selecting genes for Taqman qPCR reaction for TME genes in FL: 
The most important publication that initiated investigation of the impact of TME in FL with 
disease prognosis is Dave and colleagues’ paper published in the New England Journal of 
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Medicine (NEJM) in 2004. These authors identified two sets of genes representing TME 
cells. They named the first group “immune-response 1 signature genes”; these were 42 genes 
predicting good prognosis and represent genes expressed mainly in T cells and sometimes 
monocytes. The other group were “immune-response 2 signature genes” (24 genes). This 
second group of genes are expressed in monocytes and/or FDCs but not T cells. The immune-
response 2 signature genes were associated with poor disease outcome (95).  
In 2008, Byers and colleagues (273) designed a Taqman qPCR reaction to measure 
expression of 35 genes studied by Dave et al. and Glas et al. (95, 388). From lists presented 
in these papers, six indicator genes were selected to explore their correlation with AID 
expression. The selection of these genes was based on the following factors: First, these 
genes were studied in at least two of these publications. Second, they are proposed to be 
expressed in specific types of TME cells (T cells vs macrophages or FDCs). Third, the qPCR 
measurement of gene transcription had been optimized for these genes. Three genes were 
supposed to be associated with good prognosis and mainly expressed in T cells or monocytes 
(CD2, LEF1 and STAT4), and 3 genes were associated with bad prognosis and are expressed 
mainly in macrophages or FDCs (LGMN, C3AR1 and MAPK1). However, MAPK1 is not 
specific to macrophages and can be expressed in other human cells (273). Some of these 
cells are NK cells, eosinophils and epithelial cells (389-391). 
Details of types of cells expressing these genes and cellular pathways associated with these 
genes can be seen in Chapter 2, Table 2.13. These genes represent specific types of cells in 
TME and the Taqman qPCR expression for these genes has been optimized by Byers and 
colleagues. In addition, these genes were found to be clearly associated with disease 
prognosis in FL in Dave and colleagues’ work.  
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6.2.4 Selecting cell lines to be used as a control for selected genes: 
To identify controls for these six genes representing TME expression signatures, cDNA from 
different haematological cell lines in our department was utilised. An optimized and 
published qPCR protocol to identify these genes’ expression in cell lines was used (273). 
TME genes were tested in these cell lines: Raji cell line (Burkett’s lymphoma) (257), Karpas 
422 cell line (Diffuse Large B Cell Lymphoma) (274), Daudy cell line (Burkett’s lymphoma) 
(275) and Jurkat cell line (Acute T cell Leukaemia) (276). 
It was confirmed that genes that are associated mainly with macrophages and FDCs 
(MAPK1, C3AR1and LGMN) have lower Ct values of qPCR in the Daudi cell line.  
On the other hand, genes associated with T cell expression (CD2, LEF1 and STAT4) 
appeared in earlier qPCR cycles in a human T lymphocyte cell line (Jurkat cell line). 
6.3 Results of TME gene expression profile: 
qPCR reaction details and optimizations were discussed in Chapter 2, Section 2.7. For every 
patient in the cohort, qPCR expression (Ct value) for each of the six genes and the EC gene 
(GAPDH) was repeated three times (technical replicates). Positive control cell lines qPCR 
expression was repeated three times also, and a water control was added to identify possible 
qPCR contamination.   
Regarding genes associated with good prognosis of FL, the ratio of STAT/GAPDH among 
all cases ranged between 0.0001-0.07, with a mean of 0.011. LEF1/GAPDH ranged between 
0.0001- 0.046, the average was 0.008. CD2/GAPDH expression was 0.0002-0.211 and the 
mean was 0.041. 
With respect to those genes associated with bad prognosis of FL, firstly we had 
C3AR1/GAPDH average of 0.0073 and range of 0.0001 - 0.025. LGMN/GAPDH mean in all 
cases was 0.0077 with a range of 0.0009 - 0.033 and finally MAPK1/GAPDH expression 
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range was between 0.0048 - 0.31 and the mean was 0.089. Expression of genes was variable 
among cases. A heat map representing gene expression among all cases is seen in Figure 6.1.  
0.0001                                         Colour scale                                     0.3059
Bad prognosis genes
AID 
protein
Good prognosis genes
STAT4 LEF1 CD2 C3AR1 LGMN MAPK1
0.0216 0.0159 0.0938 0.0003 0.0202 0.0450
0.0470 0.0186 0.1813 0.0240 0.0086 0.2062
0.0003 0.0002 0.0018 0.0033 0.0029 0.0344
0.0130 0.0319 0.1081 0.0179 0.0128 0.3059
0.0073 0.0103 0.0157 0.0101 0.0091 0.0927
0.0087 0.0093 0.0629 0.0083 0.0131 0.0987
0.0677 0.0355 0.1955 0.0159 0.0112 0.1632
0.0194 0.0024 0.0158 0.0002 0.0015 0.0379
Low AID 0.0198 0.0038 0.0668 0.0146 0.0325 0.1241
0.0090 0.0091 0.0756 0.0070 0.0149 0.0619
0.0007 0.0003 0.0037 0.0248 0.0060 0.0504
0.0003 0.0003 0.0022 0.0006 0.0028 0.0048
0.0004 0.0004 0.0024 0.0025 0.0133 0.0659
0.0268 0.0459 0.2110 0.0072 0.0161 0.2849
0.0014 0.0007 0.0041 0.0095 0.0029 0.0897
0.0022 0.0010 0.0041 0.0034 0.0023 0.0886
0.0004 0.0002 0.0015 0.0037 0.0020 0.0704
0.0003 0.0003 0.0025 0.0048 0.0027 0.0736
0.0001 0.0001 0.0014 0.0053 0.0009 0.0624
0.0497 0.0249 0.0912 0.0069 0.0138 0.1411
0.0009 0.0003 0.0022 0.0026 0.0024 0.0661
0.0007 0.0018 0.0023 0.0069 0.0063 0.0776
0.0207 0.0128 0.0604 0.0001 0.0027 0.0522
High AID 0.0001 0.0001 0.0002 0.0040 0.0029 0.0423
0.0092 0.0114 0.0483 0.0048 0.0083 0.0589
0.0004 0.0002 0.0024 0.0062 0.0019 0.0902
0.0007 0.0003 0.0032 0.0050 0.0069 0.0832
0.0001 0.0001 0.0008 0.0028 0.0020 0.0230
0.0003 0.0003 0.0018 0.0095 0.0025 0.0261
0.0029 0.0025 0.0075 0.0037 0.0042 0.0902
0.0020 0.0014 0.0103 0.0091 0.0095 0.0561
 
Figure 6.1: Heat map of genes representing TME and predicting prognosis in FL among cases of low and  high 
AID. The ratio of gene expression to GAPDH increased gradually from low (green colour) to yellow then red 
(highest expression).  
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6.3.1 Correlations between different gene expressions: 
The correlation of expression level among the three genes reported to be associated with 
good prognosis in FL patients was explored. A strong significant positive correlation was 
observed between all of these genes as analysed using Spearman’s correlation test. As shown 
in Figure 6.2, LEF1/GAPDH and STAT4/GAPDH were significantly correlated (r= 0.933, 
P< 0.001). LEF1/GAPDH and CD2/GAPDH were also positively and significantly 
correlated (r= 0.943, P< 0.001). STAT4/GAPDH and CD2/GAPDH had the strongest 
positive correlation (r= 0.95, P< 0.001). 
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Figure 6.2: A significant positive correlation was observed between all of the three genes expressed in T cells 
in TME and reportedly associated with good prognosis in FL. Spearman’s correlation analysis was used in all 
figures. 
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In addition, weak correlations were also observed between genes associated with bad 
prognosis. C3AR1/GAPDH and LGMN/GAPDH were significantly correlated (r= 0.419, P= 
0.019). C3AR1/GAPDH and MAPK1/GAPDH were also positively and significantly 
correlated (r= 0.569, P= 0.001), as were LGMN/GAPDH and MAPK1/GAPDH (r= 0.441, 
P= 0.013) (Figure 6.3). 
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Figure 6.3: Results of Spearman’s correlation analyses between genes expressed in TME and associated with 
poor prognosis in FL. 
 
6.3.1 Correlation between AID expression and gene signatures of FL 
microenvironment: 
To explore the relationship between AID expression and TME genes, the expression of these 
genes was correlated with mRNA qPCR and total IHC protein expression of AID. 
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6.3.1.1 Relation between AID/GAPDH mRNA expression and TME genes: 
No correlation was found between AID/GAPDH mRNA ratio and genes representing TME 
and predicting prognosis in FL. Correlations between AID/GAPDH mRNA and 
CD2/GAPDH (r= 0.031, P= 0.868), STAT4/GAPDH (r= 0.102, P= 0.587) and 
LEF1/GAPDH (r= 0.102, P= 0.578), C3AR1/GAPDH (r= - 0.002, P= 0.991), 
LGMN/GAPDH (r= - 0.151, P= 0.417) and MAPK1/GAPDH were also not correlated (r 
=0.096, P= 0.608) (Spearman’s correlation).  
6.3.2 Relationship between AID protein and TME gene signatures of FL:  
Based on AID protein expression by IHC, patients were divided into two groups. Seventeen 
patients with low AID protein (IHC=1) and 14 cases with high AID protein (IHC ≥ 4) were 
selected, then TME genes were compared between the two groups. 
A significant negative correlation was identified between two of the genes associated with 
good prognosis and AID protein. Higher STAT4/GAPDH (P= 0.048) and CD2/GAPDH (P= 
0.026) gene expression was found in cases with lower total AID protein. A non-significant 
negative trend was also identified between AID protein expression and the 3rd gene of good 
prognosis in FL (LEF1/GAPDH) (P= 0.071). A Mann-Whitney U test was used in all 
calculations (Figure 6.4). 
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Figure 6.4: A significant negative correlation was found between AID protein expression and two 
genes predicting good prognosis in FL. A Mann-Whitney U test was performed. 
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No correlation was identified between any of the bad prognosis genes and AID protein. 
However, a negative trend was identified between AID expression and LGMN/GAPDH gene 
(P= 0.053). The correlations between AID protein level and C3AR1/GAPDH was (P= 0.297) 
and MAPK1/GAPDH association with AID was (P= 0.262) (Mann-Whitney U test).  
It is important to note that, for the good prognosis genes, which are negatively correlated 
with AID protein, the degree of increase in the median of gene expression with decreasing 
AID protein is 6.32 – 12.7 fold. However, in the LGMN gene, which had no statistically 
significant negative correlation with AID protein, the change in expression was only 3.3 fold 
(Table 6.1). 
 
 
 
 
 
P value 
 
 
Folds of 
change 
Median of gene 
expression in 
high AID 
protein group 
Median of gene 
expression in low 
AID protein 
group 
 
 
Gene 
 
0.048 12.4 0.0007 0.0087 STAT4 Good 
prognosis 
genes 
0.026 6.32 0.0025 0.0158 CD2 
0.071 12.7 0.0003 0.0038 LEF1 
0.053 3.3 0.0028 0.0091 LGMN Bad 
prognosis 
genes 
0.297 1.5 0.0049 0.0072 C3AR1 
0.262 1.4 0.0643 0.0885 MAPK1 
Table 6.1: Folds of increase in gene expression of the examined genes with decreased AID protein. 
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6.3.3: Association between TME genes and nuclear/cytoplasmic ratio of AID: 
Only 14 out of 31 patients had data for N/C AID ratio. The relationship between 
this ratio and TME was explored. No significant relationship was identified 
between any of these genes and N/C ratio of AID.  
Correlations between N/C ratio of AID and CD2/GAPDH (r= - 0.152, P= 0.605), 
STAT4/GAPDH (r= - 0.332, P= 0.246) and LEF1/GAPDH (r= - 0.068, P= 0.817), 
C3AR1/GAPDH (r= 0.231, P= 0.427), LGMN/GAPDH (r= - 0.09, P= 0.759) and 
MAPK1/GAPDH (r =0.363, P= 0.203) were found. Spearman’s correlation was used in all 
tests.  
6.3.4 Correlation between EC gene in qPCR and Taqman qPCR reactions: 
In order to confirm the accuracy of gene transcription level using Taqman qPCR, Ct value 
of GAPDH gene using SYBR Green dye in qPCR that was discussed in Chapter 2, Section 
2.3.7 was compared to GAPDH Ct values using Taqman reagents of qPCR. A positive 
significant correlation was noted between the GAPDH gene measured by qPCR for mRNA 
expression of AID/GAPDH and the Taqman method (r= 0.865, p< 0.001, n= 31) 
(Spearman’s correlation) (Figure 6.5). 
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Figure 6.5: A positive significant correlation between Ct values of GAPDH measured by qPCR and Taqman 
qPCR (Spearman’s correlation). 
 
 
 
6.3.5 Association betweenTME genes’ expression and ongoing mutation: 
Out of 31 samples used in this chapter, we had ongoing mutation results for 11 FL samples 
only. The association between TME genes and IGHV ongoing mutation was explored. 
Ongoing mutation represents folds of PCR error rate mutations; the method of quantification 
was discussed in Chapter 5, Section 5.3.5. No correlation was found between ongoing 
mutation and any of the expressed genes (Table 6.2). 
200 
 
 
Table 6.2: Correlations between ongoing mutation in IGHV and TME gene expression. Spearman’s 
correlation was used in all tests.  
 
6.3.6 Relationship between TME gene expressions with clinical data at entry to clinical 
trial: 
The correlations between TME gene expression and patient clinical data was explored. This 
is because there is controversy in the literature regarding the correlation of these genes with 
clinical outcome. Some of those genes were correlated with good and poor prognosis of FL 
in some studies, while not in others (details provided in the discussion section). We wanted 
to explore this association in more detail, as outlined below. 
6.3.6.1 Relationship between sex of patients and TME genes: 
Out of 31 patients in our cohort, 16 were males (52%) and 15 (48%) were females. No 
correlation was identified between sex of patients and any of the TME genes. A Mann-
Whitney U test was used to identify all relationships (Table 6.3). 
  
TME Gene 
Correlation between ongoing 
mutation and TME genes 
r value P value 
 
 
 
Good prognosis genes 
STAT4/GAPDH - 0.418 0.201 
LEF1/GAPDH - 0.355 0.285 
CD2/GAPDH - 0.291 0.385 
    
 
 
 
Bad prognosis genes 
C3AR1/GAPDH - 0.136 0.689 
LGMN/GAPDH - 0.055 0.873 
MAPK1/GAPDH 0.036 0.915 
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Table 6.3: Correlations between ongoing mutation and TME gene expression. Mann-Whitney U test used in 
all correlations. 
6.3.6.2 Correlation between age of patients and TME genes: 
The age of patients ranged between (64 to 84) with an average of 70.6 years. Age of patients 
was compared to TME genes. A weak negative correlation was identified between age of 
patients and LGMN/GAPDH expression (r= - 0.376) (P= 0.037) (Spearman’s correlation).  
No correlation was identified between the other five genes and age of patients. Relationships 
between age and STAT4/GAPDH (r= - 0.136) (P= 0.465), LEF1/GAPDH (r= - 0.209) (P= 
0.259), CD2/GAPDH (r= - 0.13) (P= 0.487), C3AR1/GAPDH (r= - 0.118 (P= 0.4529), 
MAPK1/GAPDH (r= - 0.017) (P= 0.929) are as reported here. Spearman’s correlation was 
used in all tests.     
6.3.6.3 Association between number of LNs and TME genes: 
The number of LNs of patients were divided into two groups; those with five or less enlarged 
LNs were group one, forming ten out of 31 patients (32%). Patients with six or more LNs 
were group 2; those were 21 cases (68%). Patients were divided into these two groups  
 
 
  
TME Gene 
Correlation between sex of 
patients and TME genes               
(P value) 
 
 
Good prognosis 
genes 
STAT4/GAPDH 0.8 
LEF1/GAPDH 0.47 
CD2/GAPDH 0.711 
 
 
Bad prognosis genes 
C3AR1/GAPDH 0.232 
LGMN/GAPDH 0.922 
MAPK1/GAPDH 0.545 
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because on trial data sheets, for any patient with six or more LNs, the number 6 was written. 
No correlation was observed between any of the six genes expressed in TME and the two 
groups of enlarged LNs. A Mann-Whitney U test was used to explore correlations between 
the number of enlarged LNs and genes (Table 6.4). 
Table 6.4: Association between genes predicting good and bad prognosis in FL and groups of patients with 
low and high number of enlarged LNs. Mann-Whitney U test used. 
 
6.3.6.4 Relationship between TME genes and LDH level: 
The LDH level ranged between (109 and 862 U/L), with an average of 407 U/L in our 31 
patient cohort. When the correlation between LDH level and expression of TME genes was 
explored, it was found that there was no correlation between LDH level and any of the TME 
genes. Spearman’s correlation was used in all tests (Table 6.5). 
 
 
 
  
 
TME Gene 
Mean ± SD in 
patients with 
≤ 5 enlarged 
LNs 
Mean ± SD in 
patients with ≥ 
6 enlarged 
LNs 
 
 
P value 
 
 
Good prognosis  
genes 
STAT4/GAPDH 0.014 ± 0.024 0.009 ± 0.012 0.852 
LEF1/GAPDH 0.007 ± 0.012 0.008 ± 0.012 0.884 
CD2/GAPDH 0.049 ± 0.079 0.038 ± 0.053 0.917 
 
 
Bad prognosis 
genes 
C3AR1/GAPDH 0.009 ± 0.009 0.006 ± 0.004 0.724 
LGMN/GAPDH 0.008 ± 0.006 0.008 ± 0.008 0.466 
MAPK1/GAPDH 0.084± 0.058  0.092 ± 0.08  0.724 
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Table 6.5: Correlations between LDH level and TME gene expression. Spearman’s correlation was used in all 
tests. 
 
 
6.3.6.5 Association between grade of FL and TME genes: 
Patients with FL were divided into three grades. Our cohort in this chapter was 31 samples. 
Six patients were in grade 1 disease (19%), 17 samples had grade 2 by IHC (55%) and eight 
patients were grade 3 disease (26%). No correlation was observed between any of the TME 
genes and grade of FL. A Kruskal-Wallis test was used in all correlations (Table 6.6).  
 
 
 
 
 
 
  
TME Gene 
Correlation between TME genes 
and LDH level 
r value P value 
 
 
Good prognosis  
genes 
STAT4/GAPDH 0.018 0.922 
LEF1/GAPDH 0.11 0.556 
CD2/GAPDH 0.013 0.944 
 
 
Bad prognosis genes 
C3AR1/GAPDH - 0.335 0.066 
LGMN/GAPDH - 0.125 0.501 
MAPK1/GAPDH - 0.16 0.389 
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Table 6.6: Association between grade of disease and TME gene expression. Kruskal-Wallis test used in all 
correlations. 
 
6.3.6.6 Association between stage and FLIPI score of FL with TME genes: 
Patients were divided into two groups. The low stage disease group (stage Π and III) were 
18 patients and the high stage group (stage IV) were 13 patients. Only four out of 31 patients 
(13 %) were in stage Π disease. So, these patients were combined with those at stage III. The 
association between TME and stage of disease was explored. No correlation between the 
two groups was identified (Table 6.7). 
 
 
 
 
  
 
TME Gene 
 
Mean ± SD 
for grade 1 
disease (n= 6) 
 
Mean ± SD 
for grade 2 
disease        
(n= 17) 
 
Mean ± SD 
for grade 3 
disease (n= 8) 
TME 
genes and 
grade of 
disease 
correlation 
(P value) 
 
 
Good 
prognosis  
genes 
STAT4/GAPDH 0.016 ± 0.06 0.01 ± 0.02 0.01 ± 0.01 0.324 
LEF1/GAPDH 0.006 ± 0.01 0.007 ± 0.012 0.012 ± 0.016 0.772 
CD2/GAPDH 0.032 ± 0.038 0.04 ± 0.07 0.053 ± 0.073 0.477 
 
Bad 
prognosis 
genes 
C3AR1/GAPDH 0.011 ± 0.008 0.008 ± 0.0068 0.004 ± 0.003 0.149 
LGMN/GAPDH 0.011 ± 0.011 0.007 ± 0.005 0.008 ± 0.007 0.629 
MAPK1/GAPDH 0.083 ± 0.042 0.1 ± 0.07 0.074 ± 0.088 0.12 
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Table 6.7: Correlations between stage of disease and TME gene expression. Mann-Whitney U test used in all 
correlations. 
Again, no correlation was identified between the FLIPI score and TME genes (Table 6.8) 
Table 6.8: No association between TME genes and FLIPI score, Kruskal-Wallis test was used in all 
correlations. 
6.4 Discussion: 
In this chapter, an exploration into the correlation between AID expression and function with 
immune signature of FL was initiated by measuring qPCR expression of six genes. Three of 
  
TME Gene 
Mean ± SD 
for stage  Π 
and III  
disease 
Mean ± SD for 
stage IV 
disease 
TME genes 
and stage of 
disease 
correlation 
(P value) 
 
 
Good prognosis  
genes 
STAT4/GAPDH 0.012 ± 0.019 0.009 ± 0.014 0.737 
LEF1/GAPDH 0.01 ± 0.015 0.005 ± 0.006 0.54 
CD2/GAPDH 0.043 ± 0.067 0.039 ± 0.055 0.953 
 
 
Bad prognosis genes 
C3AR1/GAPDH 0.008 ± 0.007 0.007 ± 0.0067 0.89 
LGMN/GAPDH 0.007 ± 0.005 0.009 ± 0.009 0.737 
MAPK1/GAPDH 0.097 ± 0.08 0.079 ± 0.05 0.921 
  
TME Gene 
Mean ± SD 
for FLIPI 0 
Mean ± SD 
for FLIPI 1 
Mean ± SD 
for FLIPI 2 
correlation 
(P value) 
 
 
Good 
prognosis  
genes 
STAT4/GAPDH 0.023±0.039 0.007±0.001 0.01±0.014 0.605 
LEF1/GAPDH 0.012 ± 0.02 0.004±0.001 0.008±0.012 0.806 
CD2/GAPDH 0.067±0.111 0.02 ± 0.003 0.043±0.058 0.565 
 
 
Bad prognosis 
genes 
C3AR1/GAPDH 0.015±0.011 0.008±0.004 0.007±0.006 0.423 
LGMN/GAPDH 0.007±0.0047 0.007±0.006 0.008±0.008 0.976 
MAPK1/GAPDH 0.083 ± 0.07 0.066±0.032 0.094±0.073 0.696 
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these genes (C3AR1, LGMN and MAPK1) were found to be mainly expressed in 
macrophages and are associated with poor prognosis, while CD2, STAT4 and LEF1 are 
expressed mainly by T cells and are associated with good prognosis (273).   
Only 17 cases with low and 14 samples of high AID protein had sufficient concentration of 
good quality mRNA to be used in the experiments undertaken. In this study, it was found 
that genes linked to good prognosis were strongly associated with each other; also, genes 
involved with poor prognosis in FL were also correlated with one another, but to a weaker 
extent (Figures 6.2 and 6.3). This is in agreement with Dave and colleagues, and is expected 
because genes that are expressed in the same cell correlated positively with each other (95).  
In this study, no significant correlation was found between AID mRNA expression and any 
of the TME genes. On the other hand, a negative significant correlation was identified 
between STAT4 and LEF1 with AID protein expression. However, the current results may 
support our hypothesis of poor disease outcome in cases with higher AID expression or 
function. Nevertheless, increasing the size of the cohort is required to further support these 
results.  
In this study, we did not identify a correlation between the functional ‘read out’ of AID 
(ongoing mutation and N/C ratio of AID) with the six genes’ expression. Also, no correlation 
was identified between these genes and clinical parameters at entry to clinical trial. The only 
exception is that we found decreased expression of LGMN with age. No studies were found 
in the literature that investigated the transcription level of this gene and lymphoma. 
However, it was found that LGMN gene expression decreases with aging of brain tissues 
(392). 
In agreement with most of our findings, Byers and colleagues used the same qPCR Taqman 
technique and the same genes that we used. They found that none of the six examined genes 
were associated with prognosis of FL (273).  
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Glas and co-workers, as well as Chevalier, found that not only the amount of T cells in the 
TME is important in prognosis, but also the location with early FL transformation if T helper 
cells are located within the neoplastic follicle (99, 393). So, it is likely that studying 
expression of TME genes alone, without determining the exact location of TME cells, is 
insufficient for predicting the prognosis in FL.  
In summary, we identified a correlation of lower AID protein expression and good prognosis 
genes in FL. However, the TME is a complex structure of stromal and blood cells. The 
number, composition and location of TME cells play a role in prognosis of disease (394).  
The addition of rituximab to chemotherapy reversed the association of  poor prognosis with 
high macrophage content in the pre-rituximab era to a good prognosis after adding rituximab 
to chemotherapy in FL patients (395).  
Hence, for this reason, data from a larger number of genes, involvement of other methods of 
gene and protein expression, and determining the number, type and location of TME cells is 
required before drawing a definite conclusion about any associations of TME with AID 
expression, and with FL prognoses. 
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Chapter 7 
 
 
Correlations between AID expression and function against 
clinical outcome of FL 
 
 
7.1 Introduction:  
AID activity is associated with ongoing SHM, ASHM and chromosomal translocations. All 
of these processes are associated with DNA damage that is linked with the pathogenesis 
and/or transformation of FL (20, 78, 139, 237, 396).  
It was of interest to correlate AID expression and activity with clinical outcome in patients 
with FL for the following reasons: 
1-AID expression and activity was heterogeneous across our cohort of patients (Chapter 4, 
Section 4.2.3), raising the possibility that it could account for the known variability in 
clinical outcome in FL. 
2- Correlations and trends were identified between AID activity and baseline clinical 
features at the time of trial entry. In particular, a significant positive correlation was 
identified between ongoing IGHV mutation and histological grade. In addition, a tendency 
towards higher ongoing mutation and more advanced anatomical stage (Chapter 5, Section 
5.4.10.3). Furthermore, a suggestive of a trend if a larger sample size could be analysed in 
future between the N/C ratio of AID and stage of disease (Chapter 4, Section 4.5). These 
correlations and trends suggest that AID activity influences the course of the disease prior 
to the point of trial entry. It was therefore logical to examine the possible role of AID in 
influencing the course of the disease after the point of trial entry. 
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3-The cohort of samples used to characterise AID expression and function were from the 
PACIFICO clinical trial, and was therefore well-defined with linked longitudinal data 
(although since the trial was still in follow-up mode, not all of this data was available). 
4- Studies analysing the correlation between AID activity and clinical outcome in FL are not 
found within the literature, although one paper did report a failure to identify any correlation 
between FL prognosis and AID protein expression by IHC (354).  
5- A significant positive correlation has previously been identified between AID expression/ 
activity and outcome in other B-cell malignancies such as DLBCL and CLL (237, 397). 
Based on the considerations outlined above, it was hypothesised that high AID activity 
(rather than expression) is associated with genomic instability and poor prognosis in FL. To 
test this hypothesis, laboratory data presented in Chapters 4, 5 and 6 were related to available 
longitudinal clinical data from the same patients. In these previous chapters, an optimization 
of nucleic acid extraction from FFPE tissues was carried out, followed by measurement of 
overall AID mRNA expression, overall AID protein expression, and the N/C AID ratio in 
these tissues. AID activity, in the form of ongoing mutation, and AID-specific mutations in 
the IGHV gene was also measured, and the correlation of AID expression with genes 
associated with the TME, were also determined. Correlations between these laboratory 
variables and longitudinal clinical data are presented in the current chapter. 
7.2 Materials and methods:  
7.2.1 Patients and data: 
Longitudinal clinical data was obtained for the 87 patients in the PACIFICO trial whose 
samples were used to generate the laboratory data presented in Chapters 4, 5 and 6. The data 
were provided by and analysed in collaboration with the trial statistician.  
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7.3 Statistical analysis:  
Progression-free survival (PFS), overall survival (OS) and the response rate (RR) at the end 
of the planned eight cycles of induction treatment were compared to laboratory data. Cox 
proportional hazards model was used to explore the effect of laboratory variables on PFS 
and OS. Boxplots and logistic regression were used to explore the effect of those data on RR 
after induction treatment (just after or before cycle 8).  
PFS is defined as disease progression or death from any cause. Response to treatment was 
based on principal investigators’ assessment, and takes four possible values: Complete 
Response (CR), Partial Response (PR), Stable Disease (SDS) and Progressive Disease (PD).  
Age was adjusted for the analysis of this chapter to eliminate the confounding effect of aging 
on clinical endpoints. 
7.4 Results: 
7.4.1 Relationship between AID expression and trial endpoints: 
In our cohort of 87 patients, only 17 have experienced a PFS event (9 progressions and 8 
deaths from any cause). The number of PFS events is smaller for the qPCR analysis (11 
only). This is because qPCR results were missing for 28 samples where the quantity or 
quality of RNA was low. The median follow-up time was 28 months while the maximum 
was 70 months. 
No association was noted between AID expression at both mRNA and protein level with 
PFS in our cohort of patients (Table 7.1). 
 
 
Table 7.1: Presents the results from the cox proportional hazards model fitted separately for each variable; the 
age-adjusted cox proportional hazards model yields a non-significant P value in both cases.HR; Hazard ratio, 
CI; Confidence Interval       
Variable HR 95% CI for HR P value 
IHC score 0.94 0.74, 1.20 0.624 
log(qPCR) 0.88 0.65, 1.20 0.433 
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Out of the 87 patients, only eleven have experienced an OS event so far. The number of OS 
events is even smaller for the qPCR analysis (7). No correlation was identified between AID 
expression and OS (Table 7.2). 
 
Variable HR 95% CI for HR P value 
IHC score 0.86 0.61, 1.22 0.404 
log(qPCR) 1.16 0.70, 1.92 0.576 
Table 7.2: No association was identified between AID expression at both mRNA and protein level with OS; 
the age-adjusted cox proportional hazards model was used. 
 
Out of the 87 patients, the response status is missing for ten patients. Among the remainder, 
31 achieved a CR, 41 achieved a PR, 3 had SDS, and 2 had PD. Hence, our analysis 
compared the patients who achieved CR against those who did not. No correlation was seen 
between AID expression and RR (Table 7.3). 
 
 
Variable OR 95% CI for HR P value 
IHC score 1.07 0.86, 1.33 0.523 
log(qPCR) 0.89 0.62, 1.25 0.494 
Table 7.3: Presents the results from the logistic model fitted separately for each variable; the age-adjusted 
logistic regression yields a non-significant P value in both cases.  
 
7.4.2. Relationship between AID N/C ratio and trial endpoints: 
AID N/C ratio, AID-specific mutation, and ongoing mutation of IGHV gene were used as 
readouts of AID function. 
The N/C ratio of AID was measured in 20 out of the 87 patients. Among these, only four 
have experienced a PFS event at the time of statistical analysis (one progression and three 
deaths). The median follow-up time is 34 months while the maximum is 70 months. No 
212 
 
correlation was identified between N/C ratio of AID and PFS in our cohort. HR= 0.92, 95% 
CI for HR= 0.78, 1.08 and P= 0.311 (Age-adjusted cox proportional hazards model). 
Out of the 20 patients, only three have experienced an OS event so far. No correlation was 
found between N/C ratio and OS in our cohort. HR= 0.93, 95% CI for HR= 0.78, 1.1 and 
P= 0.385 (Age-adjusted cox proportional hazards model).  
Box-plots and logistic regression were used to explore the effect of the N/C ratio of AID on 
RR. Out of the 20 patients, the response status was missing for one patient. Among the rest, 
five achieved a CR and 14 achieved a PR. Hence, our analysis compared patients who 
achieved a CR with those who did not. 
Although not statistically significant, these was a trend for patients who achieved a CR to a 
lower AID N/C ratio compared to those who did not achieve a CR. HR= 0.86, 95% CI for 
HR= 0.7, 1.02 and P= 0.11 (Age-adjusted logistic regression model).  
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  Figure 7.1: Lower N/C ratio of AID is associated with better response rate.  
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7.4.3 Relationship between overall cumulative IGHV mutation and trial endpoints: 
In this study, the total IGHV mutation, AID induced mutation and IGHV ongoing mutation 
were examined in 18 cases of FL. Logistic regression was used to explore the effect of 
ongoing IGHV mutation and AID-induced mutations on RR after induction treatment.  
It was found that there was a trend that was close to statistical significance between mutation 
load and superior PFS (HR= 0.9, 95% CI for HR= 0.81, 1.01 and P= 0.063).   
As was the case with PFS, here there was a statistically significant association between 
mutation load and superior OS (HR= 0.87, 95% CI for HR= 0.76, 0.99 and P= 0.044). 
However, the age-adjusted logistic regression did not yield any significant association at 5% 
level between RR with the total IGHV mutations: HR= 0.99, 95% CI for HR= 0.89, 1.14 and 
P= 0.939. 
We also explored the correlation between % of IGHV mutation and the trial endpoints. The 
% of IGHV mutation represents the difference from the germline. In our 18 patients, the 
range of % of IGHV mutation was between 2.89 and 19.22 with an average of 14.86 (details 
provided in Chapter 5, Section 5.4.4). No correlation was identified between the % of IGHV 
mutation and PFS in our cohort (HR= 0.86, 95% CI for HR= 0.69, 1.08 and P= 0.188). 
Similar to PFS, there was no association between % of IGHV mutation and OS; HR= 0.83, 
95% CI for HR= 0.65, 1.07 and P= 0.145. 
Also, there was no correlation between the percentage of IGHV mutation and RR (HR= 0.94, 
95% CI for HR= 0.73, 1.23 and P= 0.593). 
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7.4.4 Relationship between AID-related cumulative IGHV mutation and trial 
endpoints: 
Interestingly, when the percentage of AID-related IGHV mutations was related to PFS, a 
trend for worse PFS was found in patients with higher percentage of AID-related mutations 
(HR= 1.22, 95% CI for HR= 0.97, 1.53 and P= 0.086). 
However, there was no association between OS and the percentage of IGHV mutations due 
to AID (HR= 1.64, 95% CI for HR= 0.8, 3.36 and P= 0.173). 
Also, there was no correlation between the percentage of AID induced mutations among the 
total mutations and the RR: HR= 0.93, 95% CI for HR= 0.72, 1.13 and P= 0.484. 
7.4.5 Relationship between AID-unrelated cumulative IGHV mutation and trial 
endpoints: 
In contrast to results of correlation between percentage of AID related mutations and PFS, a 
higher percentage of non-AID-induced IGHV mutations was associated with a better PFS, 
although this association did not quite reach statistical significance (HR= 0.081, 95% CI for 
HR= 0.63, 1.04 and P= 0.086). Cox proportional hazards were used, and age was adjusted 
in the analysis. 
Similarly, there was no correlation between the percentage of AID unrelated mutations 
among the total mutations and the RR: HR= 1.08, 95% CI for HR= 0.88, 1.39 and P= 0.484. 
7.4.6. Relationship between ongoing IGHV mutation and trial endpoints: 
Ongoing mutation of the IGHV gene is the process of continuing mutation as indicated by 
intraclonal variation of the Ig sequence (398). The strategy to identify ongoing mutations 
was discussed in Chapter 5, Section 5.3.5. This IGHV ongoing mutation has previously been 
used by others as a read out of AID function (88, 356). In this thesis, the ongoing mutation 
and the accumulation of AID-induced mutations was examined in 18 cases of FL. Among 
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these patients, only five have experienced a PFS event at the time of analysis (two 
progressions and three deaths). The median follow-up time is 29 months, while the 
maximum is 67 months. After age adjustment, no association was identified between 
ongoing IGHV mutation and PFS, HR= 1.02, 95% CI for HR= 0.83, 1.27 and P= 0.841.  
Among the 18 patients studied for ongoing IGHV mutation, only four have experienced an 
OS event so far. The age-adjusted analysis revealed no correlation between OS and ongoing 
mutation in IGHV (HR= 1.08, 95% CI for HR= 0.86, 1.35 and P= 0.51). 
Out of the 18 patients, response data is missing for one patient, four achieved a CR, 11 
achieved a PR, one had SDS, and one had PD. Hence, our analysis compared patients who 
achieved CR with those who did not. 
The age-adjusted logistic regression did not yield any significant association between RR 
and ongoing mutation: HR= 0.93, 95% CI for HR= 0.61, 1.21 and P= 0.641.  
7.4.7 Relationship between genes expressed in the TME and trial endpoints:  
As discussed in Chapter 6, the TME plays an important role in pathogenesis and progression 
of FL (94). Three genes expressed in TME were found to be associated with clinical outcome 
in a previous study; these were (CD2, LEF1 and STAT4), and another three genes were 
associated with bad prognosis (LGMN, C3AR1 and MAPK1) (95). 
Higher expression of STAT4 and LEF1 in patients with lower expression of AID protein was 
previously reported in this thesis (Chapter 6, Section 6.3.2). However, no association 
between these genes and baseline clinical variables was found. 
The age-adjusted cox proportional hazards analysis yields a significantly higher hazard for 
progression among cases with higher LGMN gene expression. HR= 1.15, 95% CI for HR= 
1.02, 1.29 and P= 0.019. No correlation was observed between any of the rest of the five 
genes and PFS (Table 7.4). 
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Table 7.4: A significantly higher hazard for disease progression in patients with higher expression of LGMN 
gene. Cox proportional hazards test was used. 
 
 
Using the cox proportional hazards model to explore the effect of gene expression on OS, 
the age-adjusted model did not yield any significant correlation. However, a trend of higher 
hazard of death was observed in patients with higher LGMN expression. However, the P 
value is not statistically significant (Table 7.5). 
 
 Variable HR 95% CI for HR P  value 
Good 
prognosis 
genes 
STAT4 1.01 0.92, 1.09 0.987 
LEF1 1.02 0.89, 1.17 0.741 
CD2 1.01 0.98, 1.03 0.743 
Bad 
prognosis 
genes 
C3AR1 0.94 0.72, 1.22 0.628 
LGMN 1.16 0.98, 1.38 0.093 
MAPK1 0.96 0.73, 1.28 0.799 
Table 7.5: No correlation was observed between any of the genes expressed in TME of FL and OS. Cox 
proportional hazards were used in all tests. 
 
 
No correlation between any of the genes expressed in TME of FL and RR after induction 
treatment (just after or before cycle 8) was observed (Table 7.6). Logistic regression was 
used to explore the effect of those variables on RR.  
 
 
  
 Variable HR 95% CI for HR P  value 
 
Good prognosis 
genes 
STAT4 0.98 0.92, 1.04 0.549 
LEF1 0.95 0.85, 1.06 0.385 
CD2 0.99 0.98, 1.01 0.721 
Bad prognosis 
genes 
C3AR1 0.99 0.86, 1.14 0.911 
LGMN 1.15 1.02, 1.29 0.019 
MAPK1 0.96 0.81, 1.13 0.600 
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Table 7.6: No association was observed between any of the genes expressed in TME of FL and RR. Logistic 
regression was used in all tests. 
 
A summary of all associations between clinical features at diagnosis and follow up with our 
laboratory data can be found in Figure 7.2 below. 
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Figure 7.2: Summarises all correlations between AID expression and function with the clinical features and 
outcome in the cohort of FL patients studied in this thesis. The significant associations and non-significant 
trends correlates high AID function and AID related IGHV mutations with poor disease outcome; Patients with 
higher total IGHV mutations were associated with a better PFS and OS. * Negative correlation observed only 
between total IGHV mutation and shorter PFS or OS.  
 
 Statistically significant association P < 0.05 
 Non-significant trend P 0.05 – 0.11 
 No association or trend P > 0.11 
 Variable OR 95% CI for OR P value 
Good 
prognosis 
genes 
STAT4 1.01 0.97, 1.07 0.527 
LEF1 0.99 0.91, 1.08 0.980 
CD2 1.01 0.99, 1.02 0.563 
 
Bad prognosis 
genes 
C3AR1 1.02 0.90, 1.16 0.693 
LGMN 0.92 0.75, 1.06 0.317 
MAPK1 0.99 0.98, 1.01 0.655 
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7.5 Discussion: 
The aim of this chapter was to explore correlations of our laboratory data with clinical 
outcomes of our cohort of patients. Our main hypothesis was to identify the role of AID in 
FL. We hypothesised that AID expression at the genomic or protein level, or the functional 
readout of AID (N/C ratio of AID protein, ongoing IGHV mutation and AID-induced IGHV 
mutations) are associated with genomic instability, aberrant SHM and disease progression 
in FL. With the exception of a two reports that did not find a correlation between overall 
AID protein expression by IHC and prognosis, no previous studies could be found in the 
literature that had tested this hypothesis in such an FL setting (237, 354). In one of these 
papers, it was found that AID expression (both mRNA and protein) is correlated with poor 
prognosis in patients with DLBCL but not FL treated with CHOP-based chemotherapy 
(237). 
In previous chapters, we did not identify any correlations between AID expression and 
clinical variables at the point of trial entry. However, we did find correlations between such 
clinical variables and functional readouts of AID activity. For example, a tendency towards 
a higher N/C AID ratio in patients with advanced anatomical stage was noted, and a 
significant association between higher histological grade and a suggestion of a trend of more 
advanced stage with more ongoing IGHV mutation will probably become evident if more 
samples are used in the future. In this chapter, we also did not identify a correlation between 
AID expression both at mRNA and protein levels and any of the longitudinal trial endpoints 
examined. This was in agreement with the two studies of AID correlation with prognosis 
mentioned earlier in the discussion (237, 354) 
Regarding the function of AID, we did not identify a correlation between ongoing IGHV 
mutation and clinical outcome. However, there was a trend for a lower N/C AID ratio in 
patients who achieved a CR compared to those who did not. This is in keeping with the idea 
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that AID functions predominantly in the nucleus, and supports our hypothesis that high AID 
activity has a deleterious effect on outcome in FL.  
In support of this conclusion, we found a trend for worse PFS in patients with higher levels 
of AID-related IGHV mutation. In contrast, we found a trend for better PFS in patients with 
higher levels of non-AID-related IGHV mutation.  
In conclusion, the findings of this chapter are consistent with the other chapters, i.e. that the 
functional readout of AID, rather than its expression level, is more important in predicting 
the clinical features and outcomes of FL patients. 
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Chapter 8 
 
General discussion 
 
 
AID expression has been found to be responsible for chromosomal translocations that are 
involved in the pathogenesis of B-cell lymphomas (198). In addition, AID has also been 
correlated with the pathogenesis, progression and relapse in many B-cell and non B-cell 
tumours (37, 236-240). 
However, to our knowledge, no comprehensive study has so far examined the expression of 
AID at different levels in FL patients and correlated this to ongoing mutations, clinical 
features at diagnosis and clinical outcome, particularly when the only sample type available 
in most oncology centres is FFPE LN tissues that are taken at the time of diagnosis.  
So, in my thesis, the first aim was to identify and optimize methods of assessing AID 
expression in terms of mRNA, total protein and cellular localization of AID in B-cells in 
FFPE tissues from FL patients. To do this, I used pre-treatment FFPE biopsy samples 
obtained from the phase III PACIFICO trial which is comparing alternative frontline 
chemoimmunotherapy regimens in older patients with follicular lymphoma. 
After obtaining reliable measurements of AID expression from FFPE biopsies, my next aim 
was to explore AID function in the form of ongoing and AID-specific mutations in the IGHV 
gene. I also examined the relationship between AID expression and the tissue 
microenvironment. Finally, I wanted to see whether there was an association between any 
of the AID-related laboratory data I obtained and the clinical data obtained from the 
PACIFICO trial. 
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I hypothesised that AID expression and/or function is associated with genomic instability 
and progression or transformation of FL. I also predicted that AID function in the form of 
ongoing mutation would be associated with continuing subclonal evolution and disease 
relapse in FL. If my hypothesis was proved to be correct, AID could potentially serve as a 
predictive or prognostic biomarker for disease stratification in FL, as well as a therapeutic 
target. 
I spent a considerable amount of time optimizing RNA and DNA extractions from FFPE 
tissue sections. Because the test samples were obtained from a clinical trial, these tissues 
were precious and only a limited amount of material was available. 
Initially, I compared two commonly used RNA extraction kits, and found that the RNeasy 
FFPE kit from Qiagen was more suitable. I then optimized RNA extraction methods to obtain 
higher quantity from less tissue material (Chapter 3, Section 3.2.1). 
With respect to DNA extraction from FFPE tissues, I optimized the commercially available 
kits to produce a larger amount of DNA (Chapter 3, Section 3.2.2.1). 
I measured RNA quantity by using a Qubit fluorometer and quality with a bioanalyzer 2100 
in all of our cohort of 87 patients. In addition, the DNA quantity (also by Qubit fluorometer) 
and quality was measured by designing primers for PCR amplification of 200-400 bp 
fragments of the GAPDH gene in all samples. 
Although my endeavours to optimise of nucleic acid extraction from FFPE biopsies were 
primarily aimed at investigating AID expression in FL, their relevance extends to all 
conditions where characterisation of the expression of specific genes is required using FFPE 
biopsy material. 
qPCR was then chosen to estimate AID mRNA expression because of its simplicity, 
reliability, specificity and cost effectiveness for estimation of gene expression (399).  It was 
found that degraded RNA with a RIN of < 2.1 was not suitable for reliable qPCR results, 
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and this RIN number was therefore used as a cut-off for excluding RNA samples from this 
study (Chapter 4, Section 4.2.1.3). I then compared different EC genes and used the best of 
them as a control in qPCR experiments. 
After optimization and validation of all steps before and during qPCR, AID mRNA 
expression was quantified in 59 (with RIN of 2.1 or more) out of 87 samples (68%) from the 
PACIFICO trial. 
Subsequently, protein expression of AID in FL was determined using 
immunohistochemistry in FFPE tissue samples. This was performed by staining and scoring 
all of the 87 FL samples. A good correlation was observed between AID mRNA and protein 
levels (Chapter 4, Section 4.3). This provided cross-validation of the 2 techniques and 
increased the veracity of the findings. 
I then sought to establish which cells in the GC were expressing AID. To do this, I performed 
IF to examine co-expression of AID with CD3 (T cells), CD68 (macrophages) and CD20 
(B-cells). Essentially, AID expression was confined to B-cells. 
Because AID is stored in the cytoplasm and performs its function in the nucleus (400), I 
postulated that the function of AID could be better assessed if a method of exploring the N/C 
ratio of AID could be established. To do this, confocal microscopy was used to quantify the 
co-expression of AID with a nuclear stain (Chapter 4, Section 4.4.2). A positive correlation 
was identified between this N/C ratio with both mRNA and protein expression levels of AID. 
I then related AID expression to clinical features at trial entry. No statistically significant 
correlation was found between AID mRNA or protein levels and any of the clinical features 
recorded. However, a trend for more advanced-stage disease was found in patients with a 
higher AID N/C ratio. 
Because ongoing IGHV mutational activity has been associated with the acquisition and loss 
of genetic material, intraclonal heterogeneity and drug resistance in FL (357, 358), I studied 
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ongoing mutations and AID-induced mutations in this gene in my cohort of patient samples. 
I found a statistically significant association between higher rates of ongoing IGHV mutation 
and unfavourable histological grade; there was also a non-significant trend for cases with 
higher rates of ongoing IGHV mutation to have more advanced disease (Chapter 5, Section 
5.4.10.3).  
In addition, I examined whether there was an association between AID expression and/or 
function and the expression of genes associated with the FL tissue microenvironment (TME) 
that are known to correlate with patient survival. It was found that higher AID protein 
expression was associated with reduced expression of 2 out of 3 genes that are linked with 
better survival in FL. 
Finally, when I compared my laboratory data to longitudinal clinical data from the trial, it 
became apparent that a higher % of AID-related mutations in the IGHV gene was associated 
with worse survival (Chapter 7, Section 7.4.4).  
Probably one of the most important aspects achieved in this work is the optimization of 
protocols to extract larger amounts of nucleic acids from FFPE tissues. Another key 
achievement is the identification of AID expression at the mRNA and protein level including 
its subcellular localisation. 
I also established a positive correlation between AID mRNA and protein expression. 
However, one of the most important findings is that functional readouts of AID (N/C ratio, 
ongoing IGHV mutation and AID-related IGHV mutation) correlate much more closely than 
AID expression with adverse baseline and longitudinal clinical features. 
On the other hand, I faced several difficulties during the Ph.D. For example, despite 
optimising the method for extracting nucleic acids from FFPE tissues, I could not reverse 
the degradation of those substances that took place prior to nucleic acid extraction. Although 
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it was not available for my project, fresh frozen patient material is likely to have produced a 
much better yield of intact DNA and RNA.  
The other difficulty I encountered was using the Image j1x software to measure intra-nuclear 
AID. Specifically, I found that cells from FFPE tissue sections were very close to each other, 
and it was therefore difficult to identify individual cell nuclei. 
Additionally, regarding the correlation between TME and AID expression, I found that many 
updated published works noted that it was not simply the expression level of genes that 
played a role in disease outcome but rather alterations in the number, type or location of 
TME cells  (91). 
Due to time limits for this study, further future work may be required to confirm these results 
and build solid conclusions. 
Finding that the functional readout of AID, rather than its expression, is correlated to adverse 
clinical features in FL opens the door for further work. An increase in the size of my patient 
cohort to confirm these results is required, because IGHV mutation was studied in only 18 
patients and AID N/C ratio measured in only 20 patients. Furthermore, the discrepancy 
between AID expression and function calls for studies to investigate functionally important 
posttranslational modifications of AID. 
Also, in our clonal analysis of IGHV families, I found that in about half of the patients there 
was a faint band of IG in addition to the main band. We examined this faint band in one 
patient only and found that these were background B-cells. These faint bands require further 
examination, as they appeared not in one or 2 patients but in approximately half of our 
cohort. 
It would also be of interest to compare the impact of AID expression and function on the 
outcome of the 2 treatment arms of the PACIFICO trial. This was not possible within the 
framework of my Ph.D. project as patients are still being followed-up for disease progression 
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and the number of cases examined would be too small to draw any meaningful conclusions.  
However, if a larger number of patient samples could be examined for AID expression and 
function and the results related to therapy response, PFS and OS when the final trial data are 
available, it should be possible to address the question of whether the effect of AID 
expression and function on FL outcome is differentially modulated by specific drug 
regimens. If we are able to perform this future work and confirm the correlation of higher 
AID function with worse disease outcome, it may be possible to explore AID function as a 
potential biomarker for determining disease outcome in FL. Completion of this work may 
also provide us with a better understanding of the role of AID in the biology and progression 
of FL. 
Another line of investigation that would be interesting to pursue would be to correlate AID 
expression and function with mutations in genes other than IGHV that are important in FL 
biology. This work was planned in collaboration with Professor Jude Fitzgibbon at Bart’s 
cancer institute but was delayed owing to a strategy to expand the NGS panel as much as 
possible before applying it to the trial samples. 
The methodology for this work will be done as follows, DNA samples from FFPE tissues of 
the PACIFICO trial were prepared for performing NGS experiments, in collaboration with 
Bart’s Cancer Institute’s lymphoma research group led by Professor Jude Fitzgibbon; 
however, the time limit for this Ph.D. did not allow me to perform this experiment, and it 
will be accomplished as a future work. 
To select our panal  of genes, a total of 161 genes (Appendix Table 3) that are frequently 
mutated in FL and DLBCL had been selected for NGS mutation analysis (127, 401-415). 
Chosen genes were based upon importance of pathophysiology of FL formation and 
transformation in addition to mutation frequency. Agilent SureDesign software was used to 
design 28,261 probes that cover a genome size of 1.067 Mb.  
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To perform target sequencing, a capture-based approach for NGS will be performed using a 
SureSelect XT Target Enrichment System (Agilent Technologies, UK). A total of 0.5-1 µg 
of DNA is needed, physical shearing of DNA by sonication to a size range of 150-200bp 
will be done using a Covaris E210 instrument (Covaris Inc); this is followed by blunting 
gene ends, addition of adenine overhang, ligation to adapters and PCR. Biotinylated DNA 
probes designed to cover exons of our genes of interest will be included in the hybridization 
solution. After post-capture enrichment, libraries will be sequenced using the MiSeq 
platform at a coverage of 500-1000X. 
I wanted to compare the two groups of patients with high and low AID function against the 
clinical outcome, but unfortunately the number of patients with PFS or OS events were very 
low. This will be the future goal of a further study. 
Finally, it will be important to confirm an association between ongoing IGHV mutation and 
adverse clinical outcome in the PACIFICO trial as I have so far only been able to show a 
non-significant trend. 
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Conclusion 
 
In this Ph.D., I have carried out comprehensive work to explore AID expression by mRNA, 
IHC and IF that will be useful for researchers in future studies exploring AID in any FFPE 
tissues. Moreover, I improved the protocols of commercially-available kits to be able extract 
the higher yield and better quality of RNA and DNA from FFPE tissues. I demonstrated that 
AID mRNA, total protein and AID nuclear expression levels were correlated with each other. 
More importantly, I found that functional readouts of AID (rather than AID expression per 
se) correlate with clinical features. Specifically, the N/C ratio of AID and ongoing IGHV 
mutation were associated with adverse histological grades and more advanced anatomical 
stages of disease. Additionally, I found a trend for worse longitudinal outcome in patients 
with a higher N/C ratio of AID or higher % of AID-related IGHV mutations, although a 
larger cohort of patients is required to validate these results. These findings could be 
particularly important for clinicians since AID is mutagenic and may be associated with 
clonal evolution and FL transformation. 
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Appendices 
Appendix table 1: Clinical data of PACIFICO trial patients used in our study. 
Patient no Age Sex No. 
Lymph 
Nodes 
Ann 
Arbor 
Staging 
Histological 
Grade 
Date of 
Diagnosis 
LDH 
(IU/L) 
159 79 F 4 II 2 24/11/2009 394 
182 70 M 6 III 3 26/07/2012 NULL 
187 75 M 1 IV 3 03/01/2013 365 
261 67 F 6 IV 2 24/02/2009 258 
290 75 M 6 IV 2 10/07/2014 313 
202 68 M 5 II 2 30/04/2013 353 
310 76 M 6 IV 1 03/07/2013 258 
278 73 M 3 IV 2 07/05/2014 296 
166 64 F 5 II 3 03/09/2012 531 
003 68 M 6 III 2 20/01/2010 315 
013 76 M 6 III 1 19/04/2010 380 
286 73 M 6 IV 2 16/06/2014 297 
051 64 F 4 IV 2 20/12/2010 289 
120 57 M 3 IV 2 26/01/2012 158 
33 69 M 6 III 2 18/09/2010 491 
291 69 M 1 IV 3 17/07/2014 1.25 
53 70 F 6 IV 2 16/12/2010 349 
211 77 F 6 III 3 16/03/2010 427 
199 66 F 6 IV 1 22/03/2013 476 
309 73 M 5 III 1 20/06/2013 546 
256 64 M 6 IV 2 17/01/2014 658 
266 78 F 6 IV 2 12/03/2014 490 
008 78 M 4 III 3 23/02/2010 300 
016 66 F 6 III 2 27/05/2010 382 
035 66 M 6 III 3 13/09/2010 481 
045 70 M 2 II 2 28/10/2010 273 
063 54 M 6 III 1 18/02/2011 434 
142 67 M 5 III 3 23/11/2010 193 
118 72 F 6 III 1 16/01/2012 586 
156 81 F 6 III 3 02/08/2012 398 
192 64 F 6 IV 1 17/11/2012 148 
151 76 M 4 II 1 01/06/2012 167 
180 72 M 5 II 1 29/11/2012 181 
160 64 F 6 III 3 11/05/2012 151 
255 66 M 6 IV 1 19/02/2014 166 
274 89 M 6 III 1 02/05/2014 127 
289 69 F 6 IV 2 09/07/2014 213 
292 63 F 6 IV 1 02/07/2014 147 
20 82 M 6 IV 2 22/03/2010 656 
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Patient no Age Sex No. 
Lymph 
Nodes 
Ann 
Arbor 
Staging 
Histological 
Grade 
Date of 
Diagnosis 
LDH 
(IU/L) 
237 70 M 5 II 1 30/10/2013 367 
134 67 M 6 III 2 04/01/2012 203 
280 71 F 6 III 3 11/06/2014 543 
242 76 F 6 IV 3 04/12/2013 830 
84 65 M 4 III 1 19/05/2011 335 
72 77 F 6 III 3 01/03/2011 354 
221 66 F 5 III 2 02/09/2013 326 
71 63 F 6 III 2 11/06/2004 136 
11 70 F 5 III 3 29/04/2010 382 
56 64 M 6 III 3 17/02/2011 456 
157 64 M 6 IV 2 26/07/2012 494 
196 79 M 5 III 2 12/10/2012 375 
217 64 F 6 III 3 22/07/2013 411 
227 60 M 1 III 3 09/05/2013 324 
259 66 M 6 IV 2 03/03/2014 560 
179 67 M 6 IV 1 27/09/2012 251 
307 78 M 6 IV 2 25/09/2014 219 
287 61 F 4 IV 2 06/06/2014 156 
267 78 F 6 IV 2 30/01/2014 109 
296 78 F 4 III 3 07/07/2014 373 
234 76 M 2 II 2 01/11/2013 168 
269 75 M 6 IV 2 20/03/2014 358 
183 72 F 5 II 2 15/03/2012 626 
64 79 F 6 III 1 04/04/2011 552 
230 75 M 6 III 1 21/10/2013 303 
324 77 M 1 III 1 02/02/2011 419 
58 68 M 5 III 2 28/11/2005 317 
205 72 F 3 II 1 04/06/2013 213 
28 59 F 6 III 2 15/07/2010 180 
80 72 F 4 III 1 26/05/2011 178 
27 70 M 6 III 1 20/11/2007 422 
59 84 F 4 IV 3 19/08/2010 367 
113 78 F 6 IV 1 09/11/2011 333 
264 67 M 6 III 2 06/03/2014 327 
48 69 M 6 IV 2 29/12/2010 487 
200 68 M 6 IV 2 23/04/2013 862 
68 71 F 6 IV 2 08/03/2011 424 
201 54 F 6 III 3 01/05/2013 303 
244 74 F 5 IV 3 16/07/2013 443 
219 77 F 3 IV 3 22/10/2013 479 
233 64 F 6 IV 1 01/07/2013 333 
105 67 F 6 III 2 04/10/2011 168 
37 64 F 2 II 2 25/08/2010 447 
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Patient no Age Sex No. 
Lymph 
Nodes 
Ann 
Arbor 
Staging 
Histological 
Grade 
Date of 
Diagnosis 
LDH 
(IU/L) 
76 73 F 6 IV 2 14/04/2011 219 
55 78 F 6 III 2 08/02/2011 156 
42 75 M 6 III 2 13/10/2010 476 
46 72 M 6 III 2 07/12/2010 263 
38 74 M 6 IV 2 09/11/2010 563 
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Appendix Table 2: Clinical data of FL FFPE samples borrowed from Liverpool 
BioInnovation Hub;* NK is not known. 
 
 
 
 
 
Block Sex 
Age at 
diagnosis Site Diagnosis Grade IHC stains 
T54/94 Female 60 
Femoral 
Node 
NHL NK* NK 
T305/03 Female 60 
Left 
axillary 
FL 1 
bcl-6+, bc2-2+, 
CD10-/+, CD20+ 
CD79A+. 
Negative for bcl-
1, CD5, CD23 & 
light chains 
T247/99 Female 72 Spleen FL 1 
B Cell type 
CD10+ bcl-2 
negative 
T106/93 Female 66 
Left 
axillary 
NHL NK NK 
T15/98 Female 51 
Left  
axillary 
FL 2 
IgM+, lambda+, 
Kappa-, IgD-) 
and unequivocal 
stainings for 
CD79A,CD2  + 
CD45. BCL2+  
except in residual 
GCs which 
contain CD21 
positive dendritic 
cells. There is no 
CD30 positive 
cells.  CD3 in 
interfollicular 
regions. 
Scattered CD68 
positive cells are 
present. 
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Appendix Table 3: 161 important genes in pathogenesis of FL that will be studied by 
NGS. 
  
Gene Ensembl Transcipt ID Reference 
Sequence 
Function 
1 ACTB ENSG00000075624 ENST00000331789 NM_001101 Actin protein/cell 
adhesion/chromatin 
remodeling 
2 APC ENSG00000134982 ENST00000257430 NM_000038 Tumour suppressor/WNT 
signalling/ B catenin 
3 ARHGEF1 ENSG00000076928 ENST00000354532 NM_004706 GTPase activating protein for  
GNA12 and GNA13 
4 ARID1A ENSG00000117713 ENST00000324856 NM_006015 Chromatin 
remodelling/transcrition 
coactivator activity 
5 ARID1B ENSG00000049618 ENST00000346085 NM_020732 Chromatin remodelling 
6 ATM ENSG00000149311 ENST00000278616 NM_000051 DNA damage response/signal 
transduction 
7 ATP10A ENSG00000206190 ENST00000356865 NM_024490 ATPase/transport of 
phospholipids 
8 ATP13A4 ENSG00000127249 ENST00000342695 NM_032279 ATPase activity 
9 ATP6AP1 ENSG00000071553 ENST00000369762 NM_001183 V-ATPase 
10 ATP6AP2 ENSG00000182220 ENST00000378438 NM_005765 Renin and prorenin cellular 
receptor 
11 ATP6V0A1 ENSG00000033627 ENST00000343619 NM_001130021 V-ATPase 
12 ATP6V0C ENSG00000185883 ENST00000330398 NM_001694 V-ATPase 
13 ATP6V0D1 ENSG00000159720 ENST00000290949 NM_004691 V-ATPase 
14 ATP6V1A ENSG00000114573 ENST00000273398 NM_001690 V-ATPase 
15 ATP6V1B2 ENSG00000147416 ENST00000276390 NM_001693 V-ATPase 
16 ATP6V1F ENSG00000128524 ENST00000492758 NM_001198909 V-ATPase 
17 ATRX ENSG00000085224 ENST00000373344 NM_000489 Transcriptional 
regulation/chromatin 
remodelling 
18 B2M ENSG00000166710 ENST00000558401 NM_004048 Antigen presentation 
19 BCL10 ENSG00000142867 ENST00000370580 NM_003921 NF-κB/pro apoptotic 
20 BCL2 ENSG00000171791 ENST00000398117 NM_000633 Anti-apoptosis 
21 BCL6 ENSG00000113916 ENST00000406870 NM_001706 Transcriptional repressor 
22 BCL7A ENSG00000110987 ENST00000538010 NM_020993 Translocated in Burkett’s 
Lymphoma 
23 BCOR ENSG00000183337 ENST00000342274 NM_001123383 Transcriptional 
repressor/inhibits H3K7 
methylation 
24 BCR ENSG00000186716 ENST00000305877 NM_004327 Serine threonine kinase 
activity/GTPase 
25 BRD4 ENSG00000141867 ENST00000263377 NM_058243 Chromatin reader/NF-κB 
26 BTG1 ENSG00000133639 ENST00000256015 NM_001731 Anti-proliferative 
27 BTG2 ENSG00000159388 ENST00000290551 NM_006763 Anti-proliferative/cell cycle 
regulation 
28 CARD11 ENSG00000198286 ENST00000396946 NM_032415 BCR/NF-κB 
29 CCND3 ENSG00000112576 ENST00000372991 NM_001760 Cell cycle/interacts with rb1 
30 CD22 ENSG00000012124 ENST00000085219 NM_001771 B-cell signalling 
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 Gene Ensembl Transcipt ID Reference 
Sequence 
Function 
31 CD36 ENSG00000135218 ENST00000447544 NM_001001548 Cell adhesion/TLR (Toll like 
receptor) signalling/myd88 
signalling 
32 CD58 ENSG00000116815 ENST00000457047 NM_001144822 T cell activation/immune 
evasion/cell adhesion 
33 CD70 ENSG00000125726 ENST00000245903 NM_001252 T cell activation/immune 
response 
34 CD74 ENSG00000019582 ENST00000353334 NM_001025159 Immune evasion/MHC class II 
presentation 
35 CD79A ENSG00000105369 ENST00000221972 NM_001783 B-cell receptor signalling 
36 CD79B ENSG00000007312 ENST00000006750 NM_000626 B-cell receptor signalling 
37 CD83 ENSG00000112149 ENST00000379153 NM_001040280 Antigen presentation/immune 
response 
38 CDKN2A ENSG00000147889 ENST00000304494 NM_000077 Cell cycle progression/negative 
regulator of proliferation 
39 CDKN2B ENSG00000147883 ENST00000276925 NM_004936 Cell cycle progression 
40 CIITA ENSG00000179583 ENST00000324288 NM_000246 Immune response/HLA class II 
41 CREBBP ENSG00000005339 ENST00000262367 NM_004380 H3k27/18AC 
42 CRIPAK ENSG00000179979 ENST00000324803 NM_175918 PAK 1 inhibitor 
43 CXCR4 ENSG00000121966 ENST00000409817 NM_001008540 Chemokine receptor CXCL12 
44 DTX1 ENSG00000135144 ENST00000257600 NM_004416 Ubiquitan ligase/notch 
pathway 
45 DUSP2 ENSG00000158050 ENST00000288943 NM_004418 Regulate map kinases 
46 EBF1 ENSG00000164330 ENST00000313708 NM_024007 B-cell 
development/transcriptional 
coactivator 
47 EEF1A1 ENSG00000156508 ENST00000316292 NM_001402 Translation elongation 
factor/protein synthesis 
48 EP300 ENSG00000100393 ENST00000263253 NM_001429 H3K27/18AC 
49 EPHA7 ENSG00000135333 ENST00000369303 NM_001288629 Tyrosine kinase/ERK 
signalling/neuro development 
50 ETS1 ENSG00000134954 ENST00000392668 NM_001143820 Transcription factor/cell 
differentiation  and survival 
51 ETV1 ENSG00000006468 ENST00000430479 NM_004956 Transcriptional activator 
52 ETV6 ENSG00000139083 ENST00000396373 NM_001987 Transcriptional repressor 
53 EZH2 ENSG00000106462 ENST00000320356 NM_001203247 H3K27meth3 
54 FAS ENSG00000026103 ENST00000355740 NM_000043 Apoptosis 
55 FAT2 ENSG00000086570 ENST00000261800 NM_001447 Cell adhesion/proliferation/ 
cerebellar devlopment 
56 FAT4 ENSG00000196159 ENST00000394329 NM_024582 Regulates cell polarity 
57 FBXO11 ENSG00000138081 ENST00000403359 NM_001190274 The SCF(FBXO11) complex 
mediates ubiquitination 
58 FBXW7 ENSG00000109670 ENST00000281708 NM_033632 Ubiquitination/degradation of 
MYC and notch 
59 FOXO1 ENSG00000150907 ENST00000379561 NM_002015 Transcription factor 
60 FOXP1 ENSG00000114861 ENST00000318789 NM_001244810 Transcriptional repressor/b cell 
development 
61 GNA12 ENSG00000146535 ENST00000275364 NM_007353 Cell migration/guanine 
nucleotide binding protein 
62 GNA13 ENSG00000120063 ENST00000439174 NM_006572 Cell migration/guanine 
nucleotide binding protein 
63 GNAI2 ENSG00000114353 ENST00000313601 NM_001282618 GtPase 
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 Gene Ensembl Transcipt ID Reference 
Sequence 
Function 
64 HDAC7 ENSG00000061273 ENST00000080059 NM_015401 Histone deacetylase 
65 HIST1H1B ENSG00000184357 ENST00000331442 NM_005322 Chromatin remodelling 
66 HIST1H1C ENSG00000187837 ENST00000343677 NM_005319 Chromatin remodelling 
67 HIST1H1D ENSG00000124575 ENST00000244534 NM_005320 Chromatin remodelling 
68 HIST1H1E ENSG00000168298 ENST00000304218 NM_005321 Chromatin remodelling 
69 HIST1H2AC ENSG00000180573 ENST00000377791 NM_003512 Chromatin remodelling 
70 HIST1H2AE ENSG00000277075 ENST00000303910 NM_021052 Chromatin remodelling 
71 HIST1H2AG ENSG00000196787 ENST00000359193 NM_021064 Chromatin remodelling 
72 HIST1H2AL ENSG00000276903 ENST00000613174 NM_003511 Chromatin remodelling 
73 HIST1H2AM ENSG00000278677 ENST00000359611 NM_003514 Chromatin remodelling 
74 HIST1H2BC ENSG00000180596 ENST00000396984 NM_003526 Chromatin remodelling 
75 HIST1H2BD ENSG00000158373 ENST00000289316 NM_138720 Chromatin remodelling 
76 HIST1H2BG ENSG00000273802 ENST00000541790 NM_003518 Chromatin remodelling 
77 HIST1H2BJ ENSG00000124635 ENST00000541790 NP_066402 Chromatin remodelling 
78 HIST1H2BK ENSG00000197903 ENST00000396891 NM_080593 Chromatin remodelling 
79 HIST1H2BO ENSG00000274641 ENST00000616182 NM_003527 Chromatin remodelling 
80 HIST1H3B ENSG00000274267 ENST00000621411 NM_003537 Chromatin remodelling 
81 HIST1H3C ENSG00000278272 ENST00000612966 NM_003531 Chromatin remodelling 
82 HIST1H3G ENSG00000273983 ENST00000614378 NM_003534 Chromatin remodelling 
83 HIST1H3H ENSG00000278828 ENST00000369163 NM_003536 Chromatin remodelling 
84 ID3 ENSG00000117318 ENST00000374561 NM_002167 Transcriptional 
regulator/apoptosis/ 
differntiation 
85 IKZF3 ENSG00000161405 ENST00000346872 NM_012481 Transcription factor/role in B-
cell differentiation 
86 IRF4 ENSG00000137265 ENST00000380956 NM_001195286 Transcriptional activator/binds 
to MHC class I promoter 
87 IRF8 ENSG00000140968 ENST00000268638 NM_002163 Regulates interferon induced 
MHC class I genes 
88 ITPKB ENSG00000143772 ENST00000429204 NM_002221 Inositol phosphate metabolism 
89 KDM2B ENSG00000089094 ENST00000377069 NM_001005366 Histone demethylase 
90 KLHL14 ENSG00000197705 ENST00000359358 NM_020805 Unknown 
91 KLHL6 ENSG00000172578 ENST00000341319 NM_130446 Germinal centre formation 
92 LRRN3 ENSG00000173114 ENST00000451085 NM_001099660 Unknown/highly expressed in 
brain/protein phosphorylation 
93 LYN ENSG00000254087 ENST00000520220 NM_001111097 B-cell receptor 
94 LYST ENSG00000143669 ENST00000389793 NM_000081 Intracellular protein trafficking 
95 MALT1 ENSG00000172175 ENST00000348428 NM_006785 NF-κB 
96 MAP2K1 ENSG00000169032 ENST00000307102 NM_002755 Map kinase signalling 
pathway/proliferation 
97 MCL1 ENSG00000143384 ENST00000369026 NM_001197320 Apoptosis regulation 
98 MEF2B ENSG00000213999 ENST00000424583 NM_005919 Histone acetylation 
99 MEF2C ENSG00000081189 ENST00000340208 NM_001193347 Transcriptiomal activator/B-
cell development 
100 MLL/KMT2A ENSG00000118058 ENST00000534358 NM_001197104 Chromatin structure 
101 MLL2/KMT2D ENSG00000167548 ENST00000301067 NM_003482 Histone methylation 
102 MLL3/KMT2C ENSG00000055609 ENST00000262189 NM_170606 Histone methylation 
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 Gene Ensembl Transcipt ID Reference 
Sequence 
Function 
103 MPEG1 ENSG00000197629 ENST00000361050 NM_001039396 Membrane protein/expressed in 
macrophages 
104 MTOR ENSG00000198793 ENST00000361445 NM_004958 mTOR signalling 
105 MYC ENSG00000136997 ENST00000377970 NM_002467 Transcription factor 
      
107 NF-ΚBIA ENSG00000100906 ENST00000216797 NM_020529 Inhibits NF-κB 
108 NF-ΚBIE ENSG00000146232 ENST00000275015 NM_004556 NF-κB 
109 NOTCH 1 ENSG00000148400 ENST00000277541 NM_017617 Notch signalling/cellular 
differentiation and proliferation 
110 NOTCH 2 ENSG00000134250 ENST00000256646 NM_024408 Notch signalling/cellular 
differentiation and proliferation 
111 NOTCH 3 ENSG00000074181 ENST00000263388 NM_000435 Notch signalling/cellular 
differentiation and proliferation 
112 NOTCH 4 ENSG00000204301 ENST00000375023 NM_004557 Notch signalling/cellular 
differentiation and proliferation 
113 P2RY8 ENSG00000182162 ENST00000381297 NM_178129 Purinoceptor 
114 PAX5 ENSG00000196092 ENST00000358127 NM_016734 B-cell differentiation/target of 
ASHM 
115 PCLO ENSG00000186472 ENST00000333891 NM_033026 Synaptic vesicles 
116 PDL1/CD274 ENSG00000120217 ENST00000381577 NM_014143 T cell proliferation 
117 PIK3C2G ENSG00000139144 ENST00000433979 NM_004570 PI3K 
118 PIK3CD ENSG00000171608 ENST00000377346 NM_005026 PI3K pathway/immune 
response 
119 PIK3R1 ENSG00000145675 ENST00000521381 NM_181523 PI3K 
120 PIM1 ENSG00000137193 ENST00000373509 NM_001243186 Serine threonine protein 
kinase/cell proliferation/MYC 
121 PLCB1 ENSG00000182621 ENST00000378641 NM_182734 PI3K 
122 POU2F2 ENSG00000028277 ENST00000389341 NM_001207025 Transcription factor/IG gene 
expression 
123 PRDM1 ENSG00000057657 ENST00000369096 NM_001198 Plasmacytic differentiation 
124 PRKCB ENSG00000166501 ENST00000303531 NM_002738 Serine threonine protein 
kinase/b cell activation 
125 PTEN ENSG00000171862 ENST00000371953 NM_000314 PI3K/AKT (Protein kinase B) 
126 PTPN6 ENSG00000111679 ENST00000456013 NM_080549 Haematopoietic cell signalling 
127 RB1 ENSG00000139687 ENST00000267163 NM_000321 Tumour suppressor/cell 
cycle/histone methylation 
128 REL ENSG00000162924 ENST00000295025 NM_002908 NF-κB 
129 ARHH ENSG00000168421 ENST00000610353 NM_001278359 Negative regulator of 
haematopoietic progenitor cell 
130 RRAGC ENSG00000116954 ENST00000373001 NM_001271851 mTOR 
131 S1PR2 ENSG00000267534 ENST00000590320 NM_004230 Growth regulation 
132 SETD2 ENSG00000181555 ENST00000409792 NM_014159 Histone methylation 
133 SGK1 ENSG00000118515 ENST00000367858 NM_001143676 Serine threonine 
kinase/notch/NF-κB 
134 SLC22A16 ENSG00000004809 ENST00000368919 NM_033125 Doxorubicin transporter 
135 SMARCA4 ENSG00000127616 ENST00000429416 NM_001128844 Chromatin remodelling/NURF 
136 SMARCB1 ENSG00000099956 ENST00000263121 NM_003073 Chromatin remodelling 
137 SOCS1 ENSG00000185338 ENST00000332029 NM_003745 Jak-Stat 
138 SPEN ENSG00000065526 ENST00000375759 NM_015001 Transcriptional repressor/notch 
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 Gene Ensembl Transcipt ID Reference 
Sequence 
Function 
139 STAT3 ENSG00000168610 ENST00000264657 NM_003150 Transcription activator 
140 STAT6 ENSG00000166888 ENST00000300134 NM_001178078 Transcription activator 
141 SYK ENSG00000165025 ENST00000375754 NM_003177 B-cell receptor 
142 TAF1 ENSG00000147133 ENST00000423759 NM_024665 Transcription factor 
complex/histone acetylation 
143 TBL1XR1 ENSG00000177565 ENST00000457928 NM_024665 Transcription activator 
144 TCF3 ENSG00000071564 ENST00000262965 NM_003200 Transcription regulation/b cell 
differentiation 
145 TET2 ENSG00000168769 ENST00000380013 NM_001127208 DNA methylation 
146 TLR2 ENSG00000137462 ENST00000260010 NM_003264 Toll like receptor/myd88 
147 TMEM30A ENSG00000112697 ENST00000230461 NM_018247 ATPase 
148 TMSB4X ENSG00000205542 ENST00000451311 NM_021109 Actin cytoskeleton/cell 
migration and proliferation 
149 TNFAIP3 ENSG00000118503 ENST00000237289 NM_001270507 NF-κB 
150 TNFRSF14 ENSG00000157873 ENST00000355716 NM_003820 Immune response 
151 TP53 ENSG00000141510 ENST00000269305 NM_000546 Tumour suppressor/apoptosis 
152 TRAF3 ENSG00000131323 ENST00000560371 NM_003300 NF-κB 
153 UBE2A ENSG00000077721 ENST00000371558 NM_001282161 Ubiquitination/transcription 
regulation 
154 XPO1 ENSG00000082898 ENST00000401558 NM_003400 Nuclear export of proteins 
155 ZFHX3 ENSG00000140836 ENST00000268489 NM_006885 Transcriptional repressor 
156 ZMYM3 ENSG00000147130 ENST00000373998 NM_001171162 Chromatin structure 
157 NF-ΚBIZ ENSG00000144802 ENST00000326172 NM_031419 NF-κB 
158 HVCN1 ENSG00000122986 ENST00000242607 NM_001040107 Voltage gated proton channel 
159 POU2AF1 ENSG00000110777 ENST00000393067 NM_006235 Transcriptional coactivator 
160 
VMA21 ENSG00000160131 ENST00000330374 NM_001017980 
Required for the assembly of 
the V0 complex of the vacuolar 
ATPase 
161 
BCL2 
chr18:60985900-
60987443  NM_030766 Regulate cell death 
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Appendix table 4: Permissions to use published figures in my Ph.D. thesis. 
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